\r\n\tThe aim of this book will be to describe the most common forms of dermatitis putting emphasis on the pathophysiology, clinical appearance and diagnostic of each disease. We also will aim to describe the therapeutic management and new therapeutic approaches of each condition that are currently being studied and are supposed to be used in the near future.
",isbn:null,printIsbn:"979-953-307-X-X",pdfIsbn:null,doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,hash:"278931ae110500350d8b64805c70f193",bookSignature:"Dr. Eleni Papakonstantinou",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/7934.jpg",keywords:"Atopic eczema, Interleukin, Topical corticosteroids, Hand eczema, Blisters, Pruritus, Irritant contact dermatitis, Allergic contact dermatitis, Discoid eczema, Sebaceous glands, Inflammatory dermatitis, Facial rash",numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"February 5th 2019",dateEndSecondStepPublish:"March 19th 2019",dateEndThirdStepPublish:"May 18th 2019",dateEndFourthStepPublish:"August 6th 2019",dateEndFifthStepPublish:"October 5th 2019",remainingDaysToSecondStep:"2 years",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:null,kuFlag:!1,biosketch:null,coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"203520",title:"Dr.",name:"Eleni",middleName:null,surname:"Papakonstantinou",slug:"eleni-papakonstantinou",fullName:"Eleni Papakonstantinou",profilePictureURL:"https://mts.intechopen.com/storage/users/203520/images/system/203520.jpg",biography:"Dr. med. Eleni Papakonstantinou is a Doctor of Medicine graduate and board certified Dermatologist-Venereologist. She studied medicine at the Aristotle University of Thessaloniki, in Greece and she continued with her dermatology specialty in Germany (2012-2017) at the University of Magdeburg and Hannover Medical School, where she completed her dissertation in 2016 with research work on atopic dermatitis in children. During this time she gained wide experience in the whole dermatological field with special focus on the diagnosis and treatment of chronic inflammatory skin diseases and also the prevention and treatment of melanocytic and non-melanocytic skin tumors. Her research interests were beside atopic dermatitis and pruritus also the pathophysiology of blistering dermatoses. In addition to lectures at german and international congresses, she has published several articles in german and international journals and her work has been awarded with various prizes (poster prize of the German Dermatological Society for the project: 'Bullous pemphigoid and comorbidities' (DDG Leipzig 2016), 'Michael Hornstein Memorial Scholarship' (EADV Athens 2016), travel grant (EAACI Vienna 2016). Since 2017, she works as a specialist dermatologist in private practice in Dortmund, in Germany. Parallel she co-administrates an international dermatologic network, Wikiderm International and she writes a dermatology public guide for patients, as she is convinced that evidence-based knowledge has to be shared not only with colleagues but also with patients.",institutionString:"Private Practice, Dermatology and Venereology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:null}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"270941",firstName:"Sandra",lastName:"Maljavac",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/270941/images/7824_n.jpg",email:"sandra.m@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"878",title:"Phytochemicals",subtitle:"A Global Perspective of Their Role in Nutrition and Health",isOpenForSubmission:!1,hash:"ec77671f63975ef2d16192897deb6835",slug:"phytochemicals-a-global-perspective-of-their-role-in-nutrition-and-health",bookSignature:"Venketeshwer Rao",coverURL:"https://cdn.intechopen.com/books/images_new/878.jpg",editedByType:"Edited by",editors:[{id:"82663",title:"Dr.",name:"Venketeshwer",surname:"Rao",slug:"venketeshwer-rao",fullName:"Venketeshwer Rao"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4816",title:"Face Recognition",subtitle:null,isOpenForSubmission:!1,hash:"146063b5359146b7718ea86bad47c8eb",slug:"face_recognition",bookSignature:"Kresimir Delac and Mislav Grgic",coverURL:"https://cdn.intechopen.com/books/images_new/4816.jpg",editedByType:"Edited by",editors:[{id:"528",title:"Dr.",name:"Kresimir",surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"19242",title:"Currently Available Neuroimaging Approaches in Alzheimer Disease (AD) Early Diagnosis",doi:"10.5772/17012",slug:"currently-available-neuroimaging-approaches-in-alzheimer-disease-ad-early-diagnosis",body:'\n\t\t
\n\t\t\t
1. Introduction
\n\t\t\t
Alzheimer´s disease (AD) is a condition mainly diagnosed through clinical interpretation and neuropsychological testing. Unfortunately this leads to problems due to variations in expertise of the clinicians involved. Moreover, its diagnosis is usually achieved in later phases of the disease, which reduces the scope of useful interventions. In this chapter we will review the different brain imaging approaches used for both AD and mild cognitive impairment (MCI), a condition which evolves into AD in an important proportion of cases (between 10-15 % yearly)(Petersen, 2008).
\n\t\t\t
It has been hypothesized that the accumulation of β-amyloid (Aβ) in the AD brain triggers a cascade of neurodegenerative events, including inflammatory processes, neurofibrillary tangles, oxidative stress, and neuronal network dysfunction with synaptic loss and neurotransmitter deficits. Such events are manifested by progressive impairment of cognitive functions (Kadir et al, 2011). Years ago, an accurate diagnosis of AD was considered only possible using a demonstration of Aβ plaques and neurofibrillary tangles at post-mortem histopathological analysis of the brain (Wiley et al, 2009).
\n\t\t\t
At present there are promising methods for the in vivo assessment of the extent of AD. The typical findings of these brain imaging techniques are different and they are summarized in Table 1. These neuroimaging methods may help in AD early diagnosis as well as helping in differentiating AD from other neurodegenerative conditions. Although some pioneering work started in the 1970s, the explosion of knowledge regarding brain imaging methods for AD diagnosis is a matter of the last two decades.
\n\t\t\t
\n\t\t\t\t
1.1. Computerized Tomography (CT)
\n\t\t\t\t
Nowadays CT is not considered a standard technique for diagnosing AD, least of all in early stages. Its main usefulness is in differential diagnosis since it is less expensive, faster and more widely available than MRI. CT allows ruling out some clinical situations which lead to behavioural alterations but are not AD, e.g., normotensive hydrocephalus, intra and extra-axial bleeding, etc.
\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
Neuroimaging technique
\n\t\t\t\t\t\t\t
Finding
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
CT
\n\t\t\t\t\t\t\t
Tissue atrophy.
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
MRI
\n\t\t\t\t\t\t\t
Tissue atrophy. It is more specific about grey matter.
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
fMRI
\n\t\t\t\t\t\t\t
Changes in blood oxygenation level (BOLD signal) representing synaptic activity.
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
DTI
\n\t\t\t\t\t\t\t
Connectivity and organization in white matter tracts.
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
Spectroscopy
\n\t\t\t\t\t\t\t
Chemical content of the brain, such as NAA/Cr ratio or others.
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
SPECT
\n\t\t\t\t\t\t\t
Changes in cerebral perfusion.
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
PET
\n\t\t\t\t\t\t\t
Changes in glucose metabolism.
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
PET-amyloid
\n\t\t\t\t\t\t\t
Measures accumulation of β-amyloid, an AD-specific protein.
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
MEG
\n\t\t\t\t\t\t\t
Measures magnetic fields and, indirectly, yields rather precise information about brain electrical activity
\n\t\t\t\t\t\t
\n\t\t\t\t\t
Table 1.
CT = computerized tomography; MRI = magnetic resonance imaging; fMRI = functional magnetic resonance imaging; DTI = diffusion tensor imaging; SPECT = single-photon emission computed tomography; PET = positron emission tomography; MEG = magnetoencephalography; BOLD = blood oxygen level-dependent; NAA = N-acetyl aspartate; Cr = Creatinine; AD = Alzheimer’s disease
Typical findings of different brain imaging methods used in AD and MCI diagnosis
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
1.2. Magnetic Resonance Imaging (MRI)
\n\t\t\t\t
\n\t\t\t\t\t
1.2.1. Structural MRI
\n\t\t\t\t\t
This technique provides the best possible spatial resolution. Given the fact the most robust neuroimaging finding in AD is the atrophy of mesial temporal structures, structural MRI is the most widely used approach. Hippocampal atrophy is another well known finding, but atrophy within other brain areas has also been described in entorrhinal cortex, amygdala, basal ganglia (nucleus basalis of Meynert), thalamus and bilateral parietal cortex. It is relevant to mention here that in terms of early diagnosis some consider the entorrhinal cortex as the earliest area affected by AD. Other researchers have stated that the nucleus basalis of Meynert is a key structure in AD early diagnosis(Herholz et al, 2004; Grothe et al, 2010).
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
1.2.2. Functional MRI (fMRI)
\n\t\t\t\t\t
fMRI provides signal intensities images associated with a relative cerebral blood flow during cognitive tasks. Resting and activation functional MRI studies have showed a lesser coordinated activity in the hippocampus, inferior parietal lobes –both bilaterally- and cingulate cortex in patients with AD. This neuroimaging technique is nowadays used to monitor AD patients’ treatment.
\n\t\t\t\t\t
Combining genetic risk with functional MRI memory task paradigms has shown to be a very accurate pre-symptomatic predictor of cognitive decline.
\n\t\t\t\t
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
1.3. Diffusion Tensor Imaging (DTI)
\n\t\t\t\t
DTI allows visualizing neuronal connectivity or, more precisely, local fiber orientation and white matter tracts integrity. Patients with AD show decreased fiber density in temporal white matter, probably related to the medial temporal grey matter atrophy, as well as in the splenium of the corpus callosum.
\n\t\t\t\t
In mild cognitive impairment (MCI), however, this decreased fiber density has been located in the anterior part of the corpus callosum.
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
1.4. Spectroscopy
\n\t\t\t\t
It provides information on tissue substrate or metabolite concentrations. Specifically the N-acetyl aspartate (NAA) has been used as a biomarker of neuronal death, and it has been demonstrated that in patients with MCI and AD is significantly reduced compared to healthy controls.
It measures cerebral flow by detecting a single-photon emitting tracer after its intravenous injection and brain uptake. It has a very low spatial resolution and its diagnostic accuracy is lower than PET. Nevertheless, in clinical practice, it can be useful for differentiating AD from other dementias such as frontotemporal dementia.
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
1.5.2. Positron emission tomography (PET)
\n\t\t\t\t\t
Recently a new technique using PET with Pittsburg compound B (PIB; PIB-PET) has emerged. PIB is a tracer which allows marking β-amyloid plaques. This technique has been highly efficacious to detect β-amyloid in vivo and, therefore, could be rather useful to detect AD in its early phases.
\n\t\t\t\t
\n\t\t\t
\n\t\t\t
\n\t\t\t\t
1.6. Magnetoencephalography (MEG)
\n\t\t\t\t
MEG is a technique which measures brain magnetic fields both during basal state and during cognitive activation. Its time resolution is measured in milliseconds. It is precisely this very high temporal resolution which allows evaluating small changes in brain processing during cognitive stimulation. These changes may help to differentiate between AD, MCI and normality as well as providing some clues about differences in information processing in these same conditions
\n\t\t\t\t
Different studies carried out with MEG show a decrease in magnetic fields in people with AD in temporal mesial areas during memory tasks. People suffering from AD exhibit increased slow frequencies in temporoparietal areas in basal evaluation.
\n\t\t\t
\n\t\t
\n\t\t
\n\t\t\t
2. Computed Tomography (CT)
\n\t\t\t
Since the 1970s, there have been many CT studies searching for evidence of focal atrophy in the brains of subjects with AD (DeCarli et al, 1990). The search was complicated by the overlap between changes common to AD and normal ageing and because AD cases were only diagnosed clinically (Smith and Jobst, 1996). There are both generalized and focal changes, both in cortical areas as in the ventricular system, in brain atrophy. Unfortunately focal atrophy is not consistently found in standard axial CT studies though subjects with AD may show a greater degree of generalized atrophy revealed by sulci enlargement and ventricular dilatation.
\n\t\t\t
\n\t\t\t\tDeCarli et al (1990) concluded as follows: “Unfortunately, at present there is little definite evidence for clear anatomic brain changes that accurately predict the cognitive dysfunction within a group of patients suffering Alzheimer’s disease”. The dictum still remains valid.
\n\t\t\t
The standard axial CT system used internationally does not show the medial temporal lobe well, mainly because of the scan angle used. Changes in the medial temporal lobe itself have to be inferred from dilatation of the temporal horns of the lateral ventricles and enlargement of the suprasellar cisterns. Indeed, these changes have been observed in AD (Kido et al, 1989). By 1988, an alternative camera angle was used for hippocampus evaluation in patients with temporal lobe epilepsy and this system was also used by de Leon et al (1989) to study AD patients. The angle is parallel to the long axis of the temporal lobe and scanning is carried out from below and upwards until the inferior margin of the orbit is reached; in this way a complete series of images through the temporal lobe is obtained without exposing the eyes. Using this “temporal-lobe-oriented” CT procedure, de Leon et al (1989) found that 87% of patients with moderate to severe AD had dilatation of the hippocampal fissure compared with age-matched controls.
\n\t\t\t
Hippocampal atrophy detected with CT was also more common in a group that did not reach the clinical research criteria for AD but showed minimal memory impairments. This led them to suggest that hippocampal atrophy might be an AD marker which occurs early in the course of the illness, before the diagnosis is established, and predicts deterioration (De Leon et al, 1989). Hippocampal atrophy is not the only neuroimaging sign in AD, but it is rather characteristic.
\n\t\t\t
The axial temporal lobe oriented CT scan can be used to look for other possible causes of dementia, such as multiple infarcts, tumours or hydrocephalus, and the temporal lobe-oriented scan (in 1.5-2 mm slices) to reveal atrophy of the medial temporal lobe (Smith et al, 1996) (Fig 1).
\n\t\t\t
Figure 1.
CT in AD on the left and a patient with normotensive hydrocephalus on the right, where a catheter can be seen. CT is helpful to differentiate between AD and other brain conditions.
\n\t\t\t
Unfortunately CT usefulness in AD diagnosis is very limited (DeCarli et al, 1990). In the last 20 years MRI became increasingly available and the vast majority of structural neuroimaging used since then has been MRI. This is the reason why there are no relevant papers written since then where CT has been used for AD.
\n\t\t\t
Atrophy is evident, at hippocampal level too. Dilatation of the lateral ventricles can also be seen.
\n\t\t
\n\t\t
\n\t\t\t
3. Structural magnetic resonance imaging (MRI)
\n\t\t\t
MRI volumetry was one of the earliest brain imaging techniques used to identify AD. Given the temporal lobe atrophy found in AD patients, it seemed that this finding per se could diagnose AD. Further research revealed this simplistic approach was flawed.
\n\t\t\t
The first technique was manual volumetry. This required an excellent working knowledge of neuroanatomy as well as good dexterity in delineating the ROIs (regions of interest). This method is highly operator-dependent and multiple subjective issues can arise. This is overcome by double or triple-blind studies. Manual volumetry is also very time-consuming. On the other hand you have to have a prior hypothesis, such as a ROI to analyze. There have been many hypotheses in AD. Hippocampal analysis stands out (Besga et al, 2010) amongst them, though more recently other structures, such as the caudate nucleus or thalamus (Skup et al, 2011), or even corpus callosum, are being considered.
\n\t\t\t
A newer method is the so-called Voxed-based morphometry (VBM). This is an authomatized approach which allows distinguishing between grey and white matter. It also allows performing statistical studies amongst different populations (Kinkingnéhun et al, 2008).
\n\t\t\t
Multiple computer techniques have evolved since then. They allow analysing the brain, either globally or in any 3D ROI. For instance, in hippocampus, a key structure in AD, there are “radial atrophy mapping approach” or “large-deformation high dimensional brain mapping”. The former computes the 3D distance from the hippocampal centroid in each coronal section (also called a medial curve or core) to each hippocampal surface point. This provides an intuitive 3D measure of hippocampal thickness, as well as metric estimates of hippocampal atrophy that can be compared point-by-point across individuals and groups (Thompson et al, 2004). The latter is also used to study the changes in hippocampal morphology in patients with AD (Apostolova et al, 2007). Rather than relying on hippocampal manual tracings, a template hippocampus is traced on a single subject and fluidly warped to match the anatomy of new subjects. The transformation involved is high- dimensional, i.e. involves millions of degrees of freedom to produce a deformation that captures shape differences in detail. It is de facto a ‘large-deformation’ approach, that is to say the deformation model follows a continuum-mechanical law that prevents folding or tearing of the deforming template (this is known mathematically as a diffeomorphism).
Using the hippocampal radial atrophy mapping approach, Thompson et al (2004) showed profound hippocampal differences between normal controls and AD patients. These differences were correlated with MMSE scores. Two cross-sectional large-deformation high-dimensional brain mapping hippocampal studies have suggested the CA1 subfield may discriminate between normal aging and questionable AD (Clinical Dementia Rating Scale (CDR) = 0.5) (Csernansky et al, 2000; Wang et al, 2006).
\n\t\t\t
Along the last 10 years all sorts of volumetry studies aiming at early diagnosis of AD have been carried out. They mainly focus on either comparing AD versus MCI or healthy controls category or finding AD progression biomarkers progression.
\n\t\t\t
One can reliably classify AD patients and controls in the first group. Most studies revolve around temporal mesial lobe (MTL) structures. Many volumetric MCI studies measure hand-traced ROIs of specific MTL structures and most of them focus on the hippocampus. The majority of published studies indicate MCI patients have less hippocampal volume than cognitively intact controls (Becker et al, 2006; Kantarci et al, 2002), and AD patients have less volume than those with MCI (Wolf et al, 2004).
\n\t\t\t
Other studies show average entorhinal cortex volume in MCI patients is decreased compared with cognitively intact controls. Cross-sectional ROI studies have shown that the hippocampal and entorhinal volumes (Juottonen et al, 1999; Xu et al, 2000) can reliably differentiate AD subjects from normal older adults. Although some researchers claim that the precision of differentiating MCI from normal controls and MCI from AD is substantially less accurate when using hippocampal volume (MCI vs controls: sensitivity = 52– 80 % and specificity = 79–80% ; MCI vs AD: sensitivity = 45–60 % and specificity = 80%) than when using entorhinal cortex volumetry (Xu et al, 2000; Du et al, 2001; Kantarci et al, 2002), they concluded that, given the ambiguity imposed by the boundaries of the entorhinal cortex, it is easier to make these measurements in the hippocampus. Which structure is the more powerful discriminator to distinguish MCI patients from normal controls is currently being debated. Some studies side with the hippocampus and others with the entorhinal cortex (Pennanen et al, 2004).
\n\t\t\t
The second group of studies is made up of longitudinal research based on disease progression. Two hypotheses have emerged: the degree of atrophy progression and the basal atrophy found in AD patients.
\n\t\t\t
Several longitudinal studies have examined the relationship between the brain atrophy rate and its progression from MCI to AD. They have found significant group differences between MCI patients who progress to AD versus those who do not rapidly progress. They show that the hippocampus shows higher annual rates of atrophy in patients with MCI that progress to AD than in those who remain stable (Chetelat et al, 2005; Apostolova et al, 2006; Jack et al, 2004).Others have found that entorhinal cortex atrophy rate, but not hippocampus, is faster for individuals progressing to AD (Stoub et al, 2005). Moreover, other studies have shown that not only mesial temporal lobe regions show greater atrophy linked with progression towards AD, but also some cortical structures, such as posterior cingulum, precunneus or temporal medial lobe (Jack et al, 2004; Jack et al, 2005; Chetelat et al, 2005).
\n\t\t\t
Several studies have examined the accuracy of a single baseline brain MRI in predicting the progression towards AD, or stability, using a longitudinal clinical status follow-up. Studies using VBM for whole-brain analysis also find that a lower hippocampal baseline predicts progression towards MCI (Whitwell et al, 2007; Chetelat et al, 2005; Bozzali et al, 2006). Others studies using manual tracing methods have failed to replicate this association and report the entorhinal cortex as a more sensitive predictor of progression (de Toledo-Morrell et al, 2004; Stoub et al, 2005).
To summarize, it is in the last decade when we have been able to have an accurate idea about the structural brain changes in MCI as well and its progression towards AD. Those structural changes are multiple. Hippocampal atrophy is important, but there are also other important cortical biomarkers. Atrophy is more diffuse than one would expect, but pinpointing the specific regional areas of atrophy can be useful in the diagnosis of AD and differential diagnosis with other types of dementia. VBM is a technique which can help in identifying the regions of atrophy.
\n\t\t\t
Nevertheless it is important to take into account that all these studies are population ones, so none of them serves as an individual maker. Though reliable whole brain measurements can be accomplished with authomatized methods there is no way yet to know which MCI patients will evolve into AD. However these structural ancillary tests are clinically useful in combination with neuropsychological testing, augmenting significantly the prognosis accuracy.
\n\t\t
\n\t\t
\n\t\t\t
4. Functional magnetic resonance imaging (fMRI)
\n\t\t\t
It can be described as a non-invasive form (it does not require the injection of a paramagnetic contrast) of MRI. It measures the oxygen consumed by certain brain areas when they are challenged with specific stimuli or tasks. This technique has got a high spatial resolution and a rather acceptable temporal resolution too. Its major inconvenience is its high sensitivity to small head movements. It is carried out taking brain images during a specific activity and in basal state. Basal state activity is subtracted from the specific task activity to yield the specific brain areas where blood flow has increased due to the specific activity tested.
\n\t\t\t
fMRI physical foundation relies on the inherent magnetic properties of blood. Red blood cells (RBC) have a haemoglobin molecule which has an iron (Fe) atom in its centre. Oxygen binds to haemoglobin yielding oxihaemoglobin and haemoglobin configuration changes when oxygen is delivered to tissues (deoxihaemoglobin). Both oxihaemoglobin and deoxihaemoglobin have different paramagnetic properties. Deoxihaemoglobin will create an in-homogeneous magnetic field around itself which will lead to a decreased signal. In other words, when there is less deoxihaemoglobin (and more oxihaemoglobin) due to increased activity and subsequent increased blood flow and associated oxygen concentration within a specific area, there will be a greater signal. Blood oxygenation dependent level (BOLD) gives a variable signal intensity between stimulus and resting state. BOLD signal relies upon the different magnetic susceptibility of oxyhaemoglobin and deoxyhaemoglobin (Westbrook, 2000).
\n\t\t\t
Task testing is prepared according to paradigms. There is a huge variety of paradigms depending on the task. Broadly speaking these paradigms are classified into two main groups: “block design” or “event-related”. The former are characterized for stimulus presentation for a longer time while in the latter group they are presented for a shorter time and in an alternating fashion.
\n\t\t\t
Numerous studies have shown activation during memory tasks in the anterior hippocampal region in both healthy older adults and young people. This activation has a lesser extension in healthy older adults. On the other hand healthy young adults exhibit a greater activation of the prefrontal cortex and a lesser parietal cortex activation in comparison with older adults (Sperling, 2002).
\n\t\t\t
AD patients show a consistent decreased activation in hippocampal and parahippocampal areas in comparison with healthy controls (Pariente, 2005). Dickerson et al (2004) suggested the cognitive deterioration degree could be inferred from the hippocampal activation at the time of fMRI basal scanning; the more hippocampal activation, the greater the deterioration. Interestingly, an increased activity in some neocortical regions has also been described (Sperling, 2002). This may be understood as a hippocampal failure compensatory mechanism. In fact these frontal regions have been labelled “default mode network”, implying that AD patients would have difficulty in deactivating them (Buckner, 2005).
\n\t\t\t
There are few fMRI studies addressing the differences between MCI and healthy adults. Moreover, their results show disparity, from mesial temporal lobe hyperactivation (Dickerson, 2004) to hypoactivation (Johnson, 2005).
\n\t\t\t
\n\t\t\t\tDickerson et al (2004) have tried to clarify this issue and they state that whenever there is MCI, there is a compensatory hyperactivation, and both the extension and localization of this compensatory activity depends on memory tasks demands and memory performance. They also affirm that memory starts to fail in advanced MCI stages, which is shown by hippocampal hypoactivity. In this way they describe an fMRI activity non-linear trajectory in a patient which evolves from MCI to AD, presenting first a hyperactivity phase in pre-clinical stages followed by an activation decrease. This is what they called “inverse-U shape curve” (Sperling, 2007; Dickerson, 2008). This curve poses a problem if it is used as an AD biomarker, namely the brain activity pseudo-normalization when people with MCI start deteriorating more and at that moment they show a loss of the MCI characteristic hyperactivation. They conclude that if there is minimal clinical symptomatology and little atrophy of the mesial temporal lobe for a given degree of hyperactivation and more clinical symptomatology with greater mesial temporal atrophy for the same degree of activation, we are in the ascending and descending parts of the inverse-U shape curve.
\n\t\t\t
\n\t\t\t\tJohnson et al (2004) used a paradigm with repetitive presentation of faces to prove MCI patients do not show the same slope of decreasing hippocampal activity than in healthy older controls. This suggests a certain disruption of this adaptive response in the medial temporal lobe.
\n\t\t\t
\n\t\t\t\tDickerson (2008) stated the direct linear relation between the clinical deterioration and the extension of activity (measured as a function of the number of activated voxels) detected by fMRI both in hippocampus as in parahippocampus. Thus, a greater clinical deterioration correlates with a greater activity extension in the mesial temporal lobe which, in turn, correlates negatively with the degree of hippocampal atrophy.
\n\t\t\t
Amongst those studies where different patient groups have been compared (healthy ones, very mild MCI, MCI and AD), Celone et al (2006) stands out because of the strong correlation they found between the degree of preserved memory and the activity of mesial temporal areas and deactivation of precunneus and parietal cortex, using always a “default-mode network” approach.
\n\t\t
\n\t\t
\n\t\t\t
5. Diffusion tensor imaging (DTI)
\n\t\t\t
This technique is also known as diffusion MRI. Its underlying physical basis relies upon detection and quantification of the random movement of water known as the Brownian movement. Molecules undergoing the Brownian movement follow a chaotic route due to continuous impacts against other particles in their environment and their speed is directly proportional to the system temperature.
\n\t\t\t
Even though the system displacement induced by a single hydrogen molecule cannot be appreciated, the impacts of a great number of them generate a significant and quantifiable displacement of a chaotic nature. However it is possible to calculate the distance run by a particle in a given time through the formula: R=√6 D τ. D is the molecule diffusion coefficient, which is dependent on the temperature, while τ is the time interval. In biological tissues D is not the only cause of molecular movement since microcirculation, amongst other variables, throughout the capillary net has a diffusion increase net effect. This is the reason the term apparent diffusion coefficient (ADC) is used.
\n\t\t\t
When the diffusion in a structured system, such as the brain, is quantified, molecules displacement is limited by physical barriers. The latter make the displacement dependent upon direction (anisotropy). In a system without barriers a particle undergoing the Brownian movement can displace freely in any direction, with an isotropic diffusion. Whenever there are physical barriers, such as a membrane or axonal fibres, the particle loses movement freedom and the diffusion is therefore restricted (anisotropic).
\n\t\t\t
A set of DTI images permits the identification of a predominant direction of diffusion (anisotropy). The processing of diffusion values is carried out through a structure called tensor. A tensor can be defined as a set of co-existing magnitudes dependent upon direction and coordinates.
\n\t\t\t
Tractography permits the reconstruction and 3D visualization of the neuronal column structures. If is applied to white matter axon fibres, it provides information about connectivity and fibre deviations caused by tumours and infarcts (Martí-Bonmatí, 2007; Le Bihan et al, 2001; Melhem et al, 2002).
\n\t\t\t
In short, MRI water diffusion measurements include those images weighted in diffusion (DWI) and tensor diffusion (DTI). DWI provides a mean without direction (isotropic) of tissue water diffusivity. DWI is described in terms of ADC. ADC increases reflect neuronal loss and increased extracellular space, where water diffusion is faster, and it is an indirect indicator of grey or white matter integrity. DTI can be understood as an index of tissue permeability difference in different directions (anisotropic) and it is measured in terms of mean diffusivity (MD). Another important measurement to take into account is the anisotropic fraction (AF). AF is very sensitive in the evaluation of the microstructure integrity of the white matter. AF is obtained measuring water diffusivity along white matter long tracts (Ries et al, 2008).
\n\t\t\t
The use of diffusion techniques is justified because of the AD ethiopathogenic mechanism, e.g., β-amyloid depositions and neurofibrillary tangles. They seem to interfere with neuronal function at early stages producing a cascade of ultra-structural changes in axons. The resulting damage affects axonal transport, microtubules structure, neurofilaments and the integrity of the myelin sheath (Englund, 1981). All of these factors produce microstructural changes in the white matter which, in turn, affect the water protons diffusivity, a parameter measurable by DTI. This technique has the advantage of being very sensitive in detecting microstructural abnormalities, something not revealed by volumetric measurements.
\n\t\t\t
The loss of tissue organization causes a decrease in anisotrophy (or its correlate, AF). It is assumed that reduced water diffusion parallel to axonal tracts is indicative of axonal degeneration, disruption and partial breakdown of cytoarchitecture (Beaulieu, 2002) or demyelinating processes (Song et al, 2002), which modifies AF.
\n\t\t\t
We should focus on the corpus callosum (CC), the largest white matter structure in the brain. The CC provides inter-hemispheric communication and anterior-posterior connections which link cortical association areas. CC anisotropy decreases with age. Progressively reduced AF has been reported as part of the normal aging process (Sullivan et al, 2010). This AF decrease seems to follow an anterior-posterior gradient. The genu has a lower AF compared to the splenium. Several major white matter fibre bundles, including those connecting to the hippocampal structures, pass through the genu of the CC (Serra et al, 2010).
\n\t\t\t
Anatomical localization of AF reductions in amnestic MCI (aMCI) seems to be a robust finding across a variety of approaches. Thomann et al (2006) found an AF reduction in the rostral subregions and anterior body of the CC in MCI patients compared with healthy controls using region of interest (ROI) methods. Similarly Wang et al (2009) and DiPaola et al (2010), using voxel based morphometry (VBM), identified a density reduction in the genu in aMCI patients compared with healthy controls. Other researchers like Ukmar et al (2008), Cho et al (2008) or Parente et al (2008) found an AF reduction in MCI patients in the CC splenium. The splenium of the corpus callosum, crux of the fornix (Zhuang et al, 2010) and the cingulum were sensitive discriminators to differentiante between aMCI and normal subjects (Chua et al, 2008). Ortiz Alonso et al (2000) found a volume reduction of the anterior body, mid body and isthmus of the corpus callosum in a homogenous group of moderately advanced AD compared with healthy controls.
\n\t\t\t
Several theories have been proposed to explain the early involvement of frontal white matter in MCI. The pattern of white matter integrity disruption tends to follow an anterior-posterior gradient with greater damage noticeable in posterior regions in AD and MCI. The aMCI group showed significant macrostructural atrophy only in the anterior CC section. In the mild AD group this atrophy extended to posterior CC subsections and was accompanied by anterior and posterior microstructural modifications (Di Paola et al, 2010).
\n\t\t\t
It has been recently suggested that myelin breakdown is an important component of the illness process in AD (Bartzokis, 2004; DiPaola et al, 2010). According to this hypothesis late myelinating fibers should be more susceptible to myelin breakdown. This may constitute an alternative mechanism which may explain AD cortical progression in the direction opposite to myelination (Braak and Braak, 1997). Wallerian degeneration affects the posterior CC sub-region that gets afferent axons directly from those brain areas primarily affected in AD (temporoparietal regions). However the myelin breakdown process might affect the late myelination of the CC subregion, causing changes in the CC genu at early stages of the disease (DiPaola et al, 2010).
\n\t\t\t
Figure 2.
Coronal, sagital and axial planes DTIs showingAF differences between patients with MCI and controls.
\n\t\t\t
The controversial results concerning CC regional atrophy are most likely due to the methods adopted in various studies, such as different criteria used to select patients, different stages of the illness or variation in the number of participants. Those investigators who found that the genu was more adversely affected thought that earlier affectation of late maturing regions might be responsible, whereas others who found that the splenium was more affected said it might be due to the overall degenerative pattern occurring in the posterior circuitry of the temporal parietal areas.
\n\t\t\t
A positive correlation between AF values and MMSE scores has been demonstrated in several studies, arguing in favour that white matter degeneration has an impact in cognitive performance (Bozzali, 2002; Ukmar et al, 2008; Ortiz-Terán et al, submitted) Other studies (e.g., Sullivan et al, 2010) found a correlation between AF decline in the CC with performance on the alternate finger tapping test, which is a test of inter-hemispheric communication transference.
\n\t\t\t
DTI is more used nowadays for correct identification of dementia subtypes.
\n\t\t
\n\t\t
\n\t\t\t
6. Magnetic Resonance Spectroscopy (MRS)
\n\t\t\t
MRS is used to measure the levels of different metabolites in body tissues. It detects and quantifies resonance signals of certain molecules present at much lower concentrations (approximately 10-3 mol/gtissue) than water ones (circa 55 mol/gtissue). The metabolic profile of a concrete region within a specific organ can be obtained through a single voxel MRS (SVMRS) or through multivoxel MRS imaging. SVMRS provides a metabolic information average score within the selected voxel while multivoxel MRS provides, within a unique image acquisition, various molecular images which indicate the spatial distribution of different metabolites (Martí-Bonmatí, 2007).
\n\t\t\t
The major drawback of SVMRS is the lack of spatial information, though the magnetic field homogenization is excellent and, consequently, so is its spectralresolution. On the contrary, multivoxel MRS yields spatial distribution information of different metabolites but its magnetic field homogenization is rather complicated since the brain areas are bigger and their magnetic susceptibility differences greater. Hence the characterization of a given specific volume is more precise with SVMRS but multivoxel MRS generates additional molecular information about surrounding areas. The latter provides more information about the heterogeneity of the lesion, analyzes peripheral infiltrations and allows comparisons with contralateral areas (Martí-Bonmatí, 2007).
\n\t\t\t
The most common CNS metabolites measured with MRS are
\n\t\t\t
N-acetyl-aspartate (NAA), a neuronal marker localized in neurons and axons,
choline (Cho), a marker which indicates membrane changes,
Creatine/phosphocreatine (Cr/PCr), an index of energetic metabolism,
lactate (Lac), a final product of glycolisis generated because of oxidative metabolism failure which is found both in intra and extra-cellular compartments, but never found in healthy tissues,
myoinositol (mI), mainly found within astrocytes where it regulates the cell volume,
lipids (Lip) and polypeptides, mostly in myelin sheaths and cell membranes and
glutamine (Gln) and glutamate (Glu), important neurotransmitters involved in multiple synaptic processes which give complex signals because of their ubiquity, scalar coupling and multiple complexes therefore posing a real challenge for their quantification.
\n\t\t\t
In short, MRS is the only available technique for obtaining fast and simultaneous metabolic information in vivo and different molecular images within a single image acquisition. It is a reliable method for clinical molecular follow-up and studying therapeutic effectiveness in different diseases.
\n\t\t\t
Figure 3.
MRS in Alzheimer Disease Axial T2-weighted images from an AD patient (L, left) and a healthy control (R, right). These images show the left parietotemporooccipital region where the spectra was acquired, and the results are shown just below. Please note the differences between the two subjects in the mI.
\n\t\t\t
With regards to AD, and from the early nineties, MRS has become a frequently used technique. The typical 1H-MRS includes the following peaks: NAA, Cr/PCr, Cho containing compounds, Glu and mI. Most authors have opted for following up AD progression using voxels in the medial temporal lobe. However Kantarci et al (2002) states that from a biologic standpoint there is evidence from MR imaging, fluorine 18 (18F) fluoro-deoxy- glucose PET, amyloid ligand PET, and fMRI studies that the posterior cingulate gyri (bilaterally) and the inferior precuneate gyri exhibit atrophy, decreased metabolism, amyloid deposition and deactivation early in the course of AD (Whitwell et al, 2007; Petrella et al, 2007; Chetelat et al, 2003). Moreover, the quality and reliability of 1H MR spectra from these voxel locations are superior to those from the medial temporal lobe because of the close proximity of the medial temporal lobe to the skull base, an area susceptible to magnetic artefacts.
\n\t\t\t
Besides of the voxel location, NAA has been considered a prominent candidate for AD investigation and diagnosis since it is localized only in neurons and absent in glial tissue in mature brains (Simmons et al, 1991). Hence NAA is a general marker of neural integrity. The first ever described finding in relation to AD was a decrease in NAA concentration in the brain (Miller et al, 1993), a reduction positively correlated with the density of senile plaques and neurofibrillary tangles (Klunk et al, 1992). Because NAA is a neuronal metabolite, the reduction of NAA levels in patients with AD is the result of loss of neuronal components, neuronal function disruption, or both; these phenomena are strongly associated with increasing neurofibrillary degeneration. On the basis of the correlation between mitochondrial ATP production and NAA level, NAA production within the neuron is thought to be related to mitochondrial function (Bates et al, 1996).
\n\t\t\t
Both Shonk et al (1995b) and Kantarci et al (2000) described bilateral temporoparietal increase of Cr and mI concentrations as well as the mI/NAA ratio in AD. These authors also found significantly elevated mI and Cr concentrations in the parietal region in early AD stages while NAA remained largely unchanged. Based on these findings they suggested mI and Cr abnormalities could be detected with MRS prior to abnormalities in neocortical NAA (Shonk et al, 1995b). Nevertheless, only the mI/NAA ratio was capable of classifying AD and healthy controls without any overlap between the groups (Parnertti et al, 1997). Kantarci et al (2002) found a sensibility around 82% and a specificity ranging from 80 to 90% for MRS in classifying AD, clinically defined, and healthy controls.
\n\t\t\t
The observation of an increased mI concentration not coupled with a cortical NAA decrease had already been reported in a group of AD patients with a low MMSE score and, also, in a group of Down’s syndrome patients in the pre-dementia phase (Huang et al, 1999). Therefore mI, but not NAA, showed an inverse linear correlation with MMSE scores (Huang et al, 2001).
\n\t\t\t
The most plausible up-to-date explanation for the increased levels of mI in the brain of AD patients is the contribution of the glial component. Glia contains much higher concentrations of mI than neurons (Glanville et al, 1989) and gliosis may cause the increase in mI found in AD patients (Huang et al, 2001). This may suggest that glial proliferation is a sensitive measure of AD before neuronal loss, the latter reflected by NAA(Fig 3).
\n\t\t\t
\n\t\t\t\tShonk and Ross (1995a) had previously supported the aforementioned hypothesis by showing that adults with Down’s syndrome exhibited a significant elevation of mI before the onset of dementia without any concomitant reduction in NAA. On the other hand, cholinergic receptors in the CNS are believed to act in part through the phosphoinositide pathway (Honchar, 1990; Kennedy, 1990). Jolles et al (Jolles, 1992) showed a reduced activity of the inositol polyphosphate enzyme phosphatidyinositol kinase and postulated a specific defect in the inositol polyphosphate cascade in AD to such a degree that cholinergic activity could be affected. Ross et al (2005) summarized this evidence proposing that alterations in mI must have consequences for enzyme equilibrium and the metabolite concentrations in the inositol polyphosphate cascade. Accordingly, altered cholinergic sensitivity could be expected.
\n\t\t\t
During the last decade 1H MRS in vivo studies have consistently indicated NAA decreases and mI increases in patients with AD and aMCI (Valenzuela and Sachdev, 2001). The strongest association between MRS and anatomopathologic findings was observed when two metabolite ratios were combined to yield the NAA/mI ratio; this result suggests that NAA and mI have complementary roles in predicting AD pathology. As previously said, NAA is located primarily in neuron bodies, axons, and dendrites. Therefore, it is a sensitive marker for neuronal density or viability. In patients with amnestic MCI mI/Cr ratios are elevated but NAA/Cr ratios are only mildly decreased. These findings suggest that the mI/Cr ratio increase happens earlier than does the decrease in NAA/Cr ratio decrease in AD (Parnetti et al, 1997).
\n\t\t\t
In a recent 1H MRS study, Cho/Cr ratios longitudinally increased in patients with amnestic MCI who progressed to AD (Kantarci et al, 2007). In contrast, Cho/Cr ratios decreased in patients with amnestic MCI who remained stable.
Hippocampal mI/NAA increases were significantly larger than those in the posterior cingulate area (an area with a recognized relationship in the pathological progression of AD);
Hippocampal and posterior cingulated mI/NAA together provided valuable discrimination to differentiate AD, MCI and control groups and
there were significant correlations between mI/NAA in the hippocampus and the posterior cingulate area and MMSE scores.
\n\t\t\t
The posterior cingulate area suffered later neuropathological and spectroscopic changes.
\n\t\t\t
A reduced NAA was found in the right hippocampus (p = 0.01) in MCI patients while increased mI was reported in the left hippocampus (p = 0.02). mI/NAA ratios were higher in both right (p = 0.03) and left (p = 0.01) hippocampi of MCI subjects (Franczak et al, 2007). Greater mI concentrations have also been found in patients with MCI (Godbolt et al, 2006; Kantarci et al, 2000). Neuropathological studies of MCI have shown the existence of hippocampal damage. This goes along with the hypothesis that MCI is a transitional state between normal aging and AD. A recent study found reductions in NAA/mI ratios in presenilin 1 and amyloid precursor protein mutation carriers who have a nearly 100% risk of developing AD (Godbolt et al, 2006). Metastasio et al (2006) observed a significant a NAA/Cr decrease in the parietal white matter in a group of five patients who developed AD after being diagnosed with MCI. This was replicated by Pilatus et al (2009). Modrego et al (2005) identified the occipital cortex as the most sensitive area for NAA/Cr ratios. To summarize, MI/NAA ratio may be a useful biomarker for diagnosing MCI and it may help to commence early treatment in affected individuals (Franczak et al, 2007).
\n\t\t\t
In AD patients NAA levels may also return to normal within the first 6 weeks of treatment with donepezil (Krishnan et al, 2003). NAA is not just a marker for neuronal function and, possibly, neuronal mitochondrial function, but can also be a surrogate marker to evaluate progression and decline in neuronal integrity during the transition period from MCI to dementia.
\n\t\t\t
Other attempts to evaluate alternative metabolites have been done. Glu and Gln are decreased in the cingulate gyrus in AD patients (Antuono et al, 2001). However, the precise role of glutamate excitotoxicity in the development of MCI and AD remains largely unknown.
\n\t\t\t
In short, and in spite of the difficulties posed by the voxels localization in the mesial temporal lobe, this seems to be the best place to accurately discriminate between MCI and AD as well as measuring MCI progression. The most relevant metabolites in MCI and AD are mI and NAA. They also allow to correctly classify the patients between those two groups and to evaluate their response and treatment and disease progression.
Brain SPECT allows the study of regional cerebral blood flow (rCBF), which correlates at rest with the regional consumption of glucose and reflects neuronal activity. Thus, the rCBF indirectly reflects neural activity in each brain region, and allows the earlier detection of functional abnormalities, preceding the stage of symptomatic disease.
\n\t\t\t
The tracers currently used in the clinical practice are 99mTc-Hexamethyl-propylene-amine-oxime (99mTc-HMPAO), which is considered to be the most reliable SPECT method, and 99mTc-ethyl cysteinate dimer (99mTc-ECD). They enter cells due to their lipophilic character and remain trapped because of their conversion to hydrophilic compounds. Their incorporation is proportional to rCBF in the first few minutes after injection. Modifications in rCBF after injection do not change the initial distribution of the tracer because of its intracellular trapping (Farid et al, 2011).
\n\t\t\t
Both radiotracers have a similar behaviour, being captured in the brain, with a distribution pattern corresponding to the rCBF (Koyama et al, 1997). Brain SPECT reveals a specific pattern of abnormalities in AD by demonstrating reduced rCBF in the medial temporal, superior temporal, parietal, posterior cingulate cortex, and precuneus before becoming diffuse and affecting the frontal cortex in advanced stages (Farid et al, 2011).
\n\t\t\t
SPECT images represent the topography of physiopathologic changes in AD (Fig 4) and it is a promising diagnostic tool in the early diagnosis and its differentiation from other potentially treated causes of dementia such as normal pressure hydrocephalus or depression (Bartenstein et al, 1997).
\n\t\t\t
Figure 4.
SPECT in AD. Transversal slices of a 99mTc-ECD SPECT study in a patient with early AD. Bilateral temporal hipoperfusion and assymmetrical parietal hipoperfusion, more evident on the right cortex, can be seen
\n\t\t\t
\n\t\t\t\tHaxby et al (1985) were able to link metabolic function, measured with SPECT, with a variety of cognitive and behavioural domains, including memory.
\n\t\t
\n\t\t
\n\t\t\t
8. Positron emission tomography (PET)
\n\t\t\t
In the last decades there has been a progressive advance in the development of techniques able to explore neurophysiological and neurochemical processes in humans. Positron emission tomography (PET) is a powerful technique allowing the visualization of physiological and biochemical changes both in healthy and ill subjects. This type of unique information may not be available with structural brain imaging techniques. PET has been useful to elaborate the hypothesis of the pathogenesis of AD, in correlating symptoms with their biological markers and in studying individuals at increased risk (Giovacchini et al, 2011).
\n\t\t\t
Glucose is the main energy supply for the brain and its metabolism maintains ion gradients and glutamate turnover, and it is related to neuronal function at rest and during functional activation Its measurement by [18F]-2-fluoro-2-deoxy-D-glucose (18F-FDG) is based on phosphorylation of the tracer by hexokinase, which is the pivotal first step of that metabolic pathway. Measurement of regional cerebral glucose metabolism (rCMRglc) using 18F-FDG PET has become a standard technique in dementia research (Herholz et al, 2007). FDG PET is the approach most efficiently used in AD and MCI diagnosis.
\n\t\t\t
The visualization of metabolic abnormalities using 18F-FDG PET, reveals similar patterns to that of SPECT, with hipoactivity in temporal and parietal neocortex in association with AD, detected either by visual inspection or by conventional quantitative analyses selecting regions of interest (ROI).
\n\t\t\t
PET and SPECT studies using SPM-based image analysis methods have replicated temporoparietal neocortical hypoactivity findings in AD; moreover, these studies have been able to documentactivity decrements also in the medial temporal region (where the neuropathological process occurs first, with greatest severity and in the posterior cingulate gyrus and precuneus (Matsuda, 2001). That pattern of hypometabolism has been detected even in very early stages of AD (Fig 5) and in subjects at genetic risk for the disorder (Duran et al, 2007).
\n\t\t\t
As AD progresses, the frontal association cortex becomes involved, while cerebellum, striatum, basal ganglia, primary visual, and sensorial and motor cortex remain unaltered (Mosconi, 2005). Hemispherical asymmetries are often observed, especially at early stages of AD and may be attributed to co-morbidity factors (e.g., vascular brain disease) or compensatory mechanisms (e.g., neuroplasticity). This in vivo pattern of hypometabolism is found in the majority of clinically diagnosed AD patients and in over 85% pathologically confirmed AD cases (Mosconi et al, 2010).
\n\t\t\t
\n\t\t\t\t18F-FDG PET is therefore a useful diagnostic tool to identify the cause of dementia and to have a differential diagnosis with other diseases, and to determine the neurophysiological mechanisms underlying these pathologies. Table 2 shows the characteristic locations of hypometabolism according to different types of dementia. (Montz et al, 2002).
\n\t\t\t
\n\t\t\t\t18F-FDG PET is more sensitive than clinical criteria in the detection of AD and in the differential diagnosis with other dementias, reaching values of diagnostic accuracy between 80 and 100%, with sensitivity of 90-96 % and specificity of 67-97% for AD (Gambhir et al, 2001, Knopman et al, 2001\n\t\t\t\tSilverman et al, 1999).
\n\t\t\t
It should be noted that this technique has been helpful in diagnosing AD, irrespective of the degree of cognitive impairment. In fact, abnormal parietotemporal uptake patterns were
\n\t\t\t
Figure 5.
PET in AD. Transversal, coronal and sagital slices of a cerebral 18F-FDG study of a patient with mild cognitive impairment. Hypometabolism of bilateral temporal and parietal cortex including part of the posterior cingulate gyrus (left dominance) was observed, corresponding to incipient AD.
Parietal and superior/posterior temporal abnormalities; bilateral temporoparietal hypoperfusion (frontal lobe hypoperfusion may happen in conjuncion with temporoparietal hypoperfusion) Earliest changes in medial portion of parietal cortex, posterior cingulated or retrosplenial region
\n\t\t\t\t\t\t18F-FDG PET pattern of uptake in different types of dementia
\n\t\t\t
seen on 18F-FDG PET images obtained in asymptomatic members of families in which a familial form of early AD was present. Similarly, asymptomatic subjects with the apolipoprotein ε4 allele were found to have significantly less parietotemporal 18F-FDG uptake than those without this allele. 18F-FDG PET has also proved useful to follow the course of AD patients. A normal PET study indicates that pathologic progression of cognitive impairment during a 3-year follow-up period is unlikely to occur. In another study, investigators were able to predict the clinical course of patients with mild cognitive impairment by using 18F-FDG PET images obtained early in the course of disease (Hammoud et al, 2007).
\n\t\t\t
Few studies have directly compared brain perfusion SPECT and 18F-FDG PET in AD. Ishii et al. in 1999 compared 99mTc-ECD SPECT images with 18F-FDG PET images in the same ten patients with Alzheimer\'s disease.99mTc-ECD SPECT showed a reduction in parieto-temporal perfusion in 8 of the 10 patients, whereas 18F-FDG PET showed a reduction in temporoparietal metabolism in nine of them. The contrast between the radiotracer uptake in the sensorial and motor areas and that in the parietotemporal region was not as great in the ECD images as it was in the FDG images (Ishii et al, 1999). Messa et al, in 1994, performed 99mTc-HMPAO SPECT and 18F-FDG PET in patients with mild to moderate AD and in healthy control subjects. They reported that these techniques had similar abilities for visualizing decreased perfusion and metabolism in the temporoparietal cortex and similar diagnostic accuracies (Messa et al, 1994). In 2002, Herholz et al. showed good correlation between 18F-FDG PET and 99mTc-HMPAO SPECT for detecting changes in the temporoparietal cortex in mild to moderate AD by using voxel-based statistical image analysis (Herholz et al, 2002), although 18F-FDG PET demonstrated a more robust differentiation of patients with AD from healthy volunteers than did SPECT (Matsuda, 2007).
\n\t\t\t
The meta-analysis performed by Yuan et al. in 2008 comparing results of 18F-FDG PET, SPECT and structural MR imaging to predict conversion to AD in patients with mild cognitive impairment, including data from 1112 patients,showed that 18F-FDG PET had moderately better concordancewith follow-up results for the prediction of conversion. Approximately88.9% of the patients with progressive mild cognitive impairment wereconsidered affected by 18F-FDG PET, whereas 84.9% of stable patientshad negative 18F-FDG PET (Yuan et al, 2008).
\n\t\t\t
Another method for in vivo assessment of the extent of AD is the use of new radiotracers including the amyloid PET tracer Pittsburgh Compound B (11C-PIB) for visualizing fibers Aβ (Morris et al, 2009, Kadir et al, 2011) or 2-(1-{6-[(18F-fluoroethyl)(methyl)amino]-2naphthyl}ethylidene) malononitrile (18F-FDDNP) that has been reported to label not only amyloid but also neurofibrillary tangles (Tolboom et al, 2009), and these methods have generated new possibilities for early diagnosis of brain impairments.
\n\t\t\t
The first attempt to image brain Aβ accumulation in AD was reported by Friedland et al. in 1997 using a monoclonal antibody fragment labelled with 99mTc for single SPECT. This first attempt failed, but it was fundamental for subsequent efforts (Friedland et al, 1997). The second used PET, and the report of this work was published in 2002 (Shoghi-Jadid et al, 2002). The radiotracer used was 18F-FDDNP but had the disadvantage of a limited experience worldwide (Klunk & Mathis, 2008). The third study of in vivo Aβ imaging with 11C-PIB, was reported in 2004 (Klunk et al, 2004).
\n\t\t\t
The quantity of radiotracer measured must be proportional to the amount of Aβ in that area and there must be sufficient signal-to-noise ratio to detect the tracer when levels of Aβ have become clinically significant. There are some published data for PIB demonstrating these properties both in vivo and in post-mortem studies (Klunk et al, 2005, Maeda et al, 2007, Wiley et al, 2009). There is no doubt that the validation of an in-vivo Aβ tracer needs in-vivo–post-mortem correlation study in humans. 11C-PIB has the advantage of not showing significant changes over 2 years during clinical AD (Engler et al, 2006).
\n\t\t\t
Several tracers including 18F-BAY94-9172 (Wang et al, 2011) (figure 3), 18F-AV-45, 18F-AH110690, 18F-3′F-PiB, 11C-AZD2995 and 11C-AZD2184 have recently been or soon will be used in multi-centre phase II or phase III trials.
\n\t\t\t
To understand the behaviour of a tracer in neurodegenerative disease, it is important to note that the population should include not only patients with AD or healthy controls. Studies on populations with mild cognitive impairment, early onset familial autosomal dominant AD, Parkinson’s disease, Lewy body disease, fronto-temporal dementia, cerebral amyloid angiopathy, prion disease and other atypical dementias and cognitively normal aging contribute to our understanding of Aβ imaging with 11C-PIB. A third principle for acceptance should be widely available of any Aβ imaging tracer.
\n\t\t\t
The leading difference between these radionuclides is their decay ‘half-life’. The decay half-live of carbon-11 is 20 min and that of fluorine-18 is 110 min. The main advantage of carbon-11 is that it decays so rapidly that sequential imaging studies in the same patient can be performed on the same day, thus, a 11C-PIB study can be followed by a study using 18F-Fluorodeoxyglucose (FDG). This would require two different days with a fluorine-18-labeled Aβ tracer. However, the 110 min half-life of fluorine-18 allows distribution within a 2–4 h travel radius. Thus, the need for a good fluorine-18 Aβ imaging tracer is mainly a matter of widening the availability. The properties of 11C-PIB appear quite sufficient for imaging Aβ with a carbon-11 tracer, so the current goal is to obtain a fluorine-18 tracer with similar characteristics to those of 11C-PIB (Klunk & Mathis, 2008).
\n\t\t\t
To conclude about these two nuclear medicine brain imaging approaches (SPECT and PET), SPECT with 99mTc-HMPAO and 99mTc-ECD and 18F-FDG PET are very useful diagnostic tools for early diagnosis of AD, even in pre-clinical stages. Posterior cingulated hypometabolism, measured with SPECT, may help to predict progression from MCI to AD. Some authors have stated that SPECT can be highly accurate in identifying the type of dementia (Read et al, 1995). The severity of temporoparietal metabolism impairment, measured by FDG PET, is helpful to distinguish those people with a progressive course of their condition from those who have a non-progressive course. This is useful for delivering MCI prognosis. The development of new radiotracers able to demonstrate the presence of Aβ plaques in AD patients, will improve the specificity of those methods. Finally, it is worth mentioning these nuclear medicine neuroimaging methods can serve as surrogate markers in clinical trials of therapeutic agents (Mueller et al, 2005; Teipel et al, 2006).
\n\t\t
\n\t\t
\n\t\t\t
9. Magnetoencephalography (MEG)
\n\t\t\t
MEG is a non-invasive technique that allows recording the magnetic fields generated by the human brain. MEG provides an excellent temporal resolution up to milliseconds, magnitude orders better than in other methods for measuring cerebral activity, such as CT, MRI, SPECT or PET (Hämäläinen et al, 1993). It generates functional maps with delimitation of cerebral structures in the range of few cm and, even, cubic millimeters. Therefore these functional maps can be organized both temporal and spatially. MEG signal is generated by synchronous oscillations of pyramidal neurons; the MEG detects slightly different features of the simultaneous electromagnetic brain activity and MEG power represents the activity of a given number of neurons discharging synchronously.
\n\t\t\t
Some MEG background activity abnormalities in moderate and severe AD have been observed. AD patients show a decrease of MEG coherence values (Berendse et al, 2000). This biological marker is accompanied by a slowed MEG activity which becomes evident when analyzing the power spectral density of selected frequency bands. In this way, spontaneous MEG activity shows increased slow rhythms and reduced fast activity in AD patients compared with healthy subjects (Berendse et al, 2000; Fernández et al, 2002; Osipova et al, 2005).
\n\t\t\t
It has been proposed that such slowing might be due to an increase in activation of low frequency oscillators rather than slowing of existing sources (Osipova et al, 2005). Fernández et al (2002) analyzed the presence of low frequency magnetic activity (delta and theta bands) associated with AD degeneration. Their results showed that people with AD had a significant increase of this type of frequencies in the temporoparietal area greater in the left hemisphere. Moreover, the values of low frequency were associated with the cognitive and functional state of these patients. Temporoparietal delta activity predicted the scores in mental status scales such as MMSE or CAMCOG. Delta activity in right parietal areas allowed predicting the functional status (FAST stage). Fernández et al (2006C) replicated previous studies stating that temporoparietal low frequency plays a key role in the process that leads from MCI to AD. There is a slow and practically linear low frequency activity from normal aging to dementia where MCI has an intermediate position. This study, once the parietal low frequency was defined as the most relevant feature to characterize these patients, carried a follow-up study of the people with MCI. The next step was to find out if MCI patients with more marked low frequency had more probability to evolve into AD. This group showed that people with MCI and higher parietal delta activity had 3,5 times more chance to develop AD (Fernández et al, 2006A). Broadly speaking, from the perspective of spontaneous MEG activity, one can say that a tendency towards brain activity slowing means a higher risk to develop dementia.
\n\t\t\t
\n\t\t\t\tFernandez et al (2006B) carried out adetailed analysis of spontaneous MEG activity spectral changes where the frequencies spectrum 2-60 Hz was subdivided “microscopically” in 2 Hz bands. The relative power of these micro-bands was then calculated. This approach served to overcome the difficulties in comparing data with previous literature, since there is some variation in establishing the limits of traditional EEG bands. A narrow temporoparietal 20-22 Hz band differentiated clearly the AD group from healthy elderly people and was correlated with the cognitive status.
\n\t\t\t
MCI is an ideal target for this type of studies because the rate to progression to AD in healthy elderly people is about 1-2 % yearly, but in the MCI group this rate is 10-15 %. In fact AD and MCI share some characteristics which make difficult to establish a dividing line between both of them. Essentially anyone diagnosed with MCI will exhibit some cognitive impairments, specifically in the memory domain, that can be measured objectively but allow this patient to carry out a normal lifestyle. Therefore he cannot be diagnosed as suffering from dementia. Because of this fact many authors consider MCI as an intermediate or transitional state between normal aging and AD.
\n\t\t\t
Once MCI was chosen as a target, we did a first study following-up a series of normal elderly people for two years. We realized those patients developing MCI had a MEG activity reduction in medial temporal regions during a memory task compared with those who had normal aging (Maestú et al, 2006). Along this line Poza et al (2007) evaluated the discriminative power of five measures extracted from the MEG power spectrum. The best one of them was the spectral mean frequency (sensitivity = 85%, specificity = 85.71%), thus confirming the presence of spectral slowing in AD. Spectral changes can also be characterized in terms of ratios between powers in different frequency bands. In a later study Poza et al (2008)showed that a ratio of relative power in fast bands (alpha, beta and gamma) and slow ones (delta, theta) had a 75% sensitivity and a 95% specificity for the same purpose. A comparison of spectral median frequency with various nonlinear measures indicated median frequency was the single best discriminator between AD patients and controls (Hornero et al, 2008).
\n\t\t\t
Another important issue during basal MEG, as well as during basal EEG, is brain complexity. Some authors have found a global decrease in irregularity and complexity in AD during basal (rest) MEG recordings (Poza et al, 2007; Gomez et al, 2006). However, the loss of complexity has been only proven in the high frequencies when a detailed spectral analysis in several frequency bands was performed.(van Cappellen et al, 2003).
\n\t\t\t
Other approaches have focused on analyzing functional connections rather than local abnormalities in AD. A decrease of coherence values in the alpha band (Franciotti et al, 2006) and a general decrease of coherence in all frequency bands (Berendse et al, 2000) have been described. A reduced level of synchronization has also been reported in the upper alpha, beta, and gamma bands of AD patients in comparison with controls suggesting a loss of functional connectivity (Stam et al, 2002). Using resting MEG some authors have shown functional connectivity in AD is characterized by specific changes of long and short distance interactions in several frequency bands (Stam et al, 2006). Decreased levels of functional connectivity point towards the relationship of AD with an abnormal function of the large scale brain networks.
\n\t\t\t
Recently Fernández et al (2010) have shown AD non-linear analysis is characterized by a reduced complexity and connectivity. They calculated Lempel-Ziv complexity (LZC) values and found that MCI patients exhibited intermediary LZC scores between AD patients and healthy controls. A combination of age and posterior LZC scores allowed AD-MCI discrimination whereas no LZC score allowed MCI-healthy controls discrimination. AD patients and controls showed a parallel tendency towards diminished LZC scores as a function of age, but MCI patients did not exhibit such “normal” tendency. Accordingly, anterior LZC scores allowed MCI-healthy controls discrimination for subjects below 75 years. People with MCI exhibited a qualitatively distinct relationship between aging and complexity reduction, with scores higher than controls in older individuals. This fact might be considered a compensatory mechanism in MCI before fully established dementia.
\n\t\t\t
A third type of MEG studies is through brain synchronicity. There is increasing evidence that ubiquously distributed neural systems may communicate through synchronization of their activity. Synchronization here refers to the existence of a consistent relationship between activity patterns of two or more spatially separated neuronal groups. Synchronization can be defined at action potentials level or at oscillatory activity one. Synchronization in different frequency bands has been associated with various cognitive functions and the integration of information in the healthy brain (Stam, 2001).
\n\t\t\t
Using the synchronization likelihood as a measure of functional connectivity, a loss of functional interactions between brain regions in alpha, beta and gamma bands was demonstrated in AD patients (Stam et al, 2002). In the same study coherence analysis did not show any significant differences between AD patients and controls, suggesting that nonlinear coupling might play a role. In a further analysis of the same data, van Cappellen et al (2003) showed that a neural complexity measure was increased in AD in both delta and theta bands, whereas the multichannel correlation dimension was increased in the beta band; these results argue against a simple concept of ‘loss of complexity’ in AD and suggest a pattern of decreases as well as increases of functional connectivity in different frequency bands. This pattern was subsequently elucidated in another study showing a loss of mainly long distance left hemisphere functional connectivity in low alpha and beta bands, and an increase in parietal theta and occipito-parietal beta/gamma connectivity in AD patients compared to controls (Stam et al, 2006). The preferential loss of left hemisphere connectivity is interesting because some researchers (Osipova et al, 2003; Fernandez et al, 2006) have suggested a left hemisphere vulnerability rather characteristic. The increased connectivity in occipital and parietal areas is remarkable. Possibly, these changes could also reflect a kind of compensatory mechanism. Coherence analysis of the same data showed a roughly comparable pattern of changes. Furthermore, inter-hemispheric alpha band synchronization likelihood was significantly correlated with the MMSE score, suggesting the functional significance of these resting-state measurements.
\n\t\t\t
A problem of functional connectivity studies based upon correlations between raw EEG or MEG signals is a single source is often picked up by many sensors, giving rise to spurious correlations. This volume conduction problem can be solved by special measures such as the phase lag index, which eliminates possible contributions from common sources, and reflects more accurately true interactions between distributed brain areas, reconstructed functional brain networks (Stam et al, 2007). This approach allows the classification of networks on a scale ranging from completely ordered to completely random. It was shown that in the alpha band brain networks in AD were more random than brain networks of healthy controls. Finally, using a modeling approach, it could be shown that the process that gives rise to abnormal brain networks in AD probably attacks critical connections between networks hubs preferentially.
\n\t\t\t
Lastly, cognitive function studies through magnetic evoked potentials have been widely used both in MCI and AD. The MEG activity pattern during cognitive task is significantly altered (Maestú et al., 2001). A study showed greater MEG parietotemporal activity in the left hemisphere during a memory task in healthy elderly people compared with AD patients. The latter showed a reduction of MEG activity accompanied by an anomalous localization in frontal areas. This activation profile can predict performance in cognitive tests such as the MMSE or CAMCOG, as well as with daily life functional outcomes. Thus a lesser parieto-temporal activation during a memory task is associated o lower scores in cognitive tests, what makes MEG a functional neuroimaging technique useful for diagnosis.
\n\t\t\t
In combining MEG with volumetry data obtained from MRI, we have found a direct relationship between hippocampal atrophy with both an increased magnetic activity of low frequency (Fernández et al, 2003) and a decreased magnetic dipoles during a memory task (Maestú et al, 2003).
\n\t\t\t
A relevant aspect is studying those MEG normal changes which are part of normal aging. We have studied elderly people at different ages and we have found a cortical reorganization as age progresses (Maestú et al., 2004). Besga et al (2010) also found that hippocampal volume reduction allowed the discrimination between AD and MCI patients as compared with controls. The percentage of correct classification was 91.3% when AD patients versus controls were compared, and 83.3% in the case of MCI versus controls. MEG data showed that AD patients exhibit higher theta and delta activity than MCI and controls. Such higher activity was significant in parietal, temporal, and occipital areas. Left parietal theta classified correctly MCI patients (vs controls) in 78.3% of the occasions. Right occipital theta and the left parietal delta allowed correctly discrimination of AD patients (vs controls) at a 81.8% rate. Left parietal theta discriminated between AD and MCI in 56.6% of the occasions. In addition, the combination of both techniques significantly improved the rate of correct classification, thus indicating that a multidisciplinary perspective of techniques may improve the diagnostic capabilities (Besga et al, 2010).
\n\t\t\t
\n\t\t\t\tOsipova et al (2006) used source estimation of ongoing MEG oscillations to detect changes in subjects with MCI. In this study, the distribution of alpha sources did not differ between subjects with MCI and healthy elderly controls. Maestú et al (2006) suggested MEG can provide useful information about the risk of developing MCI. They recorded MEG during a memory task in 15 healthy subjects. Five of these subjects developed MCI after two years. These subjects were characterized by abnormal low frequency activity in the left temporal lobe in the initial recording. The MEG mean frequency power spectrum in MCI subjects was decreased compared to healthy controls, and increased compared to Alzheimer patients (Fernández et al, 2006 A). This suggests once more MCI is, in some respects, an intermediate state between health and AD. Furthermore, an average decrease of 0.17 Hz/year of the mean frequency in healthy subjects was shown. Slowing of MEG in MCI could be related to the risk of developing AD.
\n\t\t
\n\t\t
\n\t\t\t
10. Conclusion
\n\t\t\t
Along this chapter we have highlighted some issues in relation to MCI. MCI is less known from the brain imaging point of view than AD. The high chance to progress from MCI to AD indicates the need to do more studies on this domain. MRS and those neuroimaging techniques based on neurophysiological measurements, e.g. MEG, can throw light on this area.
\n\t\t\t
Brain imaging techniques have not reached a point yet where they can provide the confirmatory diagnosis of AD. However the likelihood of suspicion of AD can be enhanced by these methods. Table 3 summarizes these brain imaging techniques in AD and MCI.
Poor correlation with changes in function and metabolic findings
\n\t\t\t\t\t\t
Volumetry and ROI volumetry can be useful, even more so longitudinally
\n\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
fMRI
\n\t\t\t\t\t\t
Gives insight into cognitive performance
\n\t\t\t\t\t\t
Conflicting results
\n\t\t\t\t\t\t
Can be useful as well, but results interpretation may be difficult
\n\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
DTI
\n\t\t\t\t\t\t
Can assess structural connectivity
\n\t\t\t\t\t\t
Utility not proven
\n\t\t\t\t\t\t
AF reductions in aMCI is a robust finding
\n\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
Spectroscopy
\n\t\t\t\t\t\t
Provides information about brain chemical content
\n\t\t\t\t\t\t
Utility not proven
\n\t\t\t\t\t\t
NAA and mI may measure progression from MCI to AD
\n\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
SPECT
\n\t\t\t\t\t\t
Low cost compared with PET
\n\t\t\t\t\t\t
Mediocre resolution Radiation exposure
\n\t\t\t\t\t\t
Limited utility
\n\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
PET
\n\t\t\t\t\t\t
Can detect metabolic changes in AD
\n\t\t\t\t\t\t
Expensive Lack of availability
\n\t\t\t\t\t\t
Most useful tool to differentiate AD from MCI, so far
\n\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
PET-amyloid
\n\t\t\t\t\t\t
Detects most specific metabolic change linked to diagnosis
\n\t\t\t\t\t\t
Difficult interpretation as neurometabolic changes may antecede disease
\n\t\t\t\t\t\t
Can be a risk biomarker, but results interpretation may be difficult
\n\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t
MEG
\n\t\t\t\t\t\t
Gives insight into cognitive performance High temporal resolution
\n\t\t\t\t\t\t
Very expensive
\n\t\t\t\t\t\t
Some usefulness for this purpose has been demonstrated
\n\t\t\t\t\t
\n\t\t\t\t
Table 3.
CT = computerized tomography; MRI = magnetic resonance imaging; fMRI = functional magnetic resonance imaging; DTI = diffusion tensor imaging; SPECT = single-photon emission computed tomography; PET = positron emission tomography; MEG = magnetoencephalography; NAA = N-acetyl aspartate; mI = myoinositol; AD = Alzheimer’s disease; MCI = mild cognitive impairment; ROI = region of interest
Comparison of different brain imaging techniques for AD, with relative advantages and disadvantages, and usefulness for AD-MCI differentiation
\n\t\t\t
Structural MRI is nowadays a standard technique for this purpose, but cheaper techniques, such as CT, may still play a role, even more so in underdeveloped countries. Structural brain imaging, such as CT or MRI, is quite useful for the differential diagnosis of AD with non-neurodegenerative diseases. PET and SPECT are not sufficiently accurate to replace clinical judgment, though they supplement the diagnosis of AD and MCI and help to improve the accuracy of diagnosis. Neuroimaging can be very useful for differentiating AD from frontotemporal dementia as well.
\n\t\t\t
At this moment the rest of the neuroimaging techniques previously mentioned are more used for research than for clinical purposes. Part of the problem is that the brain imaging sensitivities and relative utility of each one of them in AD and MCI are not clearly established. The bulk of neuroimaging research in AD continues to be centered on glucose metabolism, perfusion and tissue content. In the future it is likely the functional neuroimaging techniques will continue to expand. Their refinement will bring greater clarity in the diagnosis of AD as well in the MCI status. Combination of brain images approaches, some of them at least based on molecular issues, such as amyloid imaging, may be promising.
\n\t\t
\n\t
Acknowledgments
\n\t\t\t
The authors would like to thank Professor Gabriel A. de Erausquin (University of Southern Florida, Tampa, USA) for his invaluable help in the preparation of this manuscript. They also would like to thank Professor Daniel G. Herrera (Harvard University, Boston, USA) and Dr. Carlos Chada Castro (Hospital de Menorca, Spain) for their helpful comments and suggestions in preparing this manuscript.
\n\t\t
\n',keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/19242.pdf",chapterXML:"https://mts.intechopen.com/source/xml/19242.xml",downloadPdfUrl:"/chapter/pdf-download/19242",previewPdfUrl:"/chapter/pdf-preview/19242",totalDownloads:1959,totalViews:357,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,dateSubmitted:"October 18th 2010",dateReviewed:"July 1st 2011",datePrePublished:null,datePublished:"September 6th 2011",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/19242",risUrl:"/chapter/ris/19242",book:{slug:"the-clinical-spectrum-of-alzheimer-s-disease-the-charge-toward-comprehensive-diagnostic-and-therapeutic-strategies"},signatures:"Laura Ortiz-Terán, Juan MR Santos, María de las Nieves Cabrera Martín and Tomás Ortiz Alonso",authors:[{id:"26990",title:"Prof.",name:"Tomas",middleName:null,surname:"Ortiz",fullName:"Tomas Ortiz",slug:"tomas-ortiz",email:"tortiz@med.ucm.es",position:null,institution:null},{id:"42082",title:"Dr.",name:"Laura",middleName:null,surname:"Ortiz-Terán",fullName:"Laura Ortiz-Terán",slug:"laura-ortiz-teran",email:"lauraortizteran@gmail.com",position:null,institution:null},{id:"42083",title:"Prof.",name:"Juan M",middleName:null,surname:"Santos",fullName:"Juan M Santos",slug:"juan-m-santos",email:"juanmatiassantos@med.ucm.es",position:null,institution:null},{id:"42084",title:"Dr.",name:"María Nieves",middleName:null,surname:"Cabrera-Martín",fullName:"María Nieves Cabrera-Martín",slug:"maria-nieves-cabrera-martin",email:"mncabreram@hotmail.com",position:null,institution:null}],sections:[{id:"sec_1",title:"1. Introduction ",level:"1"},{id:"sec_1_2",title:"1.1. Computerized Tomography (CT) ",level:"2"},{id:"sec_2_2",title:"1.2. Magnetic Resonance Imaging (MRI) ",level:"2"},{id:"sec_2_3",title:"1.2.1. Structural MRI",level:"3"},{id:"sec_3_3",title:"1.2.2. Functional MRI (fMRI) ",level:"3"},{id:"sec_5_2",title:"1.3. Diffusion Tensor Imaging (DTI) ",level:"2"},{id:"sec_6_2",title:"1.4. Spectroscopy ",level:"2"},{id:"sec_7_2",title:"1.5. Nuclear medicine brain imaging techniques ",level:"2"},{id:"sec_7_3",title:"1.5.1. Single-photon emission computed tomography (SPECT) ",level:"3"},{id:"sec_8_3",title:"1.5.2. Positron emission tomography (PET) ",level:"3"},{id:"sec_10_2",title:"1.6. Magnetoencephalography (MEG) ",level:"2"},{id:"sec_12",title:"2. Computed Tomography (CT) ",level:"1"},{id:"sec_13",title:"3. Structural magnetic resonance imaging (MRI) ",level:"1"},{id:"sec_14",title:"4. Functional magnetic resonance imaging (fMRI) ",level:"1"},{id:"sec_15",title:"5. Diffusion tensor imaging (DTI) ",level:"1"},{id:"sec_16",title:"6. Magnetic Resonance Spectroscopy (MRS) ",level:"1"},{id:"sec_17",title:"7. Single-photon emission computed tomography (SPECT) ",level:"1"},{id:"sec_18",title:"8. Positron emission tomography (PET) ",level:"1"},{id:"sec_19",title:"9. Magnetoencephalography (MEG) ",level:"1"},{id:"sec_20",title:"10. Conclusion ",level:"1"},{id:"sec_21",title:"Acknowledgments",level:"1"}],chapterReferences:[{id:"B1",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAntuono\n\t\t\t\t\t\t\tP. G.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJones\n\t\t\t\t\t\t\tJ. L.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWang\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2001\n\t\t\t\t\tDecreased glutamate and glutamine in Alzheimer’s disease detected in vivo with H-MRS at 0.5 T\n\t\t\t\t\tNeurology, 56, 737\n\t\t\t\t\t742\n\t\t\t\t\n\t\t\t'},{id:"B2",body:'\n\t\t\t\t\n\t\t\t\t\tApostolova LG, Dutton RA, Dinov ID et al.\n\t\t\t\t\t2006\n\t\t\t\t\tConversion of Mild Cognitive Impairment to Alzheimer Disease Predicted by Hippocampal Atrophy Maps.\n\t\t\t\t\tArchives of Neurology\n\t\t\t\t\t693\n\t\t\t\t\t699\n\t\t\t\t\n\t\t\t'},{id:"B3",body:'\n\t\t\t\t\n\t\t\t\t\tApostolova LG, Steiner CA, Akopyan GG et al.\n\t\t\t\t\t2007D grey matter atrophy mapping in mild cognitive impairment and mild Alzheimer’s disease. Archives of Neurology, 64, 1489\n\t\t\t\t\t1495\n\t\t\t\t\n\t\t\t'},{id:"B4",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBartenstein\n\t\t\t\t\t\t\tP.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMinoshima\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHirsch\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1997\n\t\t\t\t\tQuantitative assessment of cerebral blood flow in patients with Alzheimer’s disease by SPECT.\n\t\t\t\t\tJournal of Nuclear Medicine, 8 (7), 1095\n\t\t\t\t\t1101\n\t\t\t\t\n\t\t\t'},{id:"B5",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBartzokis\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2004\n\t\t\t\t\tAge-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease.\n\t\t\t\t\tNeurobiology of Aging\n\t\t\t\t\t5\n\t\t\t\t\t18\n\t\t\t\t\n\t\t\t'},{id:"B6",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBates\n\t\t\t\t\t\t\tT. E.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tStrangward\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKeelan\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1996\n\t\t\t\t\tInhibition of N-acetylaspartate production implications for 1H MRS studies in vivo.\n\t\t\t\t\tNeuroreport\n\t\t\t\t\t1397\n\t\t\t\t\t1400\n\t\t\t\t\n\t\t\t'},{id:"B7",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBeaulieu\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2002The basis of anisotropic water diffusion in the nervous system: a technical review. NMR in Biomedicine, 15, 435\n\t\t\t\t\t455\n\t\t\t\t\n\t\t\t'},{id:"B8",body:'\n\t\t\t\t\n\t\t\t\t\tBecker JT, Davis SW, Hayashi KM et al.\n\t\t\t\t\t2006\n\t\t\t\t\tThree-dimensional Patterns of Hippocampal Atrophy in Mild Cognitive Impairment.\n\t\t\t\t\tArchives of Neurology\n\t\t\t\t\t97\n\t\t\t\t\t101\n\t\t\t\t\n\t\t\t'},{id:"B9",body:'\n\t\t\t\t\n\t\t\t\t\tBerendse HW, Verbunt JPA, Scheltens PH et al.\n\t\t\t\t\t2000\n\t\t\t\t\tMagnetoencephalographic analysis of cortical activity in Alzheimer’s disease. A pilot study.Clinical Neurophysiology, 111, 604\n\t\t\t\t\t612\n\t\t\t\t\n\t\t\t'},{id:"B10",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBesga\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tOrtiz\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tStructural and functional patterns in healthy aging, mild cognitive impairment, and Alzheimer disease\n\t\t\t\t\tAlzheimer Disease and Associated Disorders\n\t\t\t\t\t1\n\t\t\t\t\t10\n\t\t\t\t\n\t\t\t'},{id:"B11",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBozzali\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2002\n\t\t\t\t\tWhite matter damage in Alzheimer’s disease assessed in vivo using diffusion tensor magnetic resonance imaging\n\t\t\t\t\tJournal of Neurology, Neurosurgery, and Psychiatry, 72 (6), 742\n\t\t\t\t\t746\n\t\t\t\t\n\t\t\t'},{id:"B12",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBozzali\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFilippi\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMagnani\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tThe contribution of voxel-based morphometry in staging patients with mild cognitive impairment.\n\t\t\t\t\tNeurology\n\t\t\t\t\t453\n\t\t\t\t\t460\n\t\t\t\t\n\t\t\t'},{id:"B13",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBraak\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBraak\n\t\t\t\t\t\t\tE.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t1997\n\t\t\t\t\tFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories.\n\t\t\t\t\tNeurobiology of Aging\n\t\t\t\t\t351\n\t\t\t\t\t357\n\t\t\t\t\n\t\t\t'},{id:"B14",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBrun\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEnglund\n\t\t\t\t\t\t\tE.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t1981\n\t\t\t\t\tRegional pattern of degeneration in Alzheimer’s disease: neuronal loss and histopathological grading.\n\t\t\t\t\tHistopathology, 5, 549\n\t\t\t\t\t564\n\t\t\t\t\n\t\t\t'},{id:"B15",body:'\n\t\t\t\t\n\t\t\t\t\tBuckner RL, Snyder AZ, Nyder et al.\n\t\t\t\t\t2005Molecular,structural, and functional characterization of Alzheimer’s disease, evidence for a relationship between default activity, amyloid, and memory. Journal of. Neuroscience, 25, 7709\n\t\t\t\t\t7717\n\t\t\t\t\n\t\t\t'},{id:"B16",body:'\n\t\t\t\t\n\t\t\t\t\tCelone KA, Calhoun VD, Dickerson BC et al.\n\t\t\t\t\t2006\n\t\t\t\t\tAlterations in memory networks in mild cognitive impairment and Alzheimer’s disease: An independent component analysis\n\t\t\t\t\tJournal of Neuroscience, 26, 10222\n\t\t\t\t\t10231\n\t\t\t\t\n\t\t\t'},{id:"B17",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tChetelat\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDesgranges\n\t\t\t\t\t\t\tB.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tde la Sayette\n\t\t\t\t\t\t\tV.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2003Mild cognitive impairment, can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology, 60, 1374\n\t\t\t\t\t1377\n\t\t\t\t\n\t\t\t'},{id:"B18",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tChetelat\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLandeau\n\t\t\t\t\t\t\tB.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEustache\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2005\n\t\t\t\t\tUsing voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study.\n\t\t\t\t\tNeuroimage\n\t\t\t\t\t934\n\t\t\t\t\t946\n\t\t\t\t\n\t\t\t'},{id:"B19",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCho\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tYang\n\t\t\t\t\t\t\tD. W.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tShon\n\t\t\t\t\t\t\tY. M.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t(2008\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2008\n\t\t\t\t\tAbnormal Integrity of Corticocortical Tracts in Mild Cognitive Impairment, A Diffusion Tensor Imaging Study\n\t\t\t\t\tJournal of Korean Medical Science, 23, 477\n\t\t\t\t\t483\n\t\t\t\t\n\t\t\t'},{id:"B20",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tChua\n\t\t\t\t\t\t\tT. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWen\n\t\t\t\t\t\t\tW.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMJ\n\t\t\t\t\t\t\tSlavin\n\t\t\t\t\t\t\tet.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tal\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2008\n\t\t\t\t\tDiffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease, a review\n\t\t\t\t\tCurrent Opinion in Neurology\n\t\t\t\t\t83\n\t\t\t\t\t92\n\t\t\t\t\n\t\t\t'},{id:"B21",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCsernansky\n\t\t\t\t\t\t\tJ. G.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWang\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJoshi\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2000\n\t\t\t\t\tEarly DAT is distinguished from aging by high-dimensional mapping of the hippocampusDementia of the Alzheimer type. Neurology\n\t\t\t\t\t1636\n\t\t\t\t\t1643\n\t\t\t\t\n\t\t\t'},{id:"B22",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDe Carli\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKaye\n\t\t\t\t\t\t\tJ. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHorwitz\n\t\t\t\t\t\t\tB.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1990\n\t\t\t\t\tCritical analysis of the use of computer-assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type.\n\t\t\t\t\tNeurology\n\t\t\t\t\t872\n\t\t\t\t\t878\n\t\t\t\t\n\t\t\t'},{id:"B23",body:'\n\t\t\t\t\n\t\t\t\t\tDe Leon MJ, George AE, Stylopoulos LA et al.\n\t\t\t\t\t1989\n\t\t\t\t\tEarly marker for Alzheimer’s disease, the atrophic hippocampus.\n\t\t\t\t\tLancetii, 672\n\t\t\t\t\t673\n\t\t\t\t\n\t\t\t'},{id:"B24",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDe Toledo-Morrell\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tStoub\n\t\t\t\t\t\t\tT. R.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBulgakova\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2004\n\t\t\t\t\tMRI-derived entorhinal volume is a good predictor of conversion from MCI to AD.\n\t\t\t\t\tNeurobiology of Aging\n\t\t\t\t\t1197\n\t\t\t\t\t1203\n\t\t\t\t\n\t\t\t'},{id:"B25",body:'\n\t\t\t\t\n\t\t\t\t\tDickerson BC, Salat DH, Bates JF et al.\n\t\t\t\t\t2004\n\t\t\t\t\tMedial temporal lobe function and structure in mild cognitive impairment.\n\t\t\t\t\tAnnals of Neurology\n\t\t\t\t\t27\n\t\t\t\t\t35\n\t\t\t\t\n\t\t\t'},{id:"B26",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDickerson\n\t\t\t\t\t\t\tB.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSperling\n\t\t\t\t\t\t\tR. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2008\n\t\t\t\t\tFunctional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer’s disease: Insights from functional MRI Studies\n\t\t\t\t\tNeuropsychologia\n\t\t\t\t\t1624\n\t\t\t\t\t1635\n\t\t\t\t\n\t\t\t'},{id:"B27",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDi Paola\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLuders\n\t\t\t\t\t\t\tE.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDi Iulio\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tCallosal atrophy in mild cognitive impairment and Alzheimer’s disease: Different effects in different stages\n\t\t\t\t\tNeuroimage\n\t\t\t\t\t49\n\t\t\t\t\t141\n\t\t\t\t\t149\n\t\t\t\t\n\t\t\t'},{id:"B28",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDi Paola\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDi Iulio\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCherubini\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tWhen, where, and how the corpus callosum changes in MCI and AD: A multimodal MRI study.\n\t\t\t\t\tNeurology, 74 (14), 1136\n\t\t\t\t\t1142\n\t\t\t\t\n\t\t\t'},{id:"B29",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDi Paola\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSpalletta\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCaltagirone\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tIn vivo structural neuroanatomy of corpus callosum in Alzheimer’s disease and mild cognitive impairment using different MRI techniques: a review\n\t\t\t\t\tJournal of Alzheimer’s Disease, 20 (1), 67\n\t\t\t\t\t95\n\t\t\t\t\n\t\t\t'},{id:"B30",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDu\n\t\t\t\t\t\t\tA. T.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSchuff\n\t\t\t\t\t\t\tN.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAmend\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2001\n\t\t\t\t\tMagnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease\n\t\t\t\t\tJournal of Neurology, Neurosurgery, and Psychiatry, 71, 441\n\t\t\t\t\t447\n\t\t\t\t\n\t\t\t'},{id:"B31",body:'\n\t\t\t\t\n\t\t\t\t\tDuran FL, Zampieri FG, Bottino CC et al.\n\t\t\t\t\t2007\n\t\t\t\t\tVoxel-based investigations of regional cerebral blood flow abnormalities in Alzheimer´s disease using a single-detector SPECT system.\n\t\t\t\t\tClinics (Sao Paulo), 62 (4), 377\n\t\t\t\t\t384\n\t\t\t\t\n\t\t\t'},{id:"B32",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEngler\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tForsberg\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAlmkvist\n\t\t\t\t\t\t\tO.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tTwo-year follow-up of amyloid deposition in patients with Alzheimer’s disease.\n\t\t\t\t\tBrain, 129 (11), 2856\n\t\t\t\t\t2866\n\t\t\t\t\n\t\t\t'},{id:"B33",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFarid\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCaillat-Vigneron\n\t\t\t\t\t\t\tN.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSibon\n\t\t\t\t\t\t\tI.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2011Is brain SPECT useful in degenerative dementia diagnosis? Journal of Computer Assisted Tomography, 35 (1), 1\n\t\t\t\t\t3\n\t\t\t\t\n\t\t\t'},{id:"B34",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMaestú\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAmo\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2002\n\t\t\t\t\tFocal temporoparietal slow activity in Alzheimer’s disease revealed by magnetoencephalography\n\t\t\t\t\tBiological Psychiatry, 52, 764\n\t\t\t\t\t770\n\t\t\t\t\n\t\t\t'},{id:"B35",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tArrazola\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMaestú\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2003\n\t\t\t\t\tCorrelations of hippocampal atrophy and focal low-frequency magnetic activity in Alzheimer disease, volumetric MR imaging: a magnetoencephalographic study.\n\t\t\t\t\tAmerican Journal of Neuroradiology, 24, 481\n\t\t\t\t\t487\n\t\t\t\t\n\t\t\t'},{id:"B36",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGarcía-Segura\n\t\t\t\t\t\t\tJ. M.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tOrtiz\n\t\t\t\t\t\t\tT.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2005\n\t\t\t\t\tProton Magnetic Resonance Spectroscopy and Magnetoencephalographic Estimation of Delta Dipole Density: A Combination of Techniques That May Contribute to the Diagnosis of Alzheimer’s Disease\n\t\t\t\t\tDementia and Geriatric Cognitive Disorders\n\t\t\t\t\t20\n\t\t\t\t\t169\n\t\t\t\t\t177\n\t\t\t\t\n\t\t\t'},{id:"B37",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHornero\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMayo\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006Quantitative magnetoencephalography of spontaneous brain activity in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 20, 153\n\t\t\t\t\t159C)\n\t\t\t'},{id:"B38",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernandez\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHornero\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMayo\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tMEG spectral profile in Alzheimer’s disease and mild cognitive impairment\n\t\t\t\t\tClinical Neurophysiology\n\t\t\t\t\t306\n\t\t\t\t\t314A)\n\t\t\t'},{id:"B39",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernandez\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTurrero\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tZuluaga\n\t\t\t\t\t\t\tP.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tMagnetoencephalographic parietal delta dipole density in mild cognitive impairment. Preliminary results of a method to estimate the risk of developing Alzheimer disease.\n\t\t\t\t\tArchives of Neurology\n\t\t\t\t\t427\n\t\t\t\t\t430B)\n\t\t\t'},{id:"B40",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHornero\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGómez\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tComplexity analysis of spontaneous brain activity in Alzheimer disease and mild cognitive impairment: an MEG study\n\t\t\t\t\tAlzheimer Disease and Associated Disorders\n\t\t\t\t\t182\n\t\t\t\t\t189\n\t\t\t\t\n\t\t\t'},{id:"B41",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFranciotti\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tIacono\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDella Penna\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tCortical rhythms reactivity in AD, LBD and normal subjects. A quantitative MEG study\n\t\t\t\t\tNeurobiology of Aging\n\t\t\t\t\t1100\n\t\t\t\t\t1109\n\t\t\t\t\n\t\t\t'},{id:"B42",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFriedland\n\t\t\t\t\t\t\tR. P.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKalaria\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBerridge\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1997\n\t\t\t\t\tNeuroimaging of vessel amyloid in Alzheimer’s disease.\n\t\t\t\t\tAnnals of the New York Academy of Sciences\n\t\t\t\t\t242\n\t\t\t\t\t247\n\t\t\t\t\n\t\t\t'},{id:"B43",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGambhir\n\t\t\t\t\t\t\tS. S.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCzermin\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSchwimmer\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2001\n\t\t\t\t\tA tabulated summary of the FDG PET literature\n\t\t\t\t\tJournal of Nuclear Medicine, 42, 5 Suppl, 1S\n\t\t\t\t\t93S\n\t\t\t\t\n\t\t\t'},{id:"B44",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGiovacchini\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSquitieri\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEsmaeilzadeh\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2011\n\t\t\t\t\tPET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research.\n\t\t\t\t\tJournal of Cellular Physiology\n\t\t\t\t\t948\n\t\t\t\t\t961\n\t\t\t\t\n\t\t\t'},{id:"B45",body:'\n\t\t\t\t\n\t\t\t\t\tGlanville NT, Byers DM, Cook HW et al.\n\t\t\t\t\t1989\n\t\t\t\t\tDifferences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin.\n\t\t\t\t\tBiochimica et Biophysica Acta\n\t\t\t\t\t169\n\t\t\t\t\t179\n\t\t\t\t\n\t\t\t'},{id:"B46",body:'\n\t\t\t\t\n\t\t\t\t\tGodbolt AK, Waldman AD, Macmanus DG et al.\n\t\t\t\t\t2006MRS shows abnormalities before symptoms in familiar Alzheimer disease. Neurology, 66, 718\n\t\t\t\t\t722\n\t\t\t\t\n\t\t\t'},{id:"B47",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGomez\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHornero\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAbasolo\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tComplexity analysis of the magnetoencephalogram background activity in Alzheimer’s disease patients\n\t\t\t\t\tMedical Engineering & Pysics, 28, 851\n\t\t\t\t\t859\n\t\t\t\t\n\t\t\t'},{id:"B48",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGrothe\n\t\t\t\t\t\t\tN.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tZaborszky\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAtienza\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tReduction of basal forebrain cholinergic systems parallels cognitive impairment in patients at high risk of developing Alzheimer’s disease. Cerebral Cortex, 20, 7, 1685\n\t\t\t\t\t1695\n\t\t\t\t\n\t\t\t'},{id:"B49",body:'\n\t\t\t\tHämäläinen M, Hari R, Ilmoniemi RJ et al. (1993). Magnetoencephalograpy: theory, instrumentation, and applications to noninvasive studies of the working human brain. Reviews of Modern Physics, 65 (1993) 413\n\t\t\t\t\t497\n\t\t\t\t\n\t\t\t'},{id:"B50",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHamalainen\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTervo\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGrau-Olivares\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2007\n\t\t\t\t\tVoxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment\n\t\t\t\t\tNeuroimage\n\t\t\t\t\t1122\n\t\t\t\t\t1131\n\t\t\t\t\n\t\t\t'},{id:"B51",body:'\n\t\t\t\t\n\t\t\t\t\tHammoud DA, Hoffman JM & Pomper MG.\n\t\t\t\t\t2007Molecular neuroimaging: from conventional to emerging techniques.Radiology, 245, 1, 21\n\t\t\t\t\t42\n\t\t\t\t\n\t\t\t'},{id:"B52",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHaxby\n\t\t\t\t\t\t\tJ. V.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDuara\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGrady\n\t\t\t\t\t\t\tC. L.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1985Relations between neuropcyhological and cerebral metabolic assymetries in early Alzheimer’s disease. Journal of Cerebral Blood Flow and Metabolism, 5, 193\n\t\t\t\t\t200\n\t\t\t\t\n\t\t\t'},{id:"B53",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHerholz\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSchopphoff\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSchmidt\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2002\n\t\t\t\t\tDirect comparison of spatially normalized PET and SPECT scans in Alzheimer’s disease.\n\t\t\t\t\tJournal of Nuclear Medicine, 43, 1, 21\n\t\t\t\t\t26\n\t\t\t\t\n\t\t\t'},{id:"B54",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHerholz\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWeisenbach\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tZündorf\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2004\n\t\t\t\t\tIn vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease.\n\t\t\t\t\tNeuroimage\n\t\t\t\t\t136\n\t\t\t\t\t143\n\t\t\t\t\n\t\t\t'},{id:"B55",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHerholz\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCarter\n\t\t\t\t\t\t\tS. F. .\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJones\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2007Positron emission tomography imaging in dementia. The British Journal of Radiology, 80, 2 (supplS160\n\t\t\t\t\tS167\n\t\t\t\t\n\t\t\t'},{id:"B56",body:'\n\t\t\t\t\n\t\t\t\t\tHonchar MP, Vogler GP, Gish BG et al.\n\t\t\t\t\t1990Evidence that phosphoinositide metabo- lism in rat cerebral cortex stimulated by pilo- carpine, physostigmine and pargyline in vivo is not changed by chronic lithium treatment. Neurochemistry, 55, 1521\n\t\t\t\t\t1525\n\t\t\t\t\n\t\t\t'},{id:"B57",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHornero\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEscudero\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2008\n\t\t\t\t\tSpectral and nonlinear analyses of MEG background activity in patients with Alzheimer’s disease\n\t\t\t\t\tIEEE Transactions on Biomedical Engineering\n\t\t\t\t\t1658\n\t\t\t\t\t1665\n\t\t\t\t\n\t\t\t'},{id:"B58",body:'\n\t\t\t\tHuang W, Alexander GE, Daly EM et al. (1999). High brain myoinositol levels in the predementia phase of Alzheimer’s disease in adults with Down’s syndrome: A 1H MRS study. American Journal of Psychiatry, 156, 1879\n\t\t\t\t\t1886\n\t\t\t\t\n\t\t\t'},{id:"B59",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHuang\n\t\t\t\t\t\t\tW.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAlexander\n\t\t\t\t\t\t\tG. E.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tChang\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2001\n\t\t\t\t\tBrain metabolite concentration and dementia severity in Alzheimer’s disease, a 1H-MRS study.\n\t\t\t\t\tNeurology\n\t\t\t\t\t626\n\t\t\t\t\t632\n\t\t\t\t\n\t\t\t'},{id:"B60",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tIshii\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSasaki\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSakamoto\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1999\n\t\t\t\t\tTc-99m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy-D-glucose PET in Alzheimer’s disease. Comparison of perfusion and metabolic patterns.\n\t\t\t\t\tClinical Nuclear Medicine\n\t\t\t\t\t572\n\t\t\t\t\t575\n\t\t\t\t\n\t\t\t'},{id:"B61",body:'\n\t\t\t\t\n\t\t\t\t\tJack CR Jr, Shiung MM, Gunter JL et al.\n\t\t\t\t\t2004\n\t\t\t\t\tComparison of different MRI brain atrophy rate measures with clinical disease progression in AD.\n\t\t\t\t\tNeurology\n\t\t\t\t\t591\n\t\t\t\t\t600\n\t\t\t\t\n\t\t\t'},{id:"B62",body:'\n\t\t\t\t\n\t\t\t\t\tJack CR Jr, Shiung MM, Weigand SD et al.\n\t\t\t\t\t2005\n\t\t\t\t\tBrain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.\n\t\t\t\t\tNeurology\n\t\t\t\t\t1227\n\t\t\t\t\t1231\n\t\t\t\t\n\t\t\t'},{id:"B63",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJessen\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGür\n\t\t\t\t\t\t\tO.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBlock\n\t\t\t\t\t\t\tW.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2009\n\t\t\t\t\tA multicenter 1H-MRS study of the medial temporal lobe in AD and MCI.\n\t\t\t\t\tNeurology\n\t\t\t\t\t72\n\t\t\t\t\t1735\n\t\t\t\t\t1740\n\t\t\t\t\n\t\t\t'},{id:"B64",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJohnson\n\t\t\t\t\t\t\tS. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBaxter\n\t\t\t\t\t\t\tL. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSusskind-Wilder\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2004\n\t\t\t\t\tHippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment.\n\t\t\t\t\tNeuropsychologia\n\t\t\t\t\t980\n\t\t\t\t\t989\n\t\t\t\t\n\t\t\t'},{id:"B65",body:'\n\t\t\t\t\n\t\t\t\t\tJohnson SC, Schmitz TW, Moritz CH et al.\n\t\t\t\t\t2005\n\t\t\t\t\tActivation of brain regions vulnerable to Alzheimer’s disease: the effect of mild cognitive impairment\n\t\t\t\t\tNeurobiology of Aging\n\t\t\t\t\t1604\n\t\t\t\t\t1612\n\t\t\t\t\n\t\t\t'},{id:"B66",body:'\n\t\t\t\tJolles J, Bothmer J, Markerink M et al. (1992). Journal of Neurochemistry, 58, Phosphatidylinositol kinase is reduced in Alzheimer’s disease.\n\t\t\t\t\t2326\n\t\t\t\t\t2329\n\t\t\t\t\n\t\t\t'},{id:"B67",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJuottonen\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLaakso\n\t\t\t\t\t\t\tM. P.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPartanen\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1999\n\t\t\t\t\tComparative MR Analysis of the Entorhinal Cortex and Hippocampus in Diagnosing Alzheimer Disease.\n\t\t\t\t\tAmerican Journal of Neuroradiology, 20, 139\n\t\t\t\t\t144\n\t\t\t\t\n\t\t\t'},{id:"B68",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKadir\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMarutle\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGonzalez\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2011Positron emision tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburg Compound B positron emission tomography patient with Alzheimer´s disease. Brain, 134, 1, 301\n\t\t\t\t\t317\n\t\t\t\t\n\t\t\t'},{id:"B69",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKantarci\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJack\n\t\t\t\t\t\t\tC. R.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJr Xu\n\t\t\t\t\t\t\tY. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2000\n\t\t\t\t\tRegional metabolic patterns in mild cognitive impairment and Alzheimer’s disease, A 1H MRS study.\n\t\t\t\t\tNeurology\n\t\t\t\t\t210\n\t\t\t\t\t217\n\t\t\t\t\n\t\t\t'},{id:"B70",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKantarci\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tXu\n\t\t\t\t\t\t\tY.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMM\n\t\t\t\t\t\t\tShiung\n\t\t\t\t\t\t\tet.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tal\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2002\n\t\t\t\t\tComparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer’s disease\n\t\t\t\t\tDementia and Geriatric Cognitive Disorders\n\t\t\t\t\t198\n\t\t\t\t\t207\n\t\t\t\t\n\t\t\t'},{id:"B71",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKantarci\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tReynolds\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPetersen\n\t\t\t\t\t\t\tR. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2003\n\t\t\t\t\tProton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.\n\t\t\t\t\tAmerican Journal of Neuroradiology, 24\n\t\t\t\t\t843\n\t\t\t\t\t849\n\t\t\t\t\n\t\t\t'},{id:"B72",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKantarci\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWeigand\n\t\t\t\t\t\t\tS. D.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPetersen\n\t\t\t\t\t\t\tR. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2007Longitudinal (1)H MRS changes in mild cognitive impairment and Alzheimer’s disease. Neurobiology of Aging, 28, 1330\n\t\t\t\t\t1339\n\t\t\t\t\n\t\t\t'},{id:"B73",body:'\n\t\t\t\t\n\t\t\t\t\tKennedy ED, Chaliss JRA, Ragan CL et al.\n\t\t\t\t\t1990\n\t\t\t\t\tReduced inositol polyphosphate accumulation and inositol supply induced by lithium in stimulated cerebral cortex slices.\n\t\t\t\t\tBiochemistry Journal, 267, 781\n\t\t\t\t\t786\n\t\t\t\t\n\t\t\t'},{id:"B74",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKido\n\t\t\t\t\t\t\tD. K.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCaine\n\t\t\t\t\t\t\tE. D.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLe May\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1989\n\t\t\t\t\tTemporal lobe atrophy in patients with Alzheimer disease, a CT study.\n\t\t\t\t\tAmerican Journal of Neuroradiology, 10, 551\n\t\t\t\t\t555\n\t\t\t\t\n\t\t\t'},{id:"B75",body:'\n\t\t\t\tKinkingnéhun S, Sarazin M, Lehéricy S et al. (2008).VBM anticipates the rate of progression of Alzheimer disease: a 3-year longitudinal study.Neurology, 70 (23), 2201-2211\n\t\t\t'},{id:"B76",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKlunk\n\t\t\t\t\t\t\tW. E.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPanchalingan\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMoosy\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1992N-acetyl-aspartate and other amino acid metabolites in Alzheimer’s disease brain: a preliminary proton nuclear magnetic resonance study. Neurology\n\t\t\t\t\t1578\n\t\t\t\t\t1585\n\t\t\t\t\n\t\t\t'},{id:"B77",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKlunk\n\t\t\t\t\t\t\tW. E.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tEngler\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tNordberg\n\t\t\t\t\t\t\tet.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tal\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2004\n\t\t\t\t\tImaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B.\n\t\t\t\t\tAnnals ofNeurology, 55, 3, 306\n\t\t\t\t\t319\n\t\t\t\t\n\t\t\t'},{id:"B78",body:'\n\t\t\t\t\n\t\t\t\t\tKlunk WE, Lopresti BJ, Ikonomovic MD et al.\n\t\t\t\t\t2005\n\t\t\t\t\tBinding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain.\n\t\t\t\t\tJournal of Neuroscience, 25, 46, 10598\n\t\t\t\t\t10606\n\t\t\t\t\n\t\t\t'},{id:"B79",body:'\n\t\t\t\t\n\t\t\t\t\tKlunk WE&Mathis CA.\n\t\t\t\t\t2008\n\t\t\t\t\tThe future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation\n\t\t\t\t\tCurrent Opinion in Neurology\n\t\t\t\t\t683\n\t\t\t\t\t687\n\t\t\t\t\n\t\t\t'},{id:"B80",body:'\n\t\t\t\t\n\t\t\t\t\tKnopman DS, DeKosky ST, Cummings JL et al.\n\t\t\t\t\t2001\n\t\t\t\t\tPractice parameter, diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.\n\t\t\t\t\tNeurology56,9,1143\n\t\t\t\t\t1153\n\t\t\t\t\n\t\t\t'},{id:"B81",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKoyama\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKawashima\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tIto\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1997\n\t\t\t\t\tSPECT imaging of normal subjects with technetium-99m-HMPAO and technetium-99m-ECD\n\t\t\t\t\tJournal of Nuclear Medicine, 38, 4, 587\n\t\t\t\t\t592\n\t\t\t\t\n\t\t\t'},{id:"B82",body:'\n\t\t\t\tKrishnan KR, Charles HC, Doraiswamy PM et al. (2003). Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. American Journal of Psychiatry, 160, 2003\n\t\t\t\t\t2011\n\t\t\t\t\n\t\t\t'},{id:"B83",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLassen\n\t\t\t\t\t\t\tN. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMunck\n\t\t\t\t\t\t\tO.\n\t\t\t\t\t\t\n\t\t\t\t\tThe cerebral blood flow in man determined by the use of radiactive Krypton. (1955\n\t\t\t\t\tActa Physiologica Scandinavica, 33, 1 30\n\t\t\t\t\t40\n\t\t\t\t\n\t\t\t'},{id:"B84",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLe Bihan\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMangin\n\t\t\t\t\t\t\tJ. F.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPoupon\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2001\n\t\t\t\t\tDiffusion Tensor Imaging. Journal of Magnetic Resonance Imaging, 13, 534\n\t\t\t\t\t546\n\t\t\t\t\n\t\t\t'},{id:"B85",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLerch\n\t\t\t\t\t\t\tJ. P.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPruessner\n\t\t\t\t\t\t\tJ. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tZijdenbos\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2005\n\t\t\t\t\tFocal decline of cortical thickness in Alzheimer’s disease identified by computational neuroanatomy.\n\t\t\t\t\tCerebral Cortex, 15, 995\n\t\t\t\t\t1001\n\t\t\t\t\n\t\t\t'},{id:"B86",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMaeda\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJi\n\t\t\t\t\t\t\tB.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tIrie\n\t\t\t\t\t\t\tT.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2007Longitudinal, quantitative assessment of amyloid, neuroinflammation, and antiamyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. Journal of Neuroscience, 27, 41, 10957\n\t\t\t\t\t10968\n\t\t\t\t\n\t\t\t'},{id:"B87",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMaestú\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSimos\n\t\t\t\t\t\t\tP. G.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2001\n\t\t\t\t\tSpatio-temporal patterns of brain magnetic activity during a memory task in Alzheimer’s disease.\n\t\t\t\t\tNeuroreport\n\t\t\t\t\t3917\n\t\t\t\t\t3922\n\t\t\t\t\n\t\t\t'},{id:"B88",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMaestú\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tArrazola\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2003Do cognitive patterns of brain magnetic activity correlate with hippocampal atrophy in Alzheimer’s disease? Jouranl of Neurology, Neurosurgery, and Psychiatry, 74, 208\n\t\t\t\t\t212\n\t\t\t\t\n\t\t\t'},{id:"B89",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMaestú\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSimos\n\t\t\t\t\t\t\tP. G.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2004\n\t\t\t\t\tProfiles of brain magnetic activity during a memory task in patients with Alzheimer’s disease and in non-demented elderly subjects, with or without depression\n\t\t\t\t\tJournal of Neurology, Neurosurgery, and Psychiatry, 75, 1160\n\t\t\t\t\t1662\n\t\t\t\t\n\t\t\t'},{id:"B90",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMaestú\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGarcía-Segura\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tOrtiz\n\t\t\t\t\t\t\tT.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2005\n\t\t\t\t\tEvidence of Biochemical and Biomagnetic Interactions in Alzheimer’s Disease: An MEG and MR Spectroscopy Study\n\t\t\t\t\tDementia and Geriatric Cognitive Disorders\n\t\t\t\t\t145\n\t\t\t\t\t152\n\t\t\t\t\n\t\t\t'},{id:"B91",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMaestú\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCampo\n\t\t\t\t\t\t\tP.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGil-Gregorio\n\t\t\t\t\t\t\tP.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tMedial temporal lobe neuromagnetic hypoactivation and risk for developing cognitive decline in elderly population: a 2-year follow up study\n\t\t\t\t\tNeurobiology of Aging\n\t\t\t\t\t32\n\t\t\t\t\t37\n\t\t\t\t\n\t\t\t'},{id:"B92",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMartí-Bonmatí\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMoratal\n\t\t\t\t\t\t\tPérez. D.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCelda\n\t\t\t\t\t\t\tVázquez. B.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2007\n\t\t\t\t\tAprendiendo los fundamentos de la resonancia magnética, Editorial Médica Panamericana 13978847903899Madrid (Spain)\n\t\t\t'},{id:"B93",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMatsuda\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2001\n\t\t\t\t\tCerebral blood flow and metabolic abnormalities in Alzheimer’s disease.\n\t\t\t\t\tAnnals of Nuclear Medicine\n\t\t\t\t\t85\n\t\t\t\t\t92\n\t\t\t\t\n\t\t\t'},{id:"B94",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMatsuda\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2007\n\t\t\t\t\tRole of neuroimaging in Alzheimer’s disease, with emphasis on brain perfusion SPECT.\n\t\t\t\t\tJournal of Nuclear Medicine, 48, 8, 1289\n\t\t\t\t\t1130\n\t\t\t\t\n\t\t\t'},{id:"B95",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tMelhem\n\t\t\t\t\t\tE. R.\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tMori\n\t\t\t\t\t\tS.\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tMukundan\n\t\t\t\t\t\tG.\n\t\t\t\t\t\n\t\t\t\t (2002). Diffusion tensor MR Imaging of the brain and White matter tractography. American. Jouranl of Radiology, 178, 3\n\t\t\t\t16\n\n\t\t\t'},{id:"B96",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMessa\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPerani\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLucignani\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1994\n\t\t\t\t\tHigh-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer’s disease: comparison with fluorine-18-FDG PET.\n\t\t\t\t\tJournal of Nuclear Medicine, 35, 2, 210\n\t\t\t\t\t216\n\t\t\t\t\n\t\t\t'},{id:"B97",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMiller\n\t\t\t\t\t\t\tB.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMoats\n\t\t\t\t\t\t\tR. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tShonk\n\t\t\t\t\t\t\tT.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1993Alzheimer’s disease, depiction of increased cerebral myoinositol with proton MR spectroscopy. Radiology, 187, 433\n\t\t\t\t\t437\n\t\t\t\t\n\t\t\t'},{id:"B98",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMontz\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJiménez\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCoullaut\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2002\n\t\t\t\t\tPET in neurology and psychiatry I. PET with FDG in the study of the CNS\n\t\t\t\t\tRevista Española de Medicina Nuclear, 21, 5, 370\n\t\t\t\t\t386\n\t\t\t\t\n\t\t\t'},{id:"B99",body:'\n\t\t\t\t\n\t\t\t\t\tMorris JC, Roe CM, Grant EA et al.\n\t\t\t\t\t2009Pittsburgh compound B imaging predicts progression from cognitively normal to symptomatic Alzheimer´s disease. Archives of Neurology, 66, 12, 1469\n\t\t\t\t\t1475\n\t\t\t\t\n\t\t\t'},{id:"B100",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMosconi\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2005\n\t\t\t\t\tBrain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease.\n\t\t\t\t\tEuropean Journal of Nuclear Medicine and Molecular Imaging\n\t\t\t\t\t486\n\t\t\t\t\t510\n\t\t\t\t\n\t\t\t'},{id:"B101",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMosconi\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBertia\n\t\t\t\t\t\t\tV.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGlodzika\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tPre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging\n\t\t\t\t\tJournal of Alzheimer´s Disease, 20\n\t\t\t\t\t3\n\t\t\t\t\t843\n\t\t\t\t\t854\n\t\t\t\t\n\t\t\t'},{id:"B102",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMueller\n\t\t\t\t\t\t\tS. G.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWeiner\n\t\t\t\t\t\t\tM. W.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tThal\n\t\t\t\t\t\t\tL. J.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tet\n\t\t\t\t\t\t\ta.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2005\n\t\t\t\t\tWays towards an early diagnosis of Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI)\n\t\t\t\t\tAlzheimer’s Dementia, 1, 55\n\t\t\t\t\t66\n\t\t\t\t\n\t\t\t'},{id:"B103",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tOrtiz\n\t\t\t\t\t\t\tAlonso. T.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMartínez\n\t\t\t\t\t\t\tCastillo. E.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFernández\n\t\t\t\t\t\t\tLucas. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2000Callosal atrophy and associated electromyographyc responses in Alzheimer’s disease and aging. Electromyography and Clinical Neurophysiology, 40, 465\n\t\t\t\t\t475\n\t\t\t\t\n\t\t\t'},{id:"B104",body:'\n\t\t\t\tOsipova D, Ahveninen J, Kaakkola S et al. (2003) Clinical Neurophysiology, 114, Effects of scopolamine on MEG spectral power and coherence in elderly subjects\n\t\t\t\t\t1902\n\t\t\t\t\t1907\n\t\t\t\t\n\t\t\t'},{id:"B105",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tOsipova\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAhveninen\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJensen\n\t\t\t\t\t\t\tO.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2005\n\t\t\t\t\tAltered generation of spontaneous oscillations in Alzheimer’s disease,\n\t\t\t\t\tNeuroimage\n\t\t\t\t\t835\n\t\t\t\t\t841\n\t\t\t\t\n\t\t\t'},{id:"B106",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tOsipova\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRantanen\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAhveninen\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tSource estimation of spontaneous MEG oscillations in mild cognitive impairment\n\t\t\t\t\tNeuroscience Letters\n\t\t\t\t\t57\n\t\t\t\t\t61\n\t\t\t\t\n\t\t\t'},{id:"B107",body:'\n\t\t\t\t\n\t\t\t\t\tParente DB, Gasparetto EL, da Cruz LC Jr et al.\n\t\t\t\t\t2008\n\t\t\t\t\tPotential role of diffusion tensor MRI in the differential diagnosis of mild cognitive impairment and Alzheimer’s disease\n\t\t\t\t\tAmerican Journal of Roentgenology\n\t\t\t\t\t1369\n\t\t\t\t\n\t\t\t'},{id:"B108",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPariente\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCole\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHenson\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2005Alzheimer’s patients engage an alternative network during a memory task. Annals of Neurology\n\t\t\t\t\t870\n\t\t\t\t\t879\n\t\t\t\t\n\t\t\t'},{id:"B109",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tParnetti\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTarducci\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPresciutti\n\t\t\t\t\t\t\tO.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1997\n\t\t\t\t\tProton magnetic resonance spectroscopy can differentiate Alzheimer’s disease from normal aging.\n\t\t\t\t\tMechanisms of Ageing and Development\n\t\t\t\t\t9\n\t\t\t\t\t14\n\t\t\t\t\n\t\t\t'},{id:"B110",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPennanen\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKivipelto\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTuomainen\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2004\n\t\t\t\t\tHippocampus and entorhinal cortex in mild cognitive impairment and early AD.\n\t\t\t\t\tNeurobiology of Aging\n\t\t\t\t\t303\n\t\t\t\t\t310\n\t\t\t\t\n\t\t\t'},{id:"B111",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPetersen\n\t\t\t\t\t\t\tR. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tNegash\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2008\n\t\t\t\t\tMild Cognitive Impairment. An Overview. CNS Spectrums, 1\n\t\t\t\t\t45\n\t\t\t\t\t53\n\t\t\t\t\n\t\t\t'},{id:"B112",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPetrella\n\t\t\t\t\t\t\tJ. R.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWang\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKrishnan\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2007\n\t\t\t\t\tCortical deactivation in mild cognitive impairment; high- field-strength functional MR imaging\n\t\t\t\t\tRadiology\n\t\t\t\t\t224\n\t\t\t\t\t235\n\t\t\t\t\n\t\t\t'},{id:"B113",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPilatus\n\t\t\t\t\t\t\tU.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLais\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRochmont\n\t\t\t\t\t\t\tAdu. M.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2009\n\t\t\t\t\tConversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.\n\t\t\t\t\tPsychiatry Research\n\t\t\t\t\t1\n\t\t\t\t\t7\n\t\t\t\t\n\t\t\t'},{id:"B114",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPoza\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHornero\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAbasolo\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2007\n\t\t\t\t\tExtraction of spectral based measures from MEG background oscillations in Alzheimer’s disease\n\t\t\t\t\tMedical Engineering and Physics\n\t\t\t\t\t1073\n\t\t\t\t\t1083\n\t\t\t\t\n\t\t\t'},{id:"B115",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPoza\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHornero\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAbásolo\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2008\n\t\t\t\t\tEvaluation of spectral ratio measures from spontaneous MEG recordings in patients with Alzheimer’s disease\n\t\t\t\t\tComputer Methods and Programs in Biomedicine\n\t\t\t\t\t137\n\t\t\t\t\t147\n\t\t\t\t\n\t\t\t'},{id:"B116",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRead\n\t\t\t\t\t\t\tS. L.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMiller\n\t\t\t\t\t\t\tB. L.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMena\n\t\t\t\t\t\t\tI.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1995\n\t\t\t\t\tSPECT in dementia: clinical and pathological correlation.\n\t\t\t\t\tJournal of the American Geriatric Society, 43, 1243\n\t\t\t\t\t1247\n\t\t\t\t\n\t\t\t'},{id:"B117",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRies\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCarlsson\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRowley\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2008Magnetic Resonance Imaging Characterization of Brain Structure and Function in Mild Cognitive Impairment: A Review. Journal of the American Geriatrics Society\n\t\t\t\t\t920\n\t\t\t\t\t934\n\t\t\t\t\n\t\t\t'},{id:"B118",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRoss\n\t\t\t\t\t\t\tBD Bluml. S.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCowan\n\t\t\t\t\t\t\tR.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2005In vivo magnetic resonance spectroscopy of human brain, the biophysical. Dementia and Geriatric Cognitive Disorders, 20, 169\n\t\t\t\t\t177\n\t\t\t\t\n\t\t\t'},{id:"B119",body:'\n\t\t\t\t\n\t\t\t\t\tRoy CS & Sherrington CS.\n\t\t\t\t\t1890\n\t\t\t\t\tOn the regulation of the blood supply of the brain\n\t\t\t\t\tJournal of Physiology, 11, 1-2 85\n\t\t\t\t\t108\n\t\t\t\t\n\t\t\t'},{id:"B120",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSerra\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCercignani\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLenzi\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tGrey and white matter changes at different stages of Alzheimer’s disease\n\t\t\t\t\tJournal of Alzheimer’s Disease\n\t\t\t\t\t147\n\t\t\t\t\t159\n\t\t\t\t\n\t\t\t'},{id:"B121",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSimmons\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tFrondoza\n\t\t\t\t\t\t\tC. G.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCoyle\n\t\t\t\t\t\t\tJ. T.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1991\n\t\t\t\t\tImmunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies.\n\t\t\t\t\tNeuroscience\n\t\t\t\t\t37\n\t\t\t\t\t45\n\t\t\t\t\n\t\t\t'},{id:"B122",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSingh\n\t\t\t\t\t\t\tV.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tChertkow\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLerch\n\t\t\t\t\t\t\tJ. P.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tSpatial patterns of cortical thinning in mild cognitive impairment and Alzheimer’s disease\n\t\t\t\t\tBrain\n\t\t\t\t\t2885\n\t\t\t\t\t2893\n\t\t\t\t\n\t\t\t'},{id:"B123",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tShoghi-Jadid\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSmall\n\t\t\t\t\t\t\tG. W.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tAgdeppa\n\t\t\t\t\t\t\tE. D.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2002\n\t\t\t\t\tLocalization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease\n\t\t\t\t\tAmerican Journal of Geriatric Psychiatry, 10, 1, 24\n\t\t\t\t\t35\n\t\t\t\t\n\t\t\t'},{id:"B124",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tShonk\n\t\t\t\t\t\t\tT.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBD\n\t\t\t\t\t\t\tRoss\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t1995Role of increased cerebral myoinositol in the dementia of Down syndrome. Magnetic Resonance in Medicine, 33, 858\n\t\t\t\t\t861\n\t\t\t\t\n\t\t\t'},{id:"B125",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tShonk\n\t\t\t\t\t\t\tT. K.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMoats\n\t\t\t\t\t\t\tR. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGifford\n\t\t\t\t\t\t\tP.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t1995\n\t\t\t\t\tProbable Alzheimer disease, Diagnosis with proton MR spectroscopy.\n\t\t\t\t\tRadiology\n\t\t\t\t\t65\n\t\t\t\t\t72\n\t\t\t\t\n\t\t\t'},{id:"B126",body:'\n\t\t\t\tSilverman DH, Small GW & Phelps ME. (1999). Clinical Positron Imaging\n\t\t\t\t\tClinical value of neuroimaging in the diagnosis of dementia. Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer´s disease.,\n\t\t\t\t\t3\n\t\t\t\t\t2\n\t\t\t\t\t119\n\t\t\t\t\t130\n\t\t\t\t\n\t\t\t'},{id:"B127",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSkup\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tZhu\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWang\n\t\t\t\t\t\t\tY.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2011Sex Differences in Grey Matter Atrophy Patterns Among AD and aMCI Patients: Results from ADNI.Neuroimage,56 (3), 890\n\t\t\t\t\t906\n\t\t\t\t\n\t\t\t'},{id:"B128",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSmith\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJobst\n\t\t\t\t\t\t\tK.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t1996\n\t\t\t\t\tUse of structural imaging to study the progression of Alzheimer’s disease\n\t\t\t\t\tBr Med Bull.Jul,52(3), 575\n\t\t\t\t\t586\n\t\t\t\t\n\t\t\t'},{id:"B129",body:'\n\t\t\t\t\n\t\t\t\t\tSong SK, Sun SW, Ramsbottom MJ et al.\n\t\t\t\t\t2002Dymielination revealed throught MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage, 17, 1429\n\t\t\t\t\t1722\n\t\t\t\t\n\t\t\t'},{id:"B130",body:'\n\t\t\t\t\n\t\t\t\t\tSperling RA, Bates JF, Cocchiarella AJ et al.\n\t\t\t\t\t2001\n\t\t\t\t\tEncoding novel face-name associations, a functional MRI study.\n\t\t\t\t\tHuman Brain Mapping\n\t\t\t\t\t129\n\t\t\t\t\t139\n\t\t\t\t\n\t\t\t'},{id:"B131",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSperling\n\t\t\t\t\t\t\tR. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGreve\n\t\t\t\t\t\t\tD.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDale\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2002fMRI detection of pharmacologically induced memory impairment. Procedings of the National Academy of. Science, 99, 455\n\t\t\t\t\t460b)\n\t\t\t'},{id:"B132",body:'\n\t\t\t\t\n\t\t\t\t\tSperling RA.\n\t\t\t\t\t2007Funtional MRI Studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer’s disease. Annals of the New York Academy of Sciences, 1097, 146\n\t\t\t\t\t155\n\t\t\t\t\n\t\t\t'},{id:"B133",body:'\n\t\t\t\t\n\t\t\t\t\tStam CJ.\n\t\t\t\t\t2001\n\t\t\t\t\tUse of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders\n\t\t\t\t\tJournal of Neurological Science, 15, 289 (1-2), 128\n\t\t\t\t\t134\n\t\t\t\t\n\t\t\t'},{id:"B134",body:'\n\t\t\t\t\n\t\t\t\t\tStam CJ, van Cappellen van Walsum AM, Pijnenburg YAL et al.\n\t\t\t\t\t2002Generalized synchronization of MEG recordings in Alzheimer’s disease: evidence for involvement of the gamma band. Journal of Clinical Neurophysiology, 19, 562\n\t\t\t\t\t574\n\t\t\t\t\n\t\t\t'},{id:"B135",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tStam\n\t\t\t\t\t\t\tC. J.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJones\n\t\t\t\t\t\t\tB. F.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tManshanden\n\t\t\t\t\t\t\tI.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tMagnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer’s disease\n\t\t\t\t\tNeuroimage\n\t\t\t\t\t1335\n\t\t\t\t\t1344\n\t\t\t\t\n\t\t\t'},{id:"B136",body:'\n\t\t\t\t\n\t\t\t\t\tStam CJ & Reijneveld JC.\n\t\t\t\t\t2007\n\t\t\t\t\tNonlinear Biomedical Physics\n\t\t\t\t\t3\n\t\t\t\t\n\t\t\t'},{id:"B137",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tStoub\n\t\t\t\t\t\t\tT. R.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBulgakova\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tLeurgans\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2005\n\t\t\t\t\tMRI predictors of risk of incident Alzheimer disease: A longitudinal study.\n\t\t\t\t\tNeurology\n\t\t\t\t\t1520\n\t\t\t\t\t1524\n\t\t\t\t\n\t\t\t'},{id:"B138",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tSullivan\n\t\t\t\t\t\t\tE. V.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tRohlfing\n\t\t\t\t\t\t\tT.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPfefferbaum\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2010\n\t\t\t\t\tQuantitative fiber tracking of lateral and interhemispheric white matter systems in normal aging, relations to timed performance\n\t\t\t\t\tNeurobiology of Aging\n\t\t\t\t\t464\n\t\t\t\t\t481\n\t\t\t\t\n\t\t\t'},{id:"B139",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTeipel\n\t\t\t\t\t\t\tS. J.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tDrzega\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBartenstein\n\t\t\t\t\t\t\tP.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006Effects of donezepil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer’s disease: a double blind cross-over trial. Psychopharmacology, 187, 86\n\t\t\t\t\t94\n\t\t\t\t\n\t\t\t'},{id:"B140",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tThomann\n\t\t\t\t\t\t\tP. A.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWustenberg\n\t\t\t\t\t\t\tT.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPantel\n\t\t\t\t\t\t\tJ.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tStructural changes of the corpus callosum in mild cognitive impairment and Alzheimer’s disease\n\t\t\t\t\tDementia and Geriatric Cognitive Disorders\n\t\t\t\t\t215\n\t\t\t\t\t220\n\t\t\t\t\n\t\t\t'},{id:"B141",body:'\n\t\t\t\t\n\t\t\t\t\tThompson PM, Hayashi KM, De Zubicaray GI et al.\n\t\t\t\t\t2004\n\t\t\t\t\tMapping hippocampal and ventricular change in Alzheimer disease.\n\t\t\t\t\tNeuroimage\n\t\t\t\t\t1754\n\t\t\t\t\t1766\n\t\t\t\t\n\t\t\t'},{id:"B142",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTolboom\n\t\t\t\t\t\t\tN.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tvan der Flier\n\t\t\t\t\t\t\tW. M.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tYaqub\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2009\n\t\t\t\t\tRelationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.\n\t\t\t\t\tJournal of Nuclear Medicine\n\t\t\t\t\t1464\n\t\t\t\t\t1470\n\t\t\t\t\n\t\t\t'},{id:"B143",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tUkmar\n\t\t\t\t\t\t\tM.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMakuc\n\t\t\t\t\t\t\tE.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tOnor\n\t\t\t\t\t\t\tM. L.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2008\n\t\t\t\t\tEvaluation of white matter damage in patients with Alzheimer’s disease and in patients with mild cognitive impairment by using diffusion tensor imaging\n\t\t\t\t\tLa Radiologia Medica\n\t\t\t\t\t915\n\t\t\t\t\t922\n\t\t\t\t\n\t\t\t'},{id:"B144",body:'\n\t\t\t\t\n\t\t\t\t\tVan Cappellen van Walsum AM, Pijnenburg YAL, Berendse HW et al.\n\t\t\t\t\t2003\n\t\t\t\t\tA neural complexity measure applied to MEG data in Alzheimer’s disease.\n\t\t\t\t\tClinical Neurophysiology, 114, 1034\n\t\t\t\t\t1040\n\t\t\t\t\n\t\t\t'},{id:"B145",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWang\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tMiller\n\t\t\t\t\t\t\tJ. P.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGado\n\t\t\t\t\t\t\tM. H.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2006\n\t\t\t\t\tAbnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type\n\t\t\t\t\tNeuroimage\n\t\t\t\t\t52\n\t\t\t\t\t60\n\t\t\t\t\n\t\t\t'},{id:"B146",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWang\n\t\t\t\t\t\t\tZ.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tZhao\n\t\t\t\t\t\t\tC.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tYu\n\t\t\t\t\t\t\tL.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2009\n\t\t\t\t\tRegional Metabolic Changes in the Hippocampus and Posterior Cingulate Area Detected with 3-Tesla Magnetic Resonance Spectroscopy in Patients with Mild Cognitive Impairment and Alzheimer Disease\n\t\t\t\t\tActa Radiologica\n\t\t\t\t\t312\n\t\t\t\t\t319\n\t\t\t\t\n\t\t\t'},{id:"B147",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWang\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tShi\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tYu\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJiang\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTang\n\t\t\t\t\t\t\tG.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2011Facile and rapid one-step radiosynthesis of [(18)F]BAY94-9172 with a new precursor. Nuclear Medicine and Biology, 38, 1, 121\n\t\t\t\t\t127\n\t\t\t\t\n\t\t\t'},{id:"B148",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWhitwell\n\t\t\t\t\t\t\tJ. L.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPetersen\n\t\t\t\t\t\t\tR. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tNegash\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2007\n\t\t\t\t\tPatterns of atrophy differ among specific subtypes of mild cognitive impairment.\n\t\t\t\t\tArchives of Neurology\n\t\t\t\t\t1130\n\t\t\t\t\t1138\n\t\t\t\t\n\t\t\t'},{id:"B149",body:'\n\t\t\t\t\n\t\t\t\t\tWhitwell JL, Shiung MM, Przybelski SA, et al.\n\t\t\t\t\t2008\n\t\t\t\t\tMRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment\n\t\t\t\t\tNeurology\n\t\t\t\t\t512\n\t\t\t\t\t520\n\t\t\t\t\n\t\t\t'},{id:"B150",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tCA\n\t\t\t\t\t\t\tWiley\n\t\t\t\t\t\t\tLopresti. B. J.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tVenneti\n\t\t\t\t\t\t\tS.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2009Carbon 11-labeled Pittsburg Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Archives of Neurology, 66, 1, 60\n\t\t\t\t\t67\n\t\t\t\t\n\t\t\t'},{id:"B151",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWolf\n\t\t\t\t\t\t\tH.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tHensel\n\t\t\t\t\t\t\tA.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tKruggel\n\t\t\t\t\t\t\tF.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2004\n\t\t\t\t\tStructural correlates of mild cognitive impairment.\n\t\t\t\t\tNeurobiology of Aging\n\t\t\t\t\t913\n\t\t\t\t\t924\n\t\t\t\t\n\t\t\t'},{id:"B152",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tXu\n\t\t\t\t\t\t\tY.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJack\n\t\t\t\t\t\t\tC. R.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tJr O’Brien\n\t\t\t\t\t\t\tP. C.\n\t\t\t\t\t\t\n\t\t\t\t\t\tet al.\n\t\t\t\t\t\n\t\t\t\t\t2000\n\t\t\t\t\tUsefulness of MRI measures of entorhinal cortex versus hippocampus in AD.\n\t\t\t\t\tNeurology\n\t\t\t\t\t1760\n\t\t\t\t\t1767\n\t\t\t\t\n\t\t\t'},{id:"B153",body:'\n\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tYuan\n\t\t\t\t\t\t\tY.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tGu\n\t\t\t\t\t\t\tZ. X.\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tWei\n\t\t\t\t\t\t\tW. X.\n\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t2008Fluorodeoxyglucose-Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis.American Journal of Neuroradiology, 30, 2, 404\n\t\t\t\t\t410\n\t\t\t\t\n\t\t\t'},{id:"B154",body:'\n\t\t\t\t\n\t\t\t\t\tZhuang et al.\n\t\t\t\t\t2010\n\t\t\t\t\tWhite matter integrity in mild cognitive impairment, A tract-based spatial statistics study\n\t\t\t\t\tNeuroimage\n\t\t\t\t\t16\n\t\t\t\t\t25\n\t\t\t\t\n\t\t\t'}],footnotes:[],contributors:[{corresp:null,contributorFullName:"Laura Ortiz-Terán",address:null,affiliation:'
Department of Radiology, Massachussets General Hospital,Harvard University, Boston, USA
Departamento de Psiquiatría y Psicología Médica,Universidad Complutense, Madrid, Spain
'}],corrections:null},book:{id:"197",title:"The Clinical Spectrum of Alzheimer's Disease",subtitle:"The Charge Toward Comprehensive Diagnostic and Therapeutic Strategies",fullTitle:"The Clinical Spectrum of Alzheimer's Disease -The Charge Toward Comprehensive Diagnostic and Therapeutic Strategies",slug:"the-clinical-spectrum-of-alzheimer-s-disease-the-charge-toward-comprehensive-diagnostic-and-therapeutic-strategies",publishedDate:"September 6th 2011",bookSignature:"Suzanne De La Monte",coverURL:"https://cdn.intechopen.com/books/images_new/197.jpg",licenceType:"CC BY-NC-SA 3.0",editedByType:"Edited by",editors:[{id:"29111",title:"Dr.",name:"Suzanne",middleName:"M.",surname:"De La Monte",slug:"suzanne-de-la-monte",fullName:"Suzanne De La Monte"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"19235",title:"Risk Factors for Disease Progression in Alzheimer's Disease",slug:"risk-factors-for-disease-progression-in-alzheimer-s-disease",totalDownloads:2031,totalCrossrefCites:0,signatures:"Schmidt C, Wolff M, Shalash A and Zerr I",authors:[{id:"26013",title:"Prof.",name:"Inga",middleName:null,surname:"Zerr",fullName:"Inga Zerr",slug:"inga-zerr"}]},{id:"19236",title:"Alzheimer’s Disease Genomics and Clinical Applications",slug:"alzheimer-s-disease-genomics-and-clinical-applications",totalDownloads:1511,totalCrossrefCites:0,signatures:"Tih-Shih Lee and Mei Sian Chong",authors:[{id:"32509",title:"Dr.",name:"Tih-Shih",middleName:null,surname:"Lee",fullName:"Tih-Shih Lee",slug:"tih-shih-lee"},{id:"56923",title:"Dr.",name:"Mei Sian",middleName:null,surname:"Chong",fullName:"Mei Sian Chong",slug:"mei-sian-chong"}]},{id:"19237",title:"Addressing Risk Factors for Neurocognitive Decline and Alzheimer’s Disease Among African Americans in the Era of Health Disparities",slug:"addressing-risk-factors-for-neurocognitive-decline-and-alzheimer-s-disease-among-african-americans-i",totalDownloads:1897,totalCrossrefCites:0,signatures:"David L. Mount, Maria Isabel Rego, Alethea Amponsah, Annette Herron, Darin Johnson, Mario Sims,\nDeMarc Hickson and Sylvia A. Flack",authors:[null]},{id:"19238",title:"Focal Cortical Presentations Genetically Proven Alzheimer Disease",slug:"focal-cortical-presentations-genetically-proven-alzheimer-disease",totalDownloads:1516,totalCrossrefCites:0,signatures:"Naeije G, Van den Berge Delphine, Vokaer M, Fery P, Vilain C, Abramowicz M, Van den Broeck M, Van Broeckhoven C and Bier JC",authors:[{id:"25946",title:"Dr.",name:"Jean-Christophe",middleName:null,surname:"Bier",fullName:"Jean-Christophe Bier",slug:"jean-christophe-bier"},{id:"38050",title:"Dr.",name:"Gilles",middleName:null,surname:"NAEIJE",fullName:"Gilles NAEIJE",slug:"gilles-naeije"},{id:"38051",title:"Mrs",name:"Delphine",middleName:null,surname:"VAN DEN BERGE",fullName:"Delphine VAN DEN BERGE",slug:"delphine-van-den-berge"},{id:"38052",title:"Mr",name:"Mathieu",middleName:null,surname:"VOKAER",fullName:"Mathieu VOKAER",slug:"mathieu-vokaer"},{id:"38053",title:"Mr",name:"Patrick",middleName:null,surname:"FERY",fullName:"Patrick FERY",slug:"patrick-fery"},{id:"38054",title:"Mr",name:"Catheline",middleName:null,surname:"VILAIN",fullName:"Catheline VILAIN",slug:"catheline-vilain"},{id:"38055",title:"Mr",name:"Marc",middleName:null,surname:"ABRAMOWICZ",fullName:"Marc ABRAMOWICZ",slug:"marc-abramowicz"},{id:"38062",title:"Mrs",name:"Marleen",middleName:null,surname:"VAN DEN BROECK",fullName:"Marleen VAN DEN BROECK",slug:"marleen-van-den-broeck"},{id:"92088",title:"Dr.",name:"Christine",middleName:null,surname:"van Broeckhoven",fullName:"Christine van Broeckhoven",slug:"christine-van-broeckhoven"}]},{id:"19239",title:"Spatial Navigation Impairment in Healthy Aging and Alzheimer’s Disease",slug:"spatial-navigation-impairment-in-healthy-aging-and-alzheimer-s-disease",totalDownloads:2386,totalCrossrefCites:4,signatures:"Kamil Vlček",authors:[{id:"38224",title:"Dr.",name:"Kamil",middleName:null,surname:"Vlcek",fullName:"Kamil Vlcek",slug:"kamil-vlcek"}]},{id:"19240",title:"Visual Cognition in Alzheimer’s Disease and Its Functional Implications",slug:"visual-cognition-in-alzheimer-s-disease-and-its-functional-implications",totalDownloads:1287,totalCrossrefCites:0,signatures:"Philip C. Ko and Brandon A. Ally",authors:[{id:"32904",title:"Prof.",name:"Brandon",middleName:null,surname:"Ally",fullName:"Brandon Ally",slug:"brandon-ally"},{id:"42037",title:"Dr.",name:"Philip",middleName:null,surname:"Ko",fullName:"Philip Ko",slug:"philip-ko"}]},{id:"19241",title:"Olfactory Dysfunctions in Alzheimer’s Disease",slug:"olfactory-dysfunctions-in-alzheimer-s-disease",totalDownloads:2766,totalCrossrefCites:1,signatures:"Iuliana Nicola-Antoniu",authors:[{id:"52629",title:"BSc",name:"Iuliana",middleName:null,surname:"Nicola-Antoniu",fullName:"Iuliana Nicola-Antoniu",slug:"iuliana-nicola-antoniu"}]},{id:"19242",title:"Currently Available Neuroimaging Approaches in Alzheimer Disease (AD) Early Diagnosis",slug:"currently-available-neuroimaging-approaches-in-alzheimer-disease-ad-early-diagnosis",totalDownloads:1959,totalCrossrefCites:0,signatures:"Laura Ortiz-Terán, Juan MR Santos, María de las Nieves Cabrera Martín and Tomás Ortiz Alonso",authors:[{id:"26990",title:"Prof.",name:"Tomas",middleName:null,surname:"Ortiz",fullName:"Tomas Ortiz",slug:"tomas-ortiz"},{id:"42082",title:"Dr.",name:"Laura",middleName:null,surname:"Ortiz-Terán",fullName:"Laura Ortiz-Terán",slug:"laura-ortiz-teran"},{id:"42083",title:"Prof.",name:"Juan M",middleName:null,surname:"Santos",fullName:"Juan M Santos",slug:"juan-m-santos"},{id:"42084",title:"Dr.",name:"María Nieves",middleName:null,surname:"Cabrera-Martín",fullName:"María Nieves Cabrera-Martín",slug:"maria-nieves-cabrera-martin"}]},{id:"19243",title:"The Clinical Use of SPECT and PET Molecular Imaging in Alzheimer’s Disease",slug:"the-clinical-use-of-spect-and-pet-molecular-imaging-in-alzheimer-s-disease",totalDownloads:3053,totalCrossrefCites:0,signatures:"Varvara Valotassiou, Nikolaos Sifakis, John Papatriantafyllou, George Angelidis and Panagiotis Georgoulias",authors:[{id:"32702",title:"Dr.",name:"Varvara",middleName:null,surname:"Valotassiou",fullName:"Varvara Valotassiou",slug:"varvara-valotassiou"},{id:"37788",title:"Mr.",name:"Nikolaos",middleName:null,surname:"Sifakis",fullName:"Nikolaos Sifakis",slug:"nikolaos-sifakis"},{id:"37789",title:"Dr.",name:"John",middleName:null,surname:"Papatriantafyllou",fullName:"John Papatriantafyllou",slug:"john-papatriantafyllou"},{id:"37790",title:"Mr.",name:"Panagiotis",middleName:null,surname:"Georgoulias",fullName:"Panagiotis Georgoulias",slug:"panagiotis-georgoulias"},{id:"60391",title:"Dr.",name:"George",middleName:null,surname:"Angelidis",fullName:"George Angelidis",slug:"george-angelidis"}]},{id:"19244",title:"Cerebrospinal Fluid Based Diagnosis in Alzheimer’s Disease",slug:"cerebrospinal-fluid-based-diagnosis-in-alzheimer-s-disease",totalDownloads:1636,totalCrossrefCites:0,signatures:"Inga Zerr, Lisa Kaerst, Joanna Gawinecka and Daniela Varges",authors:[{id:"26013",title:"Prof.",name:"Inga",middleName:null,surname:"Zerr",fullName:"Inga Zerr",slug:"inga-zerr"}]},{id:"19245",title:"Alzheimer’s Diseases: Towards Biomarkers for an Early Diagnosis",slug:"alzheimer-s-diseases-towards-biomarkers-for-an-early-diagnosis",totalDownloads:1233,totalCrossrefCites:0,signatures:"Benaïssa Elmoualij, Ingrid Dupiereux, Jérémie Seguin, Isabelle Quadrio, Willy Zorzi, Armand Perret-Liaudet and Ernst Heinen",authors:[{id:"26949",title:"PhD.",name:"Benaissa",middleName:null,surname:"El Moualij",fullName:"Benaissa El Moualij",slug:"benaissa-el-moualij"},{id:"38547",title:"Dr.",name:"Ingrid",middleName:null,surname:"Dupiereux",fullName:"Ingrid Dupiereux",slug:"ingrid-dupiereux"},{id:"38548",title:"Dr.",name:"Willy",middleName:null,surname:"Zorzi",fullName:"Willy Zorzi",slug:"willy-zorzi"},{id:"38549",title:"Prof.",name:"Ernst",middleName:null,surname:"Heinen",fullName:"Ernst Heinen",slug:"ernst-heinen"},{id:"87923",title:"MSc.",name:"Jérémie",middleName:null,surname:"Seguin",fullName:"Jérémie Seguin",slug:"jeremie-seguin"},{id:"87926",title:"Dr.",name:"Isabelle",middleName:null,surname:"Quadrio",fullName:"Isabelle Quadrio",slug:"isabelle-quadrio"},{id:"87928",title:"Dr.",name:"Armand",middleName:null,surname:"Perret-Liaudet",fullName:"Armand Perret-Liaudet",slug:"armand-perret-liaudet"}]},{id:"19246",title:"Phospo-PKCs in Abeta1-42-Specific Human T Cells from Alzheimer’s Disease Patients",slug:"phospo-pkcs-in-abeta1-42-specific-human-t-cells-from-alzheimer-s-disease-patients",totalDownloads:1475,totalCrossrefCites:0,signatures:"Lanuti Paola, Marchisio Marco, Pierdomenico Laura and Miscia Sebastiano",authors:[{id:"42039",title:"Dr.",name:null,middleName:null,surname:"Miscia",fullName:"Miscia",slug:"miscia"}]},{id:"19247",title:"The Predictive Role of Hyposmia in Alzheimer's Disease",slug:"the-predictive-role-of-hyposmia-in-alzheimer-s-disease",totalDownloads:2569,totalCrossrefCites:0,signatures:"Alessandra B. Fioretti, Marco Fusetti and Alberto Eibenstein",authors:[{id:"30876",title:"Prof.",name:"Marco",middleName:null,surname:"Fusetti",fullName:"Marco Fusetti",slug:"marco-fusetti"},{id:"40712",title:"Dr.",name:"Alessandra",middleName:null,surname:"Fioretti",fullName:"Alessandra Fioretti",slug:"alessandra-fioretti"},{id:"40713",title:"Prof.",name:"Alberto",middleName:null,surname:"Eibenstein",fullName:"Alberto Eibenstein",slug:"alberto-eibenstein"}]},{id:"19248",title:"Retinal Nerve Fibre Layer Thinning in Alzheimer Disease",slug:"retinal-nerve-fibre-layer-thinning-in-alzheimer-disease",totalDownloads:2267,totalCrossrefCites:1,signatures:"Panitha Jindahra and Gordon T Plant",authors:[{id:"26600",title:"Dr.",name:"Panitha",middleName:null,surname:"Jindahra",fullName:"Panitha Jindahra",slug:"panitha-jindahra"},{id:"32487",title:"Dr.",name:"Gordon",middleName:null,surname:"Plant",fullName:"Gordon Plant",slug:"gordon-plant"}]},{id:"19249",title:"Modulation of Signal Transduction Pathways in Senescence-Accelerated Mice P8 Strain: A Useful Tool for Alzheimer’s Disease Research",slug:"modulation-of-signal-transduction-pathways-in-senescence-accelerated-mice-p8-strain-a-useful-tool-fo",totalDownloads:1934,totalCrossrefCites:0,signatures:"José Luis Albasanz, Carlos Alberto Castillo, Marta Barrachina, Isidre Ferrer and Mairena Martín",authors:[{id:"26059",title:"Dr.",name:"Marta",middleName:null,surname:"Barrachina",fullName:"Marta Barrachina",slug:"marta-barrachina"},{id:"29611",title:"Dr.",name:"Mairena",middleName:null,surname:"Martin",fullName:"Mairena Martin",slug:"mairena-martin"},{id:"37331",title:"Prof.",name:"Isidre",middleName:null,surname:"Ferrer",fullName:"Isidre Ferrer",slug:"isidre-ferrer"},{id:"41000",title:"Prof.",name:"Jose Luis",middleName:null,surname:"Albasanz",fullName:"Jose Luis Albasanz",slug:"jose-luis-albasanz"},{id:"82922",title:"Dr.",name:"Carlos Alberto",middleName:null,surname:"Castillo Sarmiento",fullName:"Carlos Alberto Castillo Sarmiento",slug:"carlos-alberto-castillo-sarmiento"}]},{id:"19250",title:"Valosin-Containing Protein (VCP) Disease and Familial Alzheimer’s Disease: Contrasts and Overlaps",slug:"valosin-containing-protein-vcp-disease-and-familial-alzheimer-s-disease-contrasts-and-overlaps",totalDownloads:1542,totalCrossrefCites:0,signatures:"CD Smith, M Badadani, A Nalbandian, E Dec, J Vesa, S Donkervoort, B Martin, GD Watts, V Caiozzo and V Kimonis",authors:[{id:"32651",title:"Dr.",name:null,middleName:null,surname:"Kimonis",fullName:"Kimonis",slug:"kimonis"},{id:"80878",title:"Dr.",name:"Charles",middleName:"D",surname:"Smith",fullName:"Charles Smith",slug:"charles-smith"},{id:"88563",title:"Ms.",name:"Barbara",middleName:null,surname:"Martin",fullName:"Barbara Martin",slug:"barbara-martin"}]},{id:"19251",title:"Neural Basis of Hyposmia in Alzheimer’s Disease",slug:"neural-basis-of-hyposmia-in-alzheimer-s-disease",totalDownloads:1706,totalCrossrefCites:1,signatures:"Daniel Saiz-Sánchez, Carlos de la Rosa-Prieto, Isabel Úbeda-Bañón and Alino Martínez-Marcos",authors:[{id:"30633",title:"Dr.",name:"Alino",middleName:null,surname:"Martinez-Marcos",fullName:"Alino Martinez-Marcos",slug:"alino-martinez-marcos"},{id:"35066",title:"MSc.",name:"Daniel",middleName:null,surname:"Saiz-Sanchez",fullName:"Daniel Saiz-Sanchez",slug:"daniel-saiz-sanchez"},{id:"35067",title:"MSc.",name:"Carlos",middleName:null,surname:"de la Rosa-Prieto",fullName:"Carlos de la Rosa-Prieto",slug:"carlos-de-la-rosa-prieto"},{id:"35068",title:"MSc.",name:"Isabel",middleName:null,surname:"Ubeda-Banon",fullName:"Isabel Ubeda-Banon",slug:"isabel-ubeda-banon"}]}]},relatedBooks:[{type:"book",id:"434",title:"Alzheimer's Disease Pathogenesis",subtitle:"Core Concepts, Shifting Paradigms and Therapeutic Targets",isOpenForSubmission:!1,hash:"49f4c7dbf69e8a9eaf780e37f4aae1ab",slug:"alzheimer-s-disease-pathogenesis-core-concepts-shifting-paradigms-and-therapeutic-targets",bookSignature:"Suzanne De La Monte",coverURL:"https://cdn.intechopen.com/books/images_new/434.jpg",editedByType:"Edited by",editors:[{id:"29111",title:"Dr.",name:"Suzanne",surname:"De La Monte",slug:"suzanne-de-la-monte",fullName:"Suzanne De La Monte"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"19784",title:"Alzheimer ́s Disease – The New Actors of an Old Drama",slug:"alzheimer-s-disease-the-new-actors-of-an-old-drama",signatures:"Mario Álvarez Sánchez, Carlos A. Sánchez Catasús, Ivonne Pedroso Ibañez, Maria L. Bringas and Arnoldo Padrón Sánchez",authors:[{id:"32659",title:"Dr.",name:"Mario",middleName:null,surname:"Álvarez Sánchez",fullName:"Mario Álvarez Sánchez",slug:"mario-alvarez-sanchez"},{id:"94205",title:"MSc.",name:"Carlos",middleName:null,surname:"Sánchez",fullName:"Carlos Sánchez",slug:"carlos-sanchez"},{id:"94206",title:"Dr.",name:"Ivonne",middleName:null,surname:"Pedroso Ibañez",fullName:"Ivonne Pedroso Ibañez",slug:"ivonne-pedroso-ibanez"},{id:"94207",title:"MSc.",name:"Maria L",middleName:null,surname:"Bringas",fullName:"Maria L Bringas",slug:"maria-l-bringas"},{id:"94208",title:"Dr.",name:"Arnoldo",middleName:null,surname:"Padrón Sánchez",fullName:"Arnoldo Padrón Sánchez",slug:"arnoldo-padron-sanchez"}]},{id:"19785",title:"Pathophysiology of Late Onset Alzheimer Disease",slug:"pathophysiology-of-late-onset-alzheimer-disease",signatures:"Ahmet Turan Isik and M. Refik Mas",authors:[{id:"25987",title:"Prof.",name:"Ahmet Turan",middleName:null,surname:"Isik",fullName:"Ahmet Turan Isik",slug:"ahmet-turan-isik"},{id:"41375",title:"Dr.",name:"M Refik",middleName:null,surname:"Mas",fullName:"M Refik Mas",slug:"m-refik-mas"}]},{id:"19786",title:"Expression and Cerebral Function of Amyloid Precursor Protein After Rat Traumatic Brain Injury",slug:"expression-and-cerebral-function-of-amyloid-precursor-protein-after-rat-traumatic-brain-injury",signatures:"Tatsuki Itoh, Motohiro Imano, Shozo Nishida, Masahiro Tsubaki, Shigeo Hashimoto, Akihiko Ito and Takao Satou",authors:[{id:"32664",title:"Dr.",name:"Masahiro",middleName:null,surname:"Tsubaki",fullName:"Masahiro Tsubaki",slug:"masahiro-tsubaki"}]},{id:"19787",title:"Key Enzymes and Proteins in Amyloid-Beta Production and Clearance",slug:"key-enzymes-and-proteins-in-amyloid-beta-production-and-clearance",signatures:"Cecília R A Santos, Isabel Cardoso and Isabel Gonçalves",authors:[{id:"28998",title:"Prof.",name:"Cecilia",middleName:null,surname:"Santos",fullName:"Cecilia Santos",slug:"cecilia-santos"},{id:"39732",title:"Prof.",name:"Isabel",middleName:"Theriaga",surname:"Gonçalves",fullName:"Isabel Gonçalves",slug:"isabel-goncalves"},{id:"39733",title:"Dr.",name:"Isabel",middleName:null,surname:"Cardoso",fullName:"Isabel Cardoso",slug:"isabel-cardoso"}]},{id:"19788",title:"Transporters in the Blood-Brain Barrier",slug:"transporters-in-the-blood-brain-barrier",signatures:"Masaki Ueno, Toshitaka Nakagawa and Haruhiko Sakamoto",authors:[{id:"42047",title:"Dr.",name:"Masaki",middleName:null,surname:"Ueno",fullName:"Masaki Ueno",slug:"masaki-ueno"},{id:"42244",title:"Dr.",name:"Toshitaka",middleName:null,surname:"Nakagawa",fullName:"Toshitaka Nakagawa",slug:"toshitaka-nakagawa"},{id:"42249",title:"Prof.",name:"Haruhiko",middleName:null,surname:"Sakamoto",fullName:"Haruhiko Sakamoto",slug:"haruhiko-sakamoto"}]},{id:"19789",title:"Contribution of Multivesicular Bodies to the Prion-Like Propagation of Lesions in Alzheimer’s Disease",slug:"contribution-of-multivesicular-bodies-to-the-prion-like-propagation-of-lesions-in-alzheimer-s-diseas",signatures:"Valérie Vingtdeux, Luc Buée and Nicolas Sergeant",authors:[{id:"39534",title:"Prof.",name:"Nicolas",middleName:null,surname:"Sergeant",fullName:"Nicolas Sergeant",slug:"nicolas-sergeant"},{id:"47080",title:"Ms.",name:"Vingtdeux",middleName:null,surname:"Valerie",fullName:"Vingtdeux Valerie",slug:"vingtdeux-valerie"}]},{id:"19790",title:"Pathological Stages of Abnormally Processed Tau Protein During Its Aggregation into Fibrillary Structures in Alzheimer’s Disease",slug:"pathological-stages-of-abnormally-processed-tau-protein-during-its-aggregation-into-fibrillary-struc",signatures:"Francisco García-Sierra, Gustavo Basurto-Islas, Jaime Jarero-Basulto, Hugo C. Monroy-Ramírez, Francisco M. Torres Cruz, Hernán Cortés Callejas, Héctor M. Camarillo Rojas, Zdena Kristofikova, Daniela Ripova, José Luna-Muñoz, Raúl Mena, Lester I. Binder and Siddhartha Mondragón-Rodríguez",authors:[{id:"27181",title:"Dr.",name:"Francisco",middleName:null,surname:"Garcia-Sierra",fullName:"Francisco Garcia-Sierra",slug:"francisco-garcia-sierra"},{id:"42220",title:"MSc",name:"Jaime",middleName:null,surname:"Jarero-Basulto",fullName:"Jaime Jarero-Basulto",slug:"jaime-jarero-basulto"},{id:"42221",title:"Dr.",name:"Hugo",middleName:null,surname:"Monroy-Ramírez",fullName:"Hugo Monroy-Ramírez",slug:"hugo-monroy-ramirez"},{id:"42222",title:"Dr",name:"Zdena",middleName:null,surname:"Kristofikova",fullName:"Zdena Kristofikova",slug:"zdena-kristofikova"},{id:"42224",title:"Dr.",name:"Daniela",middleName:null,surname:"Ripova",fullName:"Daniela Ripova",slug:"daniela-ripova"},{id:"42225",title:"Dr.",name:"Jose",middleName:null,surname:"Luna-Muñoz",fullName:"Jose Luna-Muñoz",slug:"jose-luna-munoz"},{id:"42226",title:"Dr.",name:"Raul",middleName:null,surname:"Mena-López",fullName:"Raul Mena-López",slug:"raul-mena-lopez"},{id:"42231",title:"Dr.",name:"Lester",middleName:null,surname:"Binder",fullName:"Lester Binder",slug:"lester-binder"},{id:"42232",title:"Dr.",name:"Gustavo",middleName:null,surname:"Basurto-Islas",fullName:"Gustavo Basurto-Islas",slug:"gustavo-basurto-islas"},{id:"82515",title:"Dr.",name:"Siddhartha",middleName:null,surname:"Mondragón-Rodríguez",fullName:"Siddhartha Mondragón-Rodríguez",slug:"siddhartha-mondragon-rodriguez"},{id:"82517",title:"MSc",name:"Francisco",middleName:"Miguel",surname:"Torres-Cruz",fullName:"Francisco Torres-Cruz",slug:"francisco-torres-cruz"},{id:"82521",title:"Mr",name:"Héctor",middleName:"Manuel",surname:"Camarillo-Rojas",fullName:"Héctor Camarillo-Rojas",slug:"hector-camarillo-rojas"},{id:"82523",title:"Dr.",name:"Hernán",middleName:null,surname:"Cortés Callejas",fullName:"Hernán Cortés Callejas",slug:"hernan-cortes-callejas"}]},{id:"19791",title:"Structure and Toxicity of the Prefibrillar Aggregation States of Beta Peptides in Alzheimer’s Disease",slug:"structure-and-toxicity-of-the-prefibrillar-aggregation-states-of-beta-peptides-in-alzheimer-s-diseas",signatures:"Angelo Perico, Denise Galante and Cristina D’Arrigo",authors:[{id:"40436",title:"Dr.",name:"Angelo",middleName:null,surname:"Perico",fullName:"Angelo Perico",slug:"angelo-perico"},{id:"40483",title:"Dr.",name:"Cristina",middleName:null,surname:"D'Arrigo",fullName:"Cristina D'Arrigo",slug:"cristina-d'arrigo"},{id:"40484",title:"Dr.",name:"Denise",middleName:null,surname:"Galante",fullName:"Denise Galante",slug:"denise-galante"}]},{id:"19792",title:"Structural and Toxic Properties of Protein Aggregates: Towards a Molecular Understanding of Alzheimer's Disease",slug:"structural-and-toxic-properties-of-protein-aggregates-towards-a-molecular-understanding-of-alzheimer",signatures:"Lei Wang and Silvia Campioni",authors:[{id:"41051",title:"Dr.",name:"Lei",middleName:null,surname:"Wang",fullName:"Lei Wang",slug:"lei-wang"},{id:"41057",title:"Dr.",name:"Silvia",middleName:null,surname:"Campioni",fullName:"Silvia Campioni",slug:"silvia-campioni"}]},{id:"19793",title:"The Role of Glycogen Synthase Kinase-3 (GSK-3) in Alzheimer’s Disease",slug:"the-role-of-glycogen-synthase-kinase-3-gsk-3-in-alzheimer-s-disease",signatures:"Miguel Medina and Jesús Avila",authors:[{id:"26577",title:"Dr.",name:"Jesús",middleName:null,surname:"Avila",fullName:"Jesús Avila",slug:"jesus-avila"},{id:"26971",title:"Dr.",name:"Miguel",middleName:null,surname:"Medina",fullName:"Miguel Medina",slug:"miguel-medina"}]},{id:"19794",title:"Pin1: A New Enzyme Pivotal for Protecting Against Alzheimer’s Disease",slug:"pin1-a-new-enzyme-pivotal-for-protecting-against-alzheimer-s-disease",signatures:"Kazuhiro Nakamura, Suk Ling Ma and Kun Ping Lu",authors:[{id:"40750",title:"Prof.",name:"Kun Ping",middleName:null,surname:"Lu",fullName:"Kun Ping Lu",slug:"kun-ping-lu"},{id:"47403",title:"Dr.",name:"Kazuhiro",middleName:null,surname:"Nakamura",fullName:"Kazuhiro Nakamura",slug:"kazuhiro-nakamura"},{id:"47404",title:"Dr.",name:"Suk Ling",middleName:null,surname:"Ma",fullName:"Suk Ling Ma",slug:"suk-ling-ma"}]},{id:"19795",title:"Selectivity of Cell Signaling in the Neuronal Response Based on NGF Mutations and Peptidomimetics in the Treatment of Alzheimers Disease",slug:"selectivity-of-cell-signaling-in-the-neuronal-response-based-on-ngf-mutations-and-peptidomimetics-in",signatures:"Kenneth E. Neet, Sidharth Mahapatra, Hrishikesh M. Mehta",authors:[{id:"41542",title:"Prof.",name:"Kenneth",middleName:"E",surname:"Neet",fullName:"Kenneth Neet",slug:"kenneth-neet"},{id:"41995",title:"Dr.",name:"Sidhartha",middleName:null,surname:"Mahapatra",fullName:"Sidhartha Mahapatra",slug:"sidhartha-mahapatra"},{id:"41996",title:"Mr.",name:"Hrishikesh",middleName:null,surname:"Mehta",fullName:"Hrishikesh Mehta",slug:"hrishikesh-mehta"}]},{id:"19796",title:"Advances in MicroRNAs and Alzheimer’s Disease Research",slug:"advances-in-micrornas-and-alzheimer-s-disease-research",signatures:"Francesca Ruberti, Silvia Pezzola and Christian Barbato",authors:[{id:"28955",title:"Dr.",name:"Francesca",middleName:null,surname:"Ruberti",fullName:"Francesca Ruberti",slug:"francesca-ruberti"},{id:"41739",title:"Dr.",name:"Christian",middleName:null,surname:"Barbato",fullName:"Christian Barbato",slug:"christian-barbato"},{id:"82891",title:"Dr.",name:"Silvia",middleName:null,surname:"Pezzola",fullName:"Silvia Pezzola",slug:"silvia-pezzola"}]},{id:"19797",title:"Role of Mitochondria in Alzheimer ́s Disease",slug:"role-of-mitochondria-in-alzheimer-s-disease",signatures:"Genaro Genaro Gabriel Ortiz, Fermín Pacheco-Moisés, José de Jesús García-Trejo, Roció E. González-Castañeda, Miguel A. Macías-Islas, José A. Cruz-Ramos, Irma E. Velázquez-Brizuela, Elva D. Árias Merino and Alfredo Célis de la Rosa",authors:[{id:"26109",title:"Dr.",name:"Genaro",middleName:"Gabriel",surname:"Ortiz",fullName:"Genaro Ortiz",slug:"genaro-ortiz"}]},{id:"19798",title:"Oxidative Stress in Alzheimer’s Disease: Pathogenesis, Biomarkers and Therapy",slug:"oxidative-stress-in-alzheimer-s-disease-pathogenesis-biomarkers-and-therapy",signatures:"Alejandro Gella and Irene Bolea",authors:[{id:"26012",title:"Dr.",name:"Alejandro",middleName:null,surname:"Gella",fullName:"Alejandro Gella",slug:"alejandro-gella"},{id:"40278",title:"Dr.",name:"Irene",middleName:null,surname:"Bolea",fullName:"Irene Bolea",slug:"irene-bolea"}]},{id:"19799",title:"Impact of Oxidative - Nitrosative Stress on Cholinergic Presynaptic Function",slug:"impact-of-oxidative-nitrosative-stress-on-cholinergic-presynaptic-function",signatures:"Stefanie A.G. Black and R. Jane Rylett",authors:[{id:"37775",title:"Dr.",name:"R Jane",middleName:null,surname:"Rylett",fullName:"R Jane Rylett",slug:"r-jane-rylett"},{id:"42088",title:"Dr.",name:"Stefanie",middleName:"A G",surname:"Black",fullName:"Stefanie Black",slug:"stefanie-black"}]},{id:"19800",title:"Metals Involvement in Alzheimer’s Disease Pathogenesis",slug:"metals-involvement-in-alzheimer-s-disease-pathogenesis",signatures:"Rosanna Squitti and Carlo Salustri",authors:[{id:"26579",title:"Dr.",name:"Rosanna",middleName:null,surname:"Squitti",fullName:"Rosanna Squitti",slug:"rosanna-squitti"},{id:"92227",title:"Dr.",name:"Carlo",middleName:null,surname:"Salustri",fullName:"Carlo Salustri",slug:"carlo-salustri"}]},{id:"19801",title:"Alzheimer’s Disease and Metal Contamination: Aspects on Genotoxicity",slug:"alzheimer-s-disease-and-metal-contamination-aspects-on-genotoxicity",signatures:"P.D.L. Lima, M.C. Vasconcellos, R.C. Montenegro and R.R. Burbano",authors:[{id:"29038",title:"Prof.",name:"Rommel",middleName:null,surname:"Burbano",fullName:"Rommel Burbano",slug:"rommel-burbano"},{id:"40473",title:"Prof.",name:"Patricia",middleName:null,surname:"Lima",fullName:"Patricia Lima",slug:"patricia-lima"},{id:"40474",title:"Prof.",name:"Raquel",middleName:null,surname:"Montenegro",fullName:"Raquel Montenegro",slug:"raquel-montenegro"},{id:"102002",title:"Dr.",name:"Marne",middleName:null,surname:"Vasconcellos",fullName:"Marne Vasconcellos",slug:"marne-vasconcellos"}]},{id:"19802",title:"Glucose Metabolism and Insulin Action in Alzheimer’s Disease Pathogenesis",slug:"glucose-metabolism-and-insulin-action-in-alzheimer-s-disease-pathogenesis",signatures:"Domenico Bosco, Massimiliano Plastino, Antonio Spanò, Caterina Ermio and Antonietta Fava",authors:[{id:"50777",title:"Dr.",name:"Domenico",middleName:null,surname:"Bosco",fullName:"Domenico Bosco",slug:"domenico-bosco"},{id:"62537",title:"Dr.",name:"Massimiliano",middleName:null,surname:"Plastino",fullName:"Massimiliano Plastino",slug:"massimiliano-plastino"},{id:"62538",title:"Dr.",name:"Antonietta",middleName:null,surname:"Fava",fullName:"Antonietta Fava",slug:"antonietta-fava"}]},{id:"19803",title:"Insulin Resistance, Cognitive Impairment and Neurodegeneration: Roles of Nitrosamine Exposure, Diet and Lifestyles",slug:"insulin-resistance-cognitive-impairment-and-neurodegeneration-roles-of-nitrosamine-exposure-diet-and",signatures:"Suzanne de la Monte, Ming Tong and Jack R. Wands",authors:[{id:"29111",title:"Dr.",name:"Suzanne",middleName:"M.",surname:"De La Monte",fullName:"Suzanne De La Monte",slug:"suzanne-de-la-monte"},{id:"42242",title:"Dr.",name:"Ming",middleName:null,surname:"Tong",fullName:"Ming Tong",slug:"ming-tong"},{id:"42243",title:"Dr.",name:"Jack",middleName:null,surname:"Wands",fullName:"Jack Wands",slug:"jack-wands"}]},{id:"19804",title:"The Relations Between the Vitamins and Alzheimer Dementia",slug:"the-relations-between-the-vitamins-and-alzheimer-dementia",signatures:"Emel Koseoglu",authors:[{id:"35806",title:"Dr.",name:"Emel",middleName:null,surname:"Koseoglu",fullName:"Emel Koseoglu",slug:"emel-koseoglu"}]},{id:"19805",title:"Hypotension in Subcortical Vascular Dementia, a New Risk Factor – Wasn’t It Hypertension?",slug:"hypotension-in-subcortical-vascular-dementia-a-new-risk-factor-wasn-t-it-hypertension-",signatures:"Rita Moretti, Francesca Esposito, Paola Torre, Rodolfo M. Antonello and Giuseppe Bellini",authors:[{id:"31246",title:"Dr.",name:"Rita",middleName:null,surname:"Moretti",fullName:"Rita Moretti",slug:"rita-moretti"},{id:"49057",title:"Dr.",name:"Paola",middleName:null,surname:"Torre",fullName:"Paola Torre",slug:"paola-torre"},{id:"49058",title:"Dr.",name:"Francesca",middleName:null,surname:"Esposito",fullName:"Francesca Esposito",slug:"francesca-esposito"},{id:"49059",title:"Prof.",name:"Giuseppe",middleName:null,surname:"Bellini",fullName:"Giuseppe Bellini",slug:"giuseppe-bellini"}]},{id:"19806",title:"Autophagy-Derived Alzheimer’s Pathogenesis",slug:"autophagy-derived-alzheimer-s-pathogenesis",signatures:"Daijun Ling and Paul M. Salvaterra",authors:[{id:"29105",title:"Prof.",name:"Paul M.",middleName:null,surname:"Salvaterra",fullName:"Paul M. Salvaterra",slug:"paul-m.-salvaterra"},{id:"105338",title:"Dr.",name:"Daijun",middleName:null,surname:"Ling",fullName:"Daijun Ling",slug:"daijun-ling"}]},{id:"19807",title:"Plasmalogen Deficit: A New and Testable Hypothesis for the Etiology of Alzheimer’s Disease",slug:"plasmalogen-deficit-a-new-and-testable-hypothesis-for-the-etiology-of-alzheimer-s-disease",signatures:"Paul L. Wood, M. Amin Khan, Rishikesh Mankidy, Tara Smith and Dayan B. Goodenowe",authors:[{id:"28939",title:"Dr.",name:"Paul",middleName:null,surname:"Wood",fullName:"Paul Wood",slug:"paul-wood"},{id:"31895",title:"Dr.",name:"Dayan",middleName:null,surname:"Goodenowe",fullName:"Dayan Goodenowe",slug:"dayan-goodenowe"}]},{id:"19808",title:"Gangliosides as a Double-Edged Swordin Neurodegenerative Disease",slug:"gangliosides-as-a-double-edged-swordin-neurodegenerative-disease",signatures:"Akio Sekigawa, Masayo Fujita, Kazunari Sekiyama, Yoshiki Takamatsu, Jianshe Wei and Makoto Hashimoto",authors:[{id:"35792",title:"Dr.",name:"Makoto",middleName:null,surname:"Hashimoto",fullName:"Makoto Hashimoto",slug:"makoto-hashimoto"},{id:"44002",title:"Dr.",name:"Akio",middleName:null,surname:"Sekigawa",fullName:"Akio Sekigawa",slug:"akio-sekigawa"},{id:"44047",title:"Dr.",name:"Masayo",middleName:null,surname:"Fujita",fullName:"Masayo Fujita",slug:"masayo-fujita"},{id:"44048",title:"Dr.",name:"Kazunari",middleName:null,surname:"Sekiyama",fullName:"Kazunari Sekiyama",slug:"kazunari-sekiyama"},{id:"44049",title:"Dr.",name:"Yoshiki",middleName:null,surname:"Takamatsu",fullName:"Yoshiki Takamatsu",slug:"yoshiki-takamatsu"},{id:"82755",title:"Prof.",name:"Jianshe",middleName:null,surname:"Wei",fullName:"Jianshe Wei",slug:"jianshe-wei"}]},{id:"19809",title:"Structure Based 3D-QSAR Studies on Cholinesterase Inhibitors",slug:"structure-based-3d-qsar-studies-on-cholinesterase-inhibitors",signatures:"Zaheer ul Haq and Reaz Uddin",authors:[{id:"29735",title:"Dr.",name:"Zaheer",middleName:null,surname:"Ul-Haq",fullName:"Zaheer Ul-Haq",slug:"zaheer-ul-haq"},{id:"41882",title:"Dr.",name:"Reaz",middleName:null,surname:"Uddin",fullName:"Reaz Uddin",slug:"reaz-uddin"}]},{id:"19810",title:"Tau Oligomers as Potential Drug Target for Alzheimer Disease (AD) Treatment",slug:"tau-oligomers-as-potential-drug-target-for-alzheimer-disease-ad-treatment",signatures:"Rakez Kayed",authors:[{id:"26010",title:"Prof.",name:"Rakez",middleName:null,surname:"Kayed",fullName:"Rakez Kayed",slug:"rakez-kayed"}]},{id:"19811",title:"In Silico Design of Preventive Drugs for Alzheimer’s Disease",slug:"in-silico-design-of-preventive-drugs-for-alzheimer-s-disease",signatures:"Arpita Yadav and Minakshi Sonker",authors:[{id:"26009",title:"Prof.",name:"Arpita",middleName:null,surname:"Yadav",fullName:"Arpita Yadav",slug:"arpita-yadav"},{id:"39431",title:"Ms.",name:"Minakshi",middleName:null,surname:"Sonker",fullName:"Minakshi Sonker",slug:"minakshi-sonker"}]},{id:"19812",title:"Protective Roles of the Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insolinotropic Polypeptide Hormones in Neurodegeneration",slug:"protective-roles-of-the-incretin-hormones-glucagon-like-peptide-1-and-glucose-dependent-insolinotrop",signatures:"Christian Hölscher",authors:[{id:"31289",title:"Dr.",name:"Christian",middleName:null,surname:"Holscher",fullName:"Christian Holscher",slug:"christian-holscher"}]}]}]},onlineFirst:{chapter:{type:"chapter",id:"72792",title:"Parkinsonism and Potential of Mucuna Beans",doi:"10.5772/intechopen.92855",slug:"parkinsonism-and-potential-of-mucuna-beans",body:'
1. Introduction
Research in plant-based medicine is gaining much more attention due to its lack of side effects, its large availability, and its multiple medicinal applications. In the past few years, this has also increased people’s awareness toward functional food, thus enhancing the consumption rate of legumes enormously [1]. The attention toward Mucuna improved colossally after 1937 when it was initially revealed that a huge quantity of levodopa is present in it. Genus Mucuna, which is familiar by different names (like: velvet beans, sea beans, cowitch, buffalo beans, cowhage, atmagupta, kapikachu, and dopa bean), is one of the conventional medicine performing crucial roles in both health and disease management. Mucuna is an excellent source of proteins, starch, micronutrients, dietary fiber, and bioactive compounds (L-DOPA), which play a great role in the traditional as well as modern medicine all over the world against Parkinson’s disease. The genus Mucuna belongs to the family Leguminosae distributed throughout the tropical and subtropical regions of various countries of the world comprising hundreds of species [2]. Recently, Pulikkalpura et al. [3] and Patil et al. [4, 5] studied the occurrence and biochemical activities of various Mucuna species in India.
Plant-based remedies are most beneficial remedies, having a cumulative effect of phytochemical and other bioactive components obtained from plants. Mucuna has various actions like antioxidant activity, anti-inflammatory activity, wound-healing activity, and activity against snake bite. Along with all this, Mucuna is also rich in nutritional and anti-nutritional compounds (rich in minerals) [6]. Mucuna is also well known for nematicidic effects and also possesses notable allelopathic activity, which was reported by Gliessman et al. [7]. In countries like Guatemala and Mexico, it is used as a coffee substitute. Along with that, in some countries (lower hills of the eastern country and Himalayas), it is commonly consumed as vegetable beans after frying and boiling. Mucuna seed powder has been used in active management of Parkinson’s disease in several countries due to its L-DOPA content.
In early health care system of India, Parkinson’s disease (PD) is known as “Kampavata”, which is a common neurological disorder related to neuromelanin containing nigrostriatal dopaminergic neuronal loss. Kampa means tremor and vata means lack of muscular movement. It was found via door-to-door survey in Bangalore (Karnataka, India) that 76 per 100, 000 (age adjusted) and 33 per 100,000 (crude prevalence) people suffered from Parkinsonism [8]. Out of that, 5–10% of individuals having PD belong to families with history of genetic disorders [9, 10]. The disease commonly occurs in the age group of 60–80. A survey on Parsi community in Mumbai shows that they were diminutively stable to PD [8]. Diagnosis of disease is sometimes difficult by clinical method, which involves analysis by considering large number of motor and non-motor symptoms in PD patients. PD is caused due to decrease in dopaminergic neurons in the substantia nigra pars compacta (SNpc) part of the brain, which leads to motor symptoms including rigidity, bradykinesia, tremor, and development of some non-motor symptoms in later stages of the disease. Although there is significant number of improvements in the medicinal and surgical actions against PD, scientists have not yet identified definite targets for disease management. According to research by Ramanan and Saykin, neurodegeneration is divided in to four main levels out of which aggregation and accumulation of abnormal or misfolded mutated proteins is crucial [11]. Some reports examine that oxidative stress (OS) and neuro-inflammation (NIF) are the main reasons of neurodegenerative disease. Thus, to tackle these neurodegenerative disorders, researchers have diverted their attention toward finding oxidative stress enzymes and pathogenesis of PD. Abraham et al. studied 115 cases of PD and concluded that catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (G-Px), and glucose-6-phosphate dehydrogenase (G6PD) levels are present in greater quantities in PD patients as compared to the control patients [11]. Various oxidative stress enzymes, pro-inflammatory cytokines, proteinase, reactive oxygen intermediates, and complement proteins are secreted by the immune cells against the neuronal cell damage response, which leads to inflammation. Along with mitochondrial dysfunction, altered proteolysis, oxidative damage of cells and Lewy bodies’ formation are some of the symptoms of Parkinson’s disease.
There are various strategies for the management for PD but there is no complete cure for this disease. The only management of the lowered dopamine levels is to control various metabolic inhibitions and enhancement pathways, preventing degeneration of neurons and other non-dopaminergic (surgelogical) treatment. L-DOPA (L-3,4 dihydroxy phenylalanine) is a non-protein amino acid used in the treatment of Parkinson’s disease. It acts as precursor of dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline). It is synthesized by plants, animals, and microbes (bacterial and fungus) and has a different role in each source. Chemical synthesis of L-DOPA is easy but the purification of L and D forms is slightly complicated and expensive. Synthetic L-DOPA is considered as anti-nutritional factor and its consumption causes abdominal distention, vomiting, dyskinesia, nausea, etc. This happens when L-DOPA is converted to dopamine in the peripheral nervous system by enzyme dopa decarboxylase. Whereas, L-dopa is also used as the treatment against infertility recovering the spermatogenic harm to some extent. Numerous other secondary metabolites produced by plants like flavonoids and phenolics illustrate strong anti-inflammatory and antioxidant potentials, which have a significant role in the management of health and disease of human beings.
The current book chapter is focused on the use of plant source of L-DOPA and neuroprotective potential of magical dopa beans and their special prominence in Parkinson’s disease treatment. Along with this we have also focused on the models and other treatments used in treating Parkinson’s disease.
2. Treatment strategies of Parkinson’s disease
2.1 Neuroprotective potential of Mucuna
Parkinson’s disease (PD) was initially discovered by Dr. James Parkinson in 1817; it is a chronic neurological disorder triggered by a progressive loss of dopaminergic neurons present in the nigrostriatal part of the brain and found to be common in U.S [12]. In 1970, only few effective drugs were available for treatment of the PD but there is no such therapy yet that completely treats PD. Only thing we can do is to stop the progression of Parkinson’s disease or delay the of PD by replacement of dopaminergic neuron or by mimicking the neuron by using substituent. Management of PD is mainly divided into two categories: first involves improving symptomatic treatment of motor and non-motor types of symptoms and second will be addressing potential causes of PD. Firstly in 1978 Vaidya et al., published the report that PD can be treated by Mucuna extract, a natural source of levodopa having better activity than the synthetic version of levodopa drug [13]. Similar studies were reported in 1990 and 1994 by Kempster et al. and Rabey et al. [14, 15]. L-DOPA is a precursor of dopamine (Figure 1), norepinephrine (noradrenaline), and epinephrine (adrenaline), together known as catecholamines. The dopamine produced cannot cross the blood–brain barrier but L-DOPA can. Outside the brain, L-DOPA can directly be converted to 3-O-methyldopa (3-OMD) by catechol-O-methyl transferase (COM T) and then further to vanillactic acid (VLA), which leads to primary same side effect. To avoid this conversion, standard clinical practices use DOPA decarboxylase inhibitor such as carbidopa or benserazide and often a catechol-O-methyl transferase (COMT) inhibitor [16, 17, 18]. L-DOPA present in Mucuna plant (anti-Parkinson’s drug) [19, 20, 21] helps to produce dopamine. Along with L-DOPA, the reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced by Mucuna are stress-producing free radicals playing a great role in the physiological functioning of the body [21, 22, 23, 24, 25, 26, 27, 28, 29, 30]. The content of antioxidant compounds using different solvents in different species of Mucuna, the concentration of antioxidants and other phytochemicals are extremely different. Ethanolic extract of Mucuna seed shows good antioxidant activity due to high phenolic content as compared to methanol, water, and acetone [31]. Some reports also conclude that water is as universal solvent, which shows the significant quantity of phenolic, flavonoids, and strong antioxidants which have the ability to scavenge free radicals using different assays. LCMS (liquid chromatography mass spectrophotometry) report of four different species (Table 1) shows that there are various components like phenolic flavonoids and bioactive compounds present in the Mucuna that are responsible for the production of reactive species [32]. Along with L-DOPA and antioxidants, other secondary metabolites like phenolics, flavonoids, vitamins, enzymes, and protein also have a cumulative effect in the management of PD. Few reports on Mucuna show correlation between L-DOPA, protein, and carbohydrates. The use of plants for the treatment of PD is more beneficial than chemically manufactured L-dopa due to its high potential required in the levo and dextro form purification. It is also studied that various compounds present in Mucuna are responsible for the antimicrobial action, which can be utilized in dealing with various infectious diseases and ulcers [31, 32, 44]. Experiments on various plant pathogens suggest that methanolic extract of Mucuna pruriens seeds showed the highest antimicrobial activity [45]. A similar type of study done by Pujari et al. also determined that methanol extracts of Mucuna pruriens seeds were found to have the best inhibiting activity among all scrutinized pathogens as compared to ethanol and acetone solvents. But alcoholic extract of Mucuna pruriens (L.) leaves has significant antioxidant and antibacterial activity [45]. Dopaminergic agonists or dopamine replacement therapy is a common and most effective way to cure PD. It decreases the signs of disease by sustaining the level of dopamine; however, it cannot regenerate or halt the degeneration. It only replaces or mimics dopamine by inhibiting its breakdown. Apomorphine, bromocriptine, pergolide, piribedil, pramipexole, and ropinirole are some dopaminergic agonists mainly used to heal the PD. All these bioactive compounds present in the Mucuna species have cumulative effect in the treatment of PD. Mucuna pruriens is a species from the Fabaceae family and Faboideae subfamily. M. pruriens is an annual twinning plant in bushes, hedges, and one of the popular medicinal plants indigenous to tropical countries like India [42]. It is useful in relieving inflammation, delirium, neuropathy, cephalalgia, and general debility, nephropathy, dysmenorrhea, amenorrhea, ulcers, constipation, elephantiasis, consumption, helminthiasis, fever, and dropsy. The trichomes of pods contain serotonin and mucunain. The trichomes are used as anthelmintic. Seeds contain glutathione, gallic acid, levodopa (4-3, 4-dihydroxy phenylalanine), lecithin, prurenine, prurenidine, glycosides, nicotine, minerals, and dark brown viscous oil [42].
Figure 1.
Synthesis pathway of L-DOPA, dopamine and further metabolites.
Natural products are valuable sources of bioactive compounds that can be exploited for novel therapeutic potential in PD pathogenesis. There are number of publications reported till now dealing with experiments on hundreds of compounds from various plant species for their different activity in curing the Parkinson’s disease [46]. However, rapid screening of plant-derived natural products and characterization of bioactive compounds is a challenging job. This problem was combated by using Drosophila melanogaster and zebrafish as experimental models at initial stages then followed by studies on various experimental models like, C. elegans, mice/rat, and also cell lines (e.g., murine BV-2 microglia and human SH-SY5Y neuroblastoma cells). Few verdicts using different models are listed underneath.
2.2.1 Drosophila melanogaster
Drosophila melanogaster, universally familiar as the fruit fly, have turned up as an outstanding model for human neurodegenerative diseases, comprising PD. Due to their high degree of conserved molecular pathways with mammalian models, Drosophila PD models serve to be an inexpensive solution to pilot stages of target validation in the drug discovery pipeline. Fruit fly acts as a screening platform to evaluate the therapeutic potential of phytochemicals from natural extracts against PD [47]. Drosophila melanogaster is a persuasive tool to explore molecular facets and physiopathology of Parkinson’s disease (PD) [48]. There are studies that compare the effects of L-DOPA vs. MP extract using a Drosophila model of autosomal recessive PD in which flies carried a mutation in the PTEN-induced putative kinase 1 (PINK-1) gene [49]. Their observations illustrates that Drosophila fed on MP had a significantly extended lifespan, showed a restored olfactory response and improved climbing behavior compared to flies that consumed L-DOPA.
2.2.2 Zebra fish (Danio rerio)
Owing to its large number of favorable properties, Zebra fish has been used widely as experimental animal for various diseases. Zebra fish are inexpensive, easy to conserve, develop rapidly, and breed in large quantities. Larval zebra fish are also extensively used in toxicity screens since they have a permeable skin through which substances added in the rearing medium are effortlessly taken up. This permits for greater control over dosage and ease of administering substances to large numbers of animals. Furthermore, larval behaviors can be exploited in assays to test the effects of the treatment. Being a vertebrate, the central nervous system of larval zebra fish expressions an extremely homologous to humans. Therefore, toxicology studies performed on larval zebra fish can be very helpful in deciding the putative targets in humans [50]. Thus Danio rerio commonly known as zebrafish is a charming popular animal model for treatments in neuropharmacology and pharmacogenetics. Both the adult and larval zebrafish are presently studied to increase the understanding of central nervous system’s function and dysfunction [51]. There are various studied reports by Gerlai et al. on the latent learning, behavior, and memory alteration of adult zebrafish [51, 52, 53, 54, 55]. Apart from fish, there are several other experimental models.
2.2.3 Mice/rat/rodents
Many clinical trials have been done on herbal extract and their isolated compound, which has opened a new scenario in the area of PD. The models of PD are induced by different chemical compounds like 6-OHDA, rotenone, and MPTP based on the aim of the experiment. Singh et al. investigated the effect of ethanolic extract of Mucuna pruriens (Mp) on the reduction of oxidative stress level, nitric oxide (NO), and subsequent influence on lipid peroxidation in paraquat (PQ)-induced Parkinsonian mouse model. MTTP-induced Parkinson mouse models were also studied by them for the reduction of estrogen by Mucuna pruriens [26, 55, 56]. Yadav et al. demonstrated that Mp seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity and the expression of tyrosine hydroxylase (TH) in SN and striatum of the brain in PQ-intoxicated mice [56]. Apoptotic pathways of dopaminergic neurons in the PQ mouse model were also found to be inhibited by the neuroprotective activity of Mucuna pruriens [57]. Experiments also reveal that the Mucuna pruriens has a resilient anti-inflammatory property that diminishes the neuroinflammation by plummeting inducible nitric oxide synthase expression in Parkinsonian mice model. Symptomatic and neuroprotective efficacy in rodent model of Parkinson’s disease using Mucuna pruriens seed extract were studied by Kasture and Pontis [58]. Significance of M. pruriens in sperm parameters and sexual behavior of streptozotocin-induced diabetic male rat were studied by Sekar Suresh et al. [59]. Earlier efforts exhibited the capability of Mucuna pruriens seeds extract to induce contralateral turning behavior in the 6-hydroxydopamine (6-OHDA)-lesion persuaded rat model of PD [60]. Likewise, the potential of Mucuna seed powder extract significantly improved activity of brain mitochondrial complex-I without disturbing total monoamine oxidase activity in vitro [61]. Mucuna pruriens also has the potential to amend immune components like tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interferon-λ (IFN-λ), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS), and interleukin-2 (IL-2) in the central nervous system, thereby, averting the progression of dopaminergic neurons degeneration, in PD [62]. Moreover M. pruriens was also assessed for levodopa pharmacokinetics by Sarrafchi et al., in a double-blinded clinical and pharmacological study. They observed that administration of M. pruriens at doses of 2.5, 5.0, or 10.0 g/kg/day for 52 weeks significantly increased the dopamine content of the cortex in animal model of PD. Therefore, they concluded that M. pruriens seed powder with natural source of levodopa probably has benefits over conventional levodopa preparations in treatment of PD due to its longer action and speedy onset without increase in adverse effect [63]. Thus, M. pruriens would seem to be a remarkable commercially viable alternative to standard L-dopa [64]. Likewise, an improvement in motor skills and dyskinesia analogous to those induced by equivalent doses of L-DOPA was also found to be induced by M. pruriens preparations in rat and macaque monkey models of PD [61]. Therefore, all these studies strongly advocate the use of Mucuna pruriens: a treasurable herbal plant for treatment of PD.
2.2.4 Human trials
Copious studies have scrutinized the effect of MP in PD patients. The bioavailability of L-DOPA in the central nervous system is about one-fifth when pooled with carbidopa or benserazide due to nonexistence of DOPA decarboxylase inhibitor (DDCI) in Mucuna [61, 62, 63, 64, 65]. Even then, the first report in 1978 revealed that 23 PD patients were treated with MP with similar effect and better tolerance than L-DOPA/benserazide. This study was followed by an open study where 60 PD patients in Hoehn and Yahr stage I–IV were treated with MP preparations for over 12 weeks, which led to momentous headways in both UPDRS score and the Hoehn and Yahr stage. This captivated the attention on the registration of Mucuna preparation (Zandopa™) as a treatment for PD in India [61]. Cilia et al. executed a crossover study (N = 14) on PD patients in an advanced stage with motor fluctuations and peak-of-dose dyskinesia. The observations indicated better motor improvement on Mucuna powder consumption in comparison to the effect imparted by intake of an equivalent dose of L-DOPA/benserazide [66]. Innumerable experiments are still under investigation by several assemblages of researchers from all over the world to understand the PD progression and come up with innovative strategies to treat Parkinson’s disease [61, 62].
2.3 Other drugs and their effects
Gargantuan improvement has been done to treat the PD for over half-century. Diverse individuals from different places have come up with different treatments. Miscellaneous categories of drugs are being used apart from levodopa. Yet to date there are no complete cure strategies for PD. But some symptomatic palliative treatments are being implemented to slow down the disease progression. There are various enzymes used in the management of PD. Enzymes monoamine oxidase-B (MAO-B) and catechol-o-methyl-transferase (COMT) are normally involved in metabolism of dopamine. Therefore, few inhibitors of the two enzymes (MAO-B and COMT) have been extensively studied. Inhibitors like selegiline, rasagiline, tolcapone, and entacapone are being used for the disease modification in PD from previous few years. N-propargyl-methamphetamine is known as selegiline, which is an irreversible inhibitor of MAO-B. Action of selegiline was studied in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism in monkeys [67]. It was used at concentration of 10 mg/day, but they found that it loses its selectivity at higher concentrations of dosage [67]. Various other reports show the neuroprotective potential of selegiline but there is no such report proving that selegiline has “disease-modification” effects [68, 69, 70]. The in vitro and in vivo experimental Parkinsonian models indicate that rasagiline (N-propargyl-1-(R)-aminoindan) acted as irreversible MAOB inhibitor exhibiting anti-apoptotic effect [68, 69, 70].
There are various studies proving that the dopamine agonist or levodopa has stronger symptomatic benefits as the MAOB inhibitor; however, there was no evidence of direct comparison between them [71, 72, 73, 74]. Older people provide more rapid onset improvement than younger patients. Dopamine agonist is more prominent in younger people with dyskinesia and older people with orthostatic hypotension and CNS effects (hallucinations). Pharmacokinetic studies revel that COMT inhibitors prevent degradation of peripheral levodopa by extending half-life and also permit it to cross the blood–brain barrier in higher concentrations. There are large number of compounds used to treat motor symptoms and motor complications occurring due to dopaminergic mode of action as reported in review by Oertel et al. Whereas carbidopa (modified form of L-dopa soluble), opicapone (COMT-inhibitor), safinamide (MAO-B-inhibitor), droxidopa (NMDA-receptor antagonist), stradefylline (noradrenaline precursor), tozadenant (Adenosine 2A receptor antagonist), pimavanserin (5HT2A inverse agonist), and donepezil (Acetyl choline esterase inhibitor) are some of the most common compounds used in the treatment internationally [16]. Along with benzhexol and orphenadrine, anticholinergic drugs are also recommended as they reduce the effect of acetylcholine in the brain by antagonizing cholinergic receptors and restore the acetylcholine/dopamine balance within the brain. They also prevent hyperkinesia.
3. Neurosurgical treatments
Apart from chemical drugs, there are some physical therapies involved in the treatment of PD that have given special attenuation toward movement (motor) symptoms of patient. In this treatment, parts of the brain involved in the progression of disease are either removed, bombard with electric impulse, or subjected to neuroimaging [75]. In pallidotomy and thalamotomy, the globus pallidus part of the brain, which is overactive in the PD patients, resulting in slackening down the body movements, is surgically destroyed permanently. This destruction of globus pallidus significantly reduces tremor, bradykinesia, balance problems, and writing problems, and eliminates rigidity, while thalamus part is involved in the involuntary movement (like tremor) [76, 77]. Deep brain stimulation (DBS) is also one of the unconventional treatments used, in which brain pace markers (microelectrode) are applied where an electrical impulse passes over the electrodes to the specific part of the brain. DBS decreases the secondary difficulties elevated due to dopaminergic replacement therapy. There are survival disadvantages of pallidotomy and thalamotomy cases due to dysphagia, hypophonia, and dysarthria [78]. DBS is having significant results over thalamotomy because it does not need hardware and have very fewer side effects and relatively lowers the risk of complications. Besides all these pharmacological and surgical treatments, few other strategies like speech therapy, mediations are being currently explored along with it for the treatment of PD. Apart from singular therapy, doctors are now recommending a combination of treatments to impart cumulative effect in the treatment of PD.
4. Conclusion
Mucuna is a natural, rich source of precursor of dopamine that acts as gold standard for the treatment of Parkinson’s disease to control body movements, hormonal balance, emotion, and memory. The Mucuna is a pharmaceutically and biochemically valuable plant used from the early days, having high market value due to its large amount of bioactive compounds. It also contains a maximum amount of phenolics, flavonoids, and antioxidants, which have a cumulative role in the release of oxidative stress produced by body systems. Drosophila melanogaster, zebrafish, mice/rat, and human models were used to check the potential of Mucuna seed powder on rotenone, MPTP-induced Parkinson’s model, and it was concluded that Mucuna seeds have great values in the treatment of PD. The book chapter also covers various other drugs and neurosurgical treatments used in Parkinson’s disease. It also gives an introduction to various other species (apart from Mucuna FSTA) used in the PD treatment and lowers the burden on commonly used(Mucuna pruriens) species.
\n',keywords:"Kampavata, L-DOPA, Mucuna, neuroprotective, experimental models, neurosurgical remedy",chapterPDFUrl:"https://cdn.intechopen.com/pdfs/72792.pdf",chapterXML:"https://mts.intechopen.com/source/xml/72792.xml",downloadPdfUrl:"/chapter/pdf-download/72792",previewPdfUrl:"/chapter/pdf-preview/72792",totalDownloads:122,totalViews:0,totalCrossrefCites:0,dateSubmitted:"January 14th 2020",dateReviewed:"May 18th 2020",datePrePublished:"July 13th 2020",datePublished:null,dateFinished:null,readingETA:"0",abstract:"Parkinson’s is a neurodegenerative disease, which is common all over the world. Various aspect like damages of reactive oxygen species, excitotoxicity, mitochondrial dysfunction, and inflammation-facilitated cell damages are included in the etiology of disease. Good-balanced nutrition is an important part involved in the body health maintenance and reduction in the risk of chronic diseases. Genus Mucuna falls under family Fabaceae, containing high contents of L-DOPA (commonly used as an anti-Parkinson drug). Plant-based medicines are the superfluous source of polyphenols, flavonoids, carotenoids, antioxidants (ROS and RNS), terpenoids, isoflavonoids, and other biologically active phytochemicals. All these molecules have health beneficial effects with superlative pharmaceutical values. The existing chapter summaries to determine the influence of different nutritional, anti-nutritional, and medicinal potential of the Mucuna species present in India and its significance in the management of Parkinson’s disease (Shaking Palsy) as well as other medicinal values. It also covers various treatment models used in studying the Parkinson’s disease like Drosophila melanogaster, zebrafish, mice, rat, and humans. This chapter also focuses light on the neurosurgical treatments used in the treatment of Parkinson’s disease. This study concluded that the use of Mucuna seeds for the treatment of Parkinson’s disease is the best choice besides chemical drugs and other therapies.",reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/72792",risUrl:"/chapter/ris/72792",signatures:"Suresh S. Suryawanshi, Prajakta P. Kamble, Vishwas A. Bapat and Jyoti P. Jadhav",book:{id:"9566",title:"Bioethics",subtitle:null,fullTitle:"Bioethics",slug:null,publishedDate:null,bookSignature:"Dr. Thomas F. Heston and Dr. Sujoy Ray",coverURL:"https://cdn.intechopen.com/books/images_new/9566.jpg",licenceType:"CC BY 3.0",editedByType:null,editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:null,sections:[{id:"sec_1",title:"1. Introduction",level:"1"},{id:"sec_2",title:"2. Treatment strategies of Parkinson’s disease",level:"1"},{id:"sec_2_2",title:"2.1 Neuroprotective potential of Mucuna",level:"2"},{id:"sec_3_2",title:"2.2 Experimental models studied for PD",level:"2"},{id:"sec_3_3",title:"2.2.1 Drosophila melanogaster",level:"3"},{id:"sec_4_3",title:"2.2.2 Zebra fish (Danio rerio)",level:"3"},{id:"sec_5_3",title:"2.2.3 Mice/rat/rodents",level:"3"},{id:"sec_6_3",title:"2.2.4 Human trials",level:"3"},{id:"sec_8_2",title:"2.3 Other drugs and their effects",level:"2"},{id:"sec_10",title:"3. Neurosurgical treatments",level:"1"},{id:"sec_11",title:"4. Conclusion",level:"1"}],chapterReferences:[{id:"B1",body:'Luthria DL, Pastor-Corrales MA. Phenolic acids content of fifteen dry edible bean (Phaseolus vulgaris L.) varieties. Journal of Food Composition and Analysis. 2006;19:205-211. DOI: 10.1016/j.jfca.2005.09.003'},{id:"B2",body:'Jeff J, Toby R, Michael J, Doyle JJ, Herendeen P, Hughes C, et al. Legume phylogeny and classification in the 21st century: Progress, prospects and lessons for other species-rich clades. Taxon. 2013;62:217-248. DOI: 10.12705/622.8'},{id:"B3",body:'Pulikkalpura H, Kurup R, Mathew PJ, Baby S. Levodopa in Mucuna pruriens and its degradation. Scientific Reports. 2015;5:2-10. DOI: 10.1038/srep11078'},{id:"B4",body:'Gaikwad SV, Gurav RV, Yadav SR. Karyotype studies in Mucuna macrocarpa wall and Mucuna sanjappae Aitawade et Yadav (Fabaceae) from India. Chromosome Botany. 2017;12:52-55. DOI: 10.3199/iscb.12.52'},{id:"B5",body:'Patil R, Aware C, Gaikwad S, Rajebhosale M, Bapat V, Yadav S, et al. RP-HPLC analysis of anti-Parkinson’s drug l-DOPA content in Mucuna species from Indian subcontinent. Proceedings of the National Academy of Sciences, India, Section B. 2019;89:1413-1420. DOI: 10.1007/s40011-018-01071-9'},{id:"B6",body:'Suryawanshi SS, Kamble PP, Bapat VA, Jadhav JP. Bioactive components of magical velvet beans. Legume;2(2020). DOI: 10.5772/intechopen.92124'},{id:"B7",body:'Gliessman SR, Garcia RE, Amador MA. The ecological basis for the application of traditional agricultural technology in the management of tropical agro-ecosystems. Agro-Ecosystems. 1981;7:173-185. DOI: 10.1016/0304-3746(81)90001-9'},{id:"B8",body:'Gourie-Devi M, Gururaj G, Satishchandra P, Subbakrishna DK. Prevalence of neurological disorders in Bangalore, India: A community-based study with a comparison between urban and rural areas. Neuroepidemiology. 2004;23:261-268. DOI: 10.1159/000080090'},{id:"B9",body:'Cookson MR, Xiromerisiou G, Singleton A. How genetics research in Parkinson’s disease is enhancing understanding of the common idiopathic forms of the disease. Current Opinion in Neurology. 2005;18:706-711. DOI: 10.1097/01.wco.0000186841.43505.e6'},{id:"B10",body:'Warner TT, Schapira AHV. Genetic and environmental factors in the cause of Parkinson’s disease. Annals of Neurology. 2003;53:16-25. DOI: 10.1002/ana.10487'},{id:"B11",body:'Ramanan VK, Saykin AJ. Pathways to neurodegeneration: Mechanistic insights from GWAS in Alzheimer’s disease, Parkinson’s disease, and related disorders. American Journal of Neurodegenerative Disease. 2013;2:145-175'},{id:"B12",body:'Hughes RC. Parkinson’s disease and its management. BMJ. 1994;308:281. DOI: 10.1136/bmj.308.6923.281'},{id:"B13",body:'Li H, Yu C, Chen R, Li J, Li J. Novel ionic liquid-type Gemini surfactants: Synthesis, surface property and antimicrobial activity. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2012;395:116-124. DOI: 10.1016/j.colsurfa.2011.12.014'},{id:"B14",body:'Kempster PA, Bogetic Z, Secombei JW, Martin HD, Balazs ND, Wahlqvist ML. Motor effects of broad beans (Vicia faba) in Parkinson’s disease: Single dose studies. Asia Pacific Journal of Clinical Nutrition. 1993;2:85-89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24352104'},{id:"B15",body:'Manyam BV. Paralysis agitans and levodopa in Ayurveda: Ancient Indian medical treatise. Movement Disorders. 1990;5:47-48. DOI: 10.1002/mds.870050112'},{id:"B16",body:'Oertel WH. Recent advances in treating Parkinson’s disease. F1000Research. 2017;6:1-14. DOI: 10.12688/f1000research.10100.1'},{id:"B17",body:'Ellis JM, Fell MJ. Current approaches to the treatment of Parkinson’s disease. Bioorganic & Medicinal Chemistry Letters. 2017;27:4247-4255. DOI: 10.1016/j.bmcl.2017.07.075'},{id:"B18",body:'Barclay CL, Suchowersky O, Rivest J. COMT inhibitors in Parkinson’s disease. The Canadian Journal of Neurological Sciences. 2008;26:34-38'},{id:"B19",body:'Lieu CA, Venkiteswaran K, Gilmour TP, Rao AN, Petticoffer AC, Gilbert EV, et al. The antiparkinsonian and antidyskinetic mechanisms of Mucuna pruriens in the MPTP-treated nonhuman primate. Evidence-based Complementary and Alternative Medicine. 2012;2012. DOI: 10.1155/2012/840247'},{id:"B20",body:'Lampariello L, Cortelazzo A, Guerranti R, Sticozzi C, Valacchi G. The magic velvet bean of Mucuna pruriens. Journal of Traditional and Complementary Medicine. 2012;2:331-339. DOI: 10.1016/S2225-4110(16)30119-5'},{id:"B21",body:'Yadav MK, Upadhyay P, Purohit S, Pandey BL, Shah H. Phytochemistry and pharmacological activity of Mucuna pruriens: A review. International Journal of Green Pharmacy. 2017;11:69-73'},{id:"B22",body:'Wong SP, Leong LP, William Koh JH. Antioxidant activities of aqueous extracts of selected plants. Food Chemistry. 2006;99:775-783. DOI: 10.1016/j.foodchem.2005.07.058'},{id:"B23",body:'Murthy SN, Malgaonkar MM, Shirolkar AR, Pawar SD, Sangvikar S. A comparative assessment of pharmacologically active principles and antioxidant activity of commonly occurring Mucuna sp. in India. International Journal of Ayurveda and Pharma Research. 2015;3:8-13'},{id:"B24",body:'Longhi JG, Perez E, de Lima JJ, Cndido LMB. In vitro evaluation of Mucuna pruriens (L.) DC. antioxidant activity. Brazilian Journal of Pharmaceutical Sciences. 2011;47:535-544. DOI: 10.1590/S1984-82502011000300011'},{id:"B25",body:'Aitawade MM, Yadav SR. Mucuna sanjappae, a new species from the North-Western Ghats, India. Kew Bulletin. 2012;67:539-543. DOI: 10.1007/s12225-012-9369-1'},{id:"B26",body:'Yadav SK, Rai SN, Singh SP. Mucuna pruriens reduces inducible nitric oxide synthase expression in Parkinsonian mice model. Journal of Chemical Neuroanatomy. 2017;80:1-10. DOI: 10.1016/j.jchemneu.2016.11.009'},{id:"B27",body:'Oseni OM, Pande V, Nailwal TK. A review on plant tissue culture, a technique for propagation and conservation of endangered plant species. International Journal of Current Microbiology and Applied Sciences. 2018;7:3778-3786. DOI: 10.20546/ijcmas.2018.707.438'},{id:"B28",body:'Misra L, Wagner H. Extraction of bioactive principles from Mucuna pruriens seeds. Indian Journal of Biochemistry & Biophysics. 2007;44:56-60'},{id:"B29",body:'Vadivel V, Biesalski HK. Bioactive compounds in velvet bean seeds: Effect of certain indigenous processing methods. International Journal of Food Properties. 2012;15:1069-1085. DOI: 10.1080/10942912.2010.513466'},{id:"B30",body:'Kavitha C, Thangamani C. Amazing bean Mucuna pruriens: A comprehensive review. Journal of Medicinal Plants Research. 2014;8:138-143. DOI: 10.5897/JMPR2013.5036'},{id:"B31",body:'Mastan SA, Ramayya PJ, Naidu LM, Mallikarjuna K. Antimicrobial activity of various extracts of Mucuna pruriens leaves. Biomedical and Pharmacology Journal. 2009;2:55-60'},{id:"B32",body:'Suryawanshi SS, Rane MR, Kshirsagar PR, Kamble PP, Jadhav JP. Antioxidant, antimicrobial activity with mineral composition and LCMS based phytochemical evaluation of some Mucuna species from India. International Journal of Pharma and Bio Sciences. 2019;9:312-324'},{id:"B33",body:'Aware C, Patil R, Gaikwad S, Yadav S, Bapat V, Jadhav J. Evaluation of L-dopa, proximate composition with in vitro anti-inflammatory and antioxidant activity of Mucuna macrocarpa beans: A future drug for Parkinson treatment. Asian Pacific Journal of Tropical Biomedicine. 2017;7:1097-1106. DOI: 10.1016/j.apjtb.2017.10.012'},{id:"B34",body:'Inamdar S, Joshi S, Jadhav J, Bapat V. Innovative use of intact seeds of Mucuna monosperma Wight for improved yield of L-DOPA. Natural Products and Bioprospecting. 2012;2:16-20. DOI: 10.1007/s13659-011-0051-3'},{id:"B35",body:'Rane M, Suryawanshi S, Patil R, Aware C, Jadhav R, Gaikwad S, et al. Exploring the proximate composition, antioxidant, anti-Parkinson’s and anti-inflammatory potential of two neglected and underutilized Mucuna species from India. South African Journal of Botany. 2019;124:304-310. DOI: 10.1016/j.sajb.2019.04.030'},{id:"B36",body:'Patil RR, Rane MR, Bapat VA, Jadhav JP. Phytochemical analysis and antioxidant activity of Mucuna sanjappae: A possible implementation in the Parkinson’s disease treatment. Journal of Pharmaceutical and Medical Research. 2016;2:48-51'},{id:"B37",body:'Patil RR, Aware C, Gaikwad S, Yadav S. RP-HPLC analysis of anti-Parkinson’s drug l-DOPA content in Mucuna species from Indian subcontinent. Proceedings of the National Academy of Sciences, India, Section B: Biological Sciences. 2019. DOI: 10.1007/s40011-018-01071-9'},{id:"B38",body:'Rai SN, Birla H, Singh SS, Zahra W, Patil RR, Jadhav JP, et al. Mucuna pruriens protects against MPTP intoxicated neuroinflammation in Parkinson’s disease through NF-$κ$B/pAKT signaling pathways. Frontiers in Aging Neuroscience. 2017;9:1-14. DOI: 10.3389/fnagi.2017.00421'},{id:"B39",body:'Contin M, Lopane G, Passini A, Poli F, Iannello C, Guarino M. Mucuna pruriens in Parkinson disease. Clinical Neuropharmacology. 2015;38:201-203. DOI: 10.1097/WNF.0000000000000098'},{id:"B40",body:'Fathima KR, Soris PT, Mohan VR. Nutritional and antinutritional assessment of Mucuna pruriens (L.) DC var. pruriens an underutilized tribal pulse. 2010;1:79-89'},{id:"B41",body:'Duangnin N, Phitak T, Pothacharoen P, Kongtawelert P. In vitro and in vivo investigation of natural compounds from seed extract of Mucuna pruriens lacking L-DOPA for the treatment of erectile dysfunction. Asian Pacific Journal of Tropical Medicine. 2017;10:238-252. DOI: 10.1016/j.apjtm.2017.03.001'},{id:"B42",body:'Suresh S, Prakash S, et al. The Journal of Sexual Medicine. 2011;8:1943-1956. DOI: 10.1111/j.1743-6109.2011.02221.x'},{id:"B43",body:'Sathiyanarayanan L, Arulmozhi S. Mucuna pruriens Linn.—A comprehensive review. Pharmacognosy Reviews. 2007;1:157-162'},{id:"B44",body:'Mohan VR. Antibacterial activity of Mucuna pruriens (L.) Dc. var. pruriens—An ethnomedicinal plant. Journal of Scientific Research and Reports. 2011;1:69-72'},{id:"B45",body:'Rayavarapu KA, Kaladhar DSVGK. Evaluation of antimicrobial activity of Mucuna pruriens on plant pathogens. Asian Journal of Biochemical and Pharmaceutical Research. 2014;1:593-600'},{id:"B46",body:'Dey A, De JN. Possible Anti-Parkinson’s Disease Therapeutics from Nature: A Review. Elsevier B.V.; 2015. DOI: 10.1016/B978-0-444-63460-3.00009-2'},{id:"B47",body:'Pokrzywa M, Pawełek K, El W, Sarbak S, Chorell E, Almqvist F, et al. Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson’s disease. 2017:1-21'},{id:"B48",body:'Maitra U. Using Drosophila as a platform for drug discovery from natural products in Parkinson’s disease. 2019:867-879. DOI: 10.1039/c9md00099b'},{id:"B49",body:'Poddighe S, De Rose F, Marotta R, Ruffilli R, Fanti M, Secci PP, et al. Mucuna pruriens (Velvet bean) rescues motor, olfactory, mitochondrial and synaptic impairment in PINK1B9 Drosophila melanogaster genetic model of Parkinson’s disease. PLoS One. 2014;9. DOI: 10.1371/journal.pone.0110802'},{id:"B50",body:'Bakthavatsalam S, Das Sharma S, Sonawane M, Thirumalai V. A zebrafish model of manganism reveals reversible and treatable symptoms that are independent of neurotoxicity. Disease Models & Mechanisms. 2014:1239-1251. DOI: 10.1242/dmm.016683'},{id:"B51",body:'Kalueff AV, Stewart AM, Gerlai R. Zebrafish as an emerging model for studying complex brain disorders. Trends in Pharmacological Sciences. 2014;35:63-75. DOI: 10.1016/j.tips.2013.12.002'},{id:"B52",body:'Gerlai R. Associative Learning in Zebrafish (Danio rerio). 3rd ed. Elsevier Ltd; 2011. DOI: 10.1016/B978-0-12-387036-0.00012-8'},{id:"B53",body:'Fernandes Y, Gerlai R. Long-term behavioral changes in response to early developmental exposure to ethanol in zebrafish. Alcoholism, Clinical and Experimental Research. 2009;33:601-609. DOI: 10.1111/j.1530-0277.2008.00874.x.Long-Term'},{id:"B54",body:'Fernandesa Y, Trana S, Abrahamb E, Gerlaia R. Embryonic alcohol exposure impairs associative learning performance in adult zebrafish. Behavioural Brain Research. 2015;15:181-187. DOI: 10.1016/j.bbr.2014.02.035.Embryonic'},{id:"B55",body:'Gómez-laplaza LM, Gerlai R. Latent learning in Zebrafish (Danio rerio). Behavioural Brain Research. 2011;208:509-515. DOI: 10.1016/j.bbr.2009.12.031.Latent'},{id:"B56",body:'Yadav SK, Prakash J, Chouhan S, Singh SP. Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model. Neurochemistry International. 2013;62:1039-1047. DOI: 10.1016/j.neuint.2013.03.015'},{id:"B57",body:'Rai SN, Birla H, Zahra W, Sen Singh S, Singh SP. The role of Mucuna pruriens and Withania somnifera in the neuroprotection and treatment of Parkinson’s disease. SOJ Neurology. 2018;5:1-7'},{id:"B58",body:'Kasture S, Pontis S, Pinna A, Schintu N, Spina L, Longoni R, et al. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson’s disease. Neurotoxicity Research. 2009;15:111-122. DOI: 10.1007/s12640-009-9011-7'},{id:"B59",body:'Suresh S, Prakash S. Effect of Mucuna pruriens (Linn.) on sexual behavior and sperm parameters in streptozotocin-induced diabetic male rat. The Journal of Sexual Medicine. 2012;9:3066-3078. DOI: 10.1111/j.1743-6109.2010.01831.x'},{id:"B60",body:'Hussain G, Manyam BV. Mucuna pruriens proves more effective than l-DOPA in Parkinson’s disease animal model. 1997;423:419-423'},{id:"B61",body:'Liebert MA. An alternative medicine treatment for Parkinson’s disease: Results of a multicenter clinical trial HP-200 in Parkinson’s Disease Study Group. Journal of Alternative and Complementary Medicine. 1995;1:249-255'},{id:"B62",body:'Rijntjes M. Knowing your beans in Parkinson’s disease: A critical assessment of current knowledge about different beans and their compounds in the treatment of Parkinson’s disease. Parkinson’s Disease. 2019;2019:1-9'},{id:"B63",body:'Marsden CD, Parkes JD, Rees JE. A year’s comparison of treatment of patients with Parkinson’s disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet. 1973;2:1-4'},{id:"B64",body:'Katzenshlager R, Evans A, Manson A, Palsalos PN, Ratnaraj N, Watt H, et al. Mucuna pruriens in Parkinson’s disease: A double blind clinical and pharmacological study. Journal of Neurology, Neurosurgery, and Psychiatry. 2004;75:1672-1677. DOI: 10.1136/jnnp.2003.028761'},{id:"B65",body:'Mars H. Modification of levodopa effect by systemic decarboxylase inhibition. Archives of Neurology. 1973;28:91-95. DOI: 10.1001/archneur.1973.00490200039004'},{id:"B66",body:'Cilia R, Laguna J, Cassani E, Cereda E, Raspini B, Barichella M, et al. Daily intake of Mucuna pruriens in advanced Parkinson’s disease: A 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism & Related Disorders. 2018;49:60-66. DOI: 10.1016/j.parkreldis.2018.01.014'},{id:"B67",body:'del S. López-Cortez M, Rosales-Martínez P, Arellano-Cárdenas S, Cornejo-Mazón M. Antioxidants properties and effect of processing methods on bioactive compounds of legumes. Grain Legumes. 2016. DOI: 10.5772/63757'},{id:"B68",body:'Maruyama W, Takahashi T, Naoi M. (−)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. Journal of Neurochemistry. 2002;70:2510-2515. DOI: 10.1046/j.1471-4159.1998.70062510.x'},{id:"B69",body:'Munirathinam S, Lakshmana MK, Raju TR. (−) Deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures. Neurodegeneration. 1996;5:161-167. DOI: 10.1006/neur.1996.0023'},{id:"B70",body:'Kamada T, Morimoto K, Ohde H, Chow T, Hiroi T, Imaoka S, et al. Metabolism of selegiline hydrochloride, a selective monoamine B-type inhibitor, in human liver microsomes. Drug Metabolism and Pharmacokinetics. 2002;17:199-206. DOI: 10.2133/dmpk.17.199'},{id:"B71",body:'Holloway RG. Pramipexole vs levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Archives of Neurology. 2004;61:1044-1053. DOI: 10.1001/archneur.61.7.1044'},{id:"B72",body:'Teo KC, Ho SL. Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson’s disease. Translational Neurodegeneration. 2013;2:1. DOI: 10.1186/2047-9158-2-19'},{id:"B73",body:'Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, et al. Ropinirole for the treatment of early Parkinson’s disease. Neurology. 1997;49:393-399. DOI: 10.1212/WNL.49.2.393'},{id:"B74",body:'Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The tempo study. Archives of Neurology. 2012;59:1937-1943'},{id:"B75",body:'Munhoz RP, Picillo M, Fox SH, Bruno V, Panisset M, Honey CR, et al. Eligibility criteria for deep brain stimulation in Parkinson’s disease, tremor, and dystonia. The Canadian Journal of Neurological Sciences. 2016;43:462-471. DOI: 10.1017/cjn.2016.35'},{id:"B76",body:'Chao Y, Gang L, Na ZL, Ming WY, Zhong WS, Mian WS. Surgical management of Parkinson’s disease: Update and review. Interventional Neuroradiology. 2007;13:359-368. DOI: 10.1177/159101990701300407'},{id:"B77",body:'Lee D, Dallapiazza R, De Vloo P, Lozano A. Current surgical treatments for Parkinson’s disease and potential therapeutic targets. Neural Regeneration Research. 2018;13:1342-1345. DOI: 10.4103/1673-5374.235220'},{id:"B78",body:'Mehanna R, Fernandez HH, Wagle Shukla A, Bajwa JA. Deep brain stimulation in Parkinson’s disease. Parkinson’s Disease. 2018;2018:3-5. DOI: 10.1155/2018/9625291'}],footnotes:[],contributors:[{corresp:null,contributorFullName:"Suresh S. Suryawanshi",address:null,affiliation:'
Department of Biochemistry, Shivaji University, Vidyanagar, India
'},{corresp:null,contributorFullName:"Prajakta P. Kamble",address:null,affiliation:'
Department of Microbiology, Shivaji University, Vidyanagar, India
'},{corresp:null,contributorFullName:"Vishwas A. Bapat",address:null,affiliation:'
Department of Biotechnology, Shivaji University, Vidyanagar, India
'},{corresp:"yes",contributorFullName:"Jyoti P. Jadhav",address:"biochemjpj@gmail.com",affiliation:'
Department of Biochemistry, Shivaji University, Vidyanagar, India
Department of Biotechnology, Shivaji University, Vidyanagar, India
'}],corrections:null},book:{id:"9566",title:"Bioethics",subtitle:null,fullTitle:"Bioethics",slug:null,publishedDate:null,bookSignature:"Dr. Thomas F. Heston and Dr. Sujoy Ray",coverURL:"https://cdn.intechopen.com/books/images_new/9566.jpg",licenceType:"CC BY 3.0",editedByType:null,editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},profile:{item:{id:"104514",title:"MSc.",name:"Davidson Clayton",middleName:null,surname:"Azevedo Sodré",email:"ofolha@hotmail.com",fullName:"Davidson Clayton Azevedo Sodré",slug:"davidson-clayton-azevedo-sodre",position:null,biography:null,institutionString:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",totalCites:0,totalChapterViews:"0",outsideEditionCount:0,totalAuthoredChapters:"1",totalEditedBooks:"0",personalWebsiteURL:null,twitterURL:null,linkedinURL:null,institution:{name:"Federal University of Para",institutionURL:null,country:{name:"Brazil"}}},booksEdited:[],chaptersAuthored:[{title:"Shark DNA Forensics: Applications and Impacts on Genetic Diversity",slug:"shark-dna-forensics-applications-and-impacts-on-genetic-diversity",abstract:null,signatures:"Luis Fernando Rodrigues-Filho, Danillo Pinhal, Davidson Sodré and Marcelo Vallinoto",authors:[{id:"104502",title:"Prof.",name:"Marcelo",surname:"Vallinoto",fullName:"Marcelo Vallinoto",slug:"marcelo-vallinoto",email:"mvallino@ufpa.br"},{id:"104511",title:"Dr.",name:"Danillo",surname:"Pinhal",fullName:"Danillo Pinhal",slug:"danillo-pinhal",email:"dlpinhal@gmail.com"},{id:"104512",title:"Dr.",name:"Luis Fernando",surname:"Rodrigues-Filho",fullName:"Luis Fernando Rodrigues-Filho",slug:"luis-fernando-rodrigues-filho",email:"lfsrf@yahoo.com.br"},{id:"104514",title:"MSc.",name:"Davidson Clayton",surname:"Azevedo Sodré",fullName:"Davidson Clayton Azevedo Sodré",slug:"davidson-clayton-azevedo-sodre",email:"ofolha@hotmail.com"}],book:{title:"Analysis of Genetic Variation in Animals",slug:"analysis-of-genetic-variation-in-animals",productType:{id:"1",title:"Edited Volume"}}}],collaborators:[{id:"58360",title:"Dr.",name:"Rogerio",surname:"Mateus",slug:"rogerio-mateus",fullName:"Rogerio Mateus",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:"Biology graduate and MSc in Genetics at IBILCE-UNESP. PhD in Genetics at USP. Has experience in Evolutionary Biology, Biochemical and Molecular Genetics, Population Genetics and Ecology.",institutionString:null,institution:null},{id:"58368",title:"Dr.",name:"Luciana",surname:"Machado",slug:"luciana-machado",fullName:"Luciana Machado",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"78585",title:"Dr.",name:"Alireza",surname:"Seidavi",slug:"alireza-seidavi",fullName:"Alireza Seidavi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Islamic Azad University",institutionURL:null,country:{name:"Iran"}}},{id:"93366",title:"Dr.",name:"Sergiu",surname:"Georgescu",slug:"sergiu-georgescu",fullName:"Sergiu Georgescu",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Bucharest",institutionURL:null,country:{name:"Romania"}}},{id:"93422",title:"Ms.",name:"Daniele C.",surname:"Silva",slug:"daniele-c.-silva",fullName:"Daniele C. Silva",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"93424",title:"MSc",name:"Daiane",surname:"Simão",slug:"daiane-simao",fullName:"Daiane Simão",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"96064",title:"Prof.",name:"Mei-Chen",surname:"Tseng",slug:"mei-chen-tseng",fullName:"Mei-Chen Tseng",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"National Pingtung University of Science and Technology",institutionURL:null,country:{name:"Taiwan"}}},{id:"100682",title:"Prof.",name:"Anila",surname:"Hoda",slug:"anila-hoda",fullName:"Anila Hoda",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"102042",title:"Prof.",name:"Marieta",surname:"Costache",slug:"marieta-costache",fullName:"Marieta Costache",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Bucharest",institutionURL:null,country:{name:"Romania"}}},{id:"130583",title:"Prof.",name:"Paolo",surname:"Ajmone Marsan",slug:"paolo-ajmone-marsan",fullName:"Paolo Ajmone Marsan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null}]},generic:{page:{slug:"types-of-publications",title:"Types of publications",intro:"
IntechOpen publishes different types of publications
",metaTitle:"Types of publications",metaDescription:"IntechOpen publishes different types of publications",metaKeywords:null,canonicalURL:null,contentRaw:'[{"type":"htmlEditorComponent","content":"
EDITED VOLUME
\\n\\n
IntechOpen Edited Volumes are integrated collections of chapters about particular topics that present new areas of research or novel syntheses of existing research and, as such, represent perspectives from various authors.
\\n\\n
Edited Volumes can be comprised of different types of chapters:
\\n\\n
RESEARCH CHAPTER – A research chapter reports the results of original research thus contributing to the body of knowledge in a particular area of study.
\\n\\n
REVIEW CHAPTER – A review chapter analyzes or examines research previously published by other scientists, rather than reporting new findings thus summarizing the current state of understanding on a topic.
\\n\\n
CASE STUDY – A case study involves an in-depth, and detailed examination of a particular topic.
\\n\\n
PERSPECTIVE CHAPTER – A perspective chapter offers a new point of view on existing problems, fundamental concepts, or common opinions on a specific topic. Perspective chapters can propose or support new hypotheses, or discuss the significance of newly achieved innovations. Perspective chapters can focus on current advances and future directions on a topic and include both original data and personal opinion.
\\n\\n
INTRODUCTORY CHAPTER – An introductory chapter states the purpose and goals of the book. The introductory chapter is written by the Academic Editor.
\\n\\n
MONOGRAPHS
\\n\\n
Monographs is a self-contained work on a particular subject, or an aspect of it, written by one or more authors. Monographs usually have between 130 and 500 pages.
\\n\\n
TYPES OF MONOGRAPHS:
\\n\\n
Single or multiple author manuscript
\\n\\n
COMPACTS
\\n\\n
Compacts provide a mid-length publishing format that bridges the gap between journal articles, book chapters, and monographs, and cover content across all scientific disciplines.
\\n\\n
Compacts are the preferred publishing option for brief research reports on new topics, in-depth case studies, dissertations, or essays exploring new ideas, issues, or broader topics on the research subject. Compacts usually have between 50 and 130 pages.
\\n\\n
CONFERENCE PROCEEDINGS
\\n\\n
Collection of papers presented at conferences, workshops, symposiums, or scientific courses, published in book format
IntechOpen Edited Volumes are integrated collections of chapters about particular topics that present new areas of research or novel syntheses of existing research and, as such, represent perspectives from various authors.
\n\n
Edited Volumes can be comprised of different types of chapters:
\n\n
RESEARCH CHAPTER – A research chapter reports the results of original research thus contributing to the body of knowledge in a particular area of study.
\n\n
REVIEW CHAPTER – A review chapter analyzes or examines research previously published by other scientists, rather than reporting new findings thus summarizing the current state of understanding on a topic.
\n\n
CASE STUDY – A case study involves an in-depth, and detailed examination of a particular topic.
\n\n
PERSPECTIVE CHAPTER – A perspective chapter offers a new point of view on existing problems, fundamental concepts, or common opinions on a specific topic. Perspective chapters can propose or support new hypotheses, or discuss the significance of newly achieved innovations. Perspective chapters can focus on current advances and future directions on a topic and include both original data and personal opinion.
\n\n
INTRODUCTORY CHAPTER – An introductory chapter states the purpose and goals of the book. The introductory chapter is written by the Academic Editor.
\n\n
MONOGRAPHS
\n\n
Monographs is a self-contained work on a particular subject, or an aspect of it, written by one or more authors. Monographs usually have between 130 and 500 pages.
\n\n
TYPES OF MONOGRAPHS:
\n\n
Single or multiple author manuscript
\n\n
COMPACTS
\n\n
Compacts provide a mid-length publishing format that bridges the gap between journal articles, book chapters, and monographs, and cover content across all scientific disciplines.
\n\n
Compacts are the preferred publishing option for brief research reports on new topics, in-depth case studies, dissertations, or essays exploring new ideas, issues, or broader topics on the research subject. Compacts usually have between 50 and 130 pages.
\n\n
CONFERENCE PROCEEDINGS
\n\n
Collection of papers presented at conferences, workshops, symposiums, or scientific courses, published in book format
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5774},{group:"region",caption:"Middle and South America",value:2,count:5240},{group:"region",caption:"Africa",value:3,count:1721},{group:"region",caption:"Asia",value:4,count:10411},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15812}],offset:12,limit:12,total:118381},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"dateEndThirdStepPublish",topicId:"6,5"},books:[{type:"book",id:"9662",title:"Vegetation Index and Dynamics",subtitle:null,isOpenForSubmission:!0,hash:"0abf2a59ee63fc1ba4fb64d77c9b1be7",slug:null,bookSignature:"Dr. Eusebio Cano Carmona, Dr. Ricardo Quinto Canas, Dr. Ana Cano Ortiz and Dr. Carmelo Maria Musarella",coverURL:"https://cdn.intechopen.com/books/images_new/9662.jpg",editedByType:null,editors:[{id:"87846",title:"Dr.",name:"Eusebio",surname:"Cano Carmona",slug:"eusebio-cano-carmona",fullName:"Eusebio Cano Carmona"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9659",title:"Fibroblasts - Advances in Cancer, Autoimmunity and Inflammation",subtitle:null,isOpenForSubmission:!0,hash:"926fa6446f6befbd363fc74971a56de2",slug:null,bookSignature:"Ph.D. Mojca Frank Bertoncelj and Ms. Katja Lakota",coverURL:"https://cdn.intechopen.com/books/images_new/9659.jpg",editedByType:null,editors:[{id:"328755",title:"Ph.D.",name:"Mojca",surname:"Frank Bertoncelj",slug:"mojca-frank-bertoncelj",fullName:"Mojca Frank Bertoncelj"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8977",title:"Protein Kinase - New Opportunities, Challenges and Future Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"6d200cc031706a565b554fdb1c478901",slug:null,bookSignature:"Dr. Rajesh Kumar Singh",coverURL:"https://cdn.intechopen.com/books/images_new/8977.jpg",editedByType:null,editors:[{id:"329385",title:"Dr.",name:"Rajesh",surname:"Singh",slug:"rajesh-singh",fullName:"Rajesh Singh"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10557",title:"Elaeis guineensis",subtitle:null,isOpenForSubmission:!0,hash:"79500ab1930271876b4e0575e2ed3966",slug:null,bookSignature:"Dr. Hesam Kamyab",coverURL:"https://cdn.intechopen.com/books/images_new/10557.jpg",editedByType:null,editors:[{id:"225957",title:"Dr.",name:"Hesam",surname:"Kamyab",slug:"hesam-kamyab",fullName:"Hesam Kamyab"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10218",title:"Flagellar Motility in Cells",subtitle:null,isOpenForSubmission:!0,hash:"5fcc15570365a82d9f2c4816f4e0ee2e",slug:null,bookSignature:"Prof. Yusuf Bozkurt",coverURL:"https://cdn.intechopen.com/books/images_new/10218.jpg",editedByType:null,editors:[{id:"90846",title:"Prof.",name:"Yusuf",surname:"Bozkurt",slug:"yusuf-bozkurt",fullName:"Yusuf Bozkurt"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10750",title:"Solanum tuberosum - a Promising Crop for Starvation Problem",subtitle:null,isOpenForSubmission:!0,hash:"516eb729eadf0d1a9d1d2e6bf31e8e9c",slug:null,bookSignature:"Prof. Mustafa Yildiz and Dr. Yasin Ozgen",coverURL:"https://cdn.intechopen.com/books/images_new/10750.jpg",editedByType:null,editors:[{id:"141637",title:"Prof.",name:"Mustafa",surname:"Yildiz",slug:"mustafa-yildiz",fullName:"Mustafa Yildiz"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10797",title:"Cell Culture",subtitle:null,isOpenForSubmission:!0,hash:"2c628f4757f9639a4450728d839a7842",slug:null,bookSignature:"Prof. Xianquan Zhan",coverURL:"https://cdn.intechopen.com/books/images_new/10797.jpg",editedByType:null,editors:[{id:"223233",title:"Prof.",name:"Xianquan",surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10772",title:"Parasitic Plants",subtitle:null,isOpenForSubmission:!0,hash:"31abd439b5674c91d18ad77dbc52500f",slug:null,bookSignature:"Dr. Ana Maria Gonzalez and Dr. Hector Sato",coverURL:"https://cdn.intechopen.com/books/images_new/10772.jpg",editedByType:null,editors:[{id:"281854",title:"Dr.",name:"Ana Maria",surname:"Gonzalez",slug:"ana-maria-gonzalez",fullName:"Ana Maria Gonzalez"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10737",title:"Equus",subtitle:null,isOpenForSubmission:!0,hash:"258ffafc92a7c9550bb85f004d7402e7",slug:null,bookSignature:"Associate Prof. Adriana Pires Neves",coverURL:"https://cdn.intechopen.com/books/images_new/10737.jpg",editedByType:null,editors:[{id:"188768",title:"Associate Prof.",name:"Adriana",surname:"Pires Neves",slug:"adriana-pires-neves",fullName:"Adriana Pires Neves"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10777",title:"Plant Reproductive Ecology - Recent Advances",subtitle:null,isOpenForSubmission:!0,hash:"3fbf391f2093649bcf3bd674f7e32189",slug:null,bookSignature:"Dr. Balkrishna Ghimire",coverURL:"https://cdn.intechopen.com/books/images_new/10777.jpg",editedByType:null,editors:[{id:"206647",title:"Dr.",name:"Balkrishna",surname:"Ghimire",slug:"balkrishna-ghimire",fullName:"Balkrishna Ghimire"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10749",title:"Legumes",subtitle:null,isOpenForSubmission:!0,hash:"49d3123cde96adbe706adadebebc5ebb",slug:null,bookSignature:"Dr. Jose Carlos Jimenez-Lopez",coverURL:"https://cdn.intechopen.com/books/images_new/10749.jpg",editedByType:null,editors:[{id:"33993",title:"Dr.",name:"Jose Carlos",surname:"Jimenez-Lopez",slug:"jose-carlos-jimenez-lopez",fullName:"Jose Carlos Jimenez-Lopez"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10751",title:"Bovine Science",subtitle:null,isOpenForSubmission:!0,hash:"9e3eb325f9fce20e6cefbce1c26d647a",slug:null,bookSignature:"Dr. Muhammad Abubakar",coverURL:"https://cdn.intechopen.com/books/images_new/10751.jpg",editedByType:null,editors:[{id:"112070",title:"Dr.",name:"Muhammad",surname:"Abubakar",slug:"muhammad-abubakar",fullName:"Muhammad Abubakar"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:19},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:5},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:21},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:6},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:25},{group:"topic",caption:"Neuroscience",value:18,count:2},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:24},popularBooks:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5252},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editedByType:"Edited by",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editedByType:"Edited by",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editedByType:"Edited by",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editedByType:"Edited by",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9669",title:"Recent Advances in Rice Research",subtitle:null,isOpenForSubmission:!1,hash:"12b06cc73e89af1e104399321cc16a75",slug:"recent-advances-in-rice-research",bookSignature:"Mahmood-ur- Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9669.jpg",editedByType:"Edited by",editors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"16",title:"Medicine",slug:"medicine",parent:{title:"Health Sciences",slug:"health-sciences"},numberOfBooks:1511,numberOfAuthorsAndEditors:39573,numberOfWosCitations:21767,numberOfCrossrefCitations:11544,numberOfDimensionsCitations:29307,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"medicine",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editedByType:"Edited by",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9406",title:"Clinical Implementation of Bone Regeneration and Maintenance",subtitle:null,isOpenForSubmission:!1,hash:"875a140c01518fa7a9bceebd688b0147",slug:"clinical-implementation-of-bone-regeneration-and-maintenance",bookSignature:"Mike Barbeck, Nahum Rosenberg, Patrick Rider, Željka Perić Kačarević and Ole Jung",coverURL:"https://cdn.intechopen.com/books/images_new/9406.jpg",editedByType:"Edited by",editors:[{id:"204918",title:"Dr.",name:"Mike",middleName:null,surname:"Barbeck",slug:"mike-barbeck",fullName:"Mike Barbeck"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9122",title:"Cosmetic Surgery",subtitle:null,isOpenForSubmission:!1,hash:"207026ca4a4125e17038e770d00ee152",slug:"cosmetic-surgery",bookSignature:"Yueh-Bih Tang",coverURL:"https://cdn.intechopen.com/books/images_new/9122.jpg",editedByType:"Edited by",editors:[{id:"202122",title:"Prof.",name:"Yueh-Bih",middleName:null,surname:"Tang",slug:"yueh-bih-tang",fullName:"Yueh-Bih Tang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9134",title:"Recent Advances in Digital System Diagnosis and Management of Healthcare",subtitle:null,isOpenForSubmission:!1,hash:"ff00a5718f23cb880b7337b1c36b5434",slug:"recent-advances-in-digital-system-diagnosis-and-management-of-healthcare",bookSignature:"Kamran Sartipi and Thierry Edoh",coverURL:"https://cdn.intechopen.com/books/images_new/9134.jpg",editedByType:"Edited by",editors:[{id:"29601",title:"Dr.",name:"Kamran",middleName:null,surname:"Sartipi",slug:"kamran-sartipi",fullName:"Kamran Sartipi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9569",title:"Methods in Molecular Medicine",subtitle:null,isOpenForSubmission:!1,hash:"691d3f3c4ac25a8093414e9b270d2843",slug:"methods-in-molecular-medicine",bookSignature:"Yusuf Tutar",coverURL:"https://cdn.intechopen.com/books/images_new/9569.jpg",editedByType:"Edited by",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editedByType:"Edited by",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editedByType:"Edited by",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editedByType:"Edited by",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editedByType:"Edited by",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9018",title:"Some RNA Viruses",subtitle:null,isOpenForSubmission:!1,hash:"a5cae846dbe3692495fc4add2f60fd84",slug:"some-rna-viruses",bookSignature:"Yogendra Shah and Eltayb Abuelzein",coverURL:"https://cdn.intechopen.com/books/images_new/9018.jpg",editedByType:"Edited by",editors:[{id:"278914",title:"Ph.D.",name:"Yogendra",middleName:null,surname:"Shah",slug:"yogendra-shah",fullName:"Yogendra Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9523",title:"Oral and Maxillofacial Surgery",subtitle:null,isOpenForSubmission:!1,hash:"5eb6ec2db961a6c8965d11180a58d5c1",slug:"oral-and-maxillofacial-surgery",bookSignature:"Gokul Sridharan",coverURL:"https://cdn.intechopen.com/books/images_new/9523.jpg",editedByType:"Edited by",editors:[{id:"82453",title:"Dr.",name:"Gokul",middleName:null,surname:"Sridharan",slug:"gokul-sridharan",fullName:"Gokul Sridharan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:1511,mostCitedChapters:[{id:"19013",doi:"10.5772/21983",title:"Cell Responses to Surface and Architecture of Tissue Engineering Scaffolds",slug:"cell-responses-to-surface-and-architecture-of-tissue-engineering-scaffolds",totalDownloads:9697,totalCrossrefCites:109,totalDimensionsCites:230,book:{slug:"regenerative-medicine-and-tissue-engineering-cells-and-biomaterials",title:"Regenerative Medicine and Tissue Engineering",fullTitle:"Regenerative Medicine and Tissue Engineering - Cells and Biomaterials"},signatures:"Hsin-I Chang and Yiwei Wang",authors:[{id:"45747",title:"Dr.",name:"Hsin-I",middleName:null,surname:"Chang",slug:"hsin-i-chang",fullName:"Hsin-I Chang"},{id:"53659",title:"Ms.",name:"Yiwei",middleName:null,surname:"Wang",slug:"yiwei-wang",fullName:"Yiwei Wang"}]},{id:"46479",doi:"10.5772/57353",title:"Floating Drug Delivery Systems for Eradication of Helicobacter pylori in Treatment of Peptic Ulcer Disease",slug:"floating-drug-delivery-systems-for-eradication-of-helicobacter-pylori-in-treatment-of-peptic-ulcer-d",totalDownloads:1995,totalCrossrefCites:79,totalDimensionsCites:180,book:{slug:"trends-in-helicobacter-pylori-infection",title:"Trends in Helicobacter pylori Infection",fullTitle:"Trends in Helicobacter pylori Infection"},signatures:"Yousef Javadzadeh and Sanaz Hamedeyazdan",authors:[{id:"94276",title:"Prof.",name:"Yousef",middleName:null,surname:"Javadzadeh",slug:"yousef-javadzadeh",fullName:"Yousef Javadzadeh"},{id:"98229",title:"Dr.",name:"Sanaz",middleName:null,surname:"Hamedeyazdan",slug:"sanaz-hamedeyazdan",fullName:"Sanaz Hamedeyazdan"}]},{id:"25512",doi:"10.5772/30872",title:"Epidemiology of Psychological Distress",slug:"epidemiology-of-psychological-distress",totalDownloads:8066,totalCrossrefCites:57,totalDimensionsCites:145,book:{slug:"mental-illnesses-understanding-prediction-and-control",title:"Mental Illnesses",fullTitle:"Mental Illnesses - Understanding, Prediction and Control"},signatures:"Aline Drapeau, Alain Marchand and Dominic Beaulieu-Prévost",authors:[{id:"84582",title:"Dr.",name:"Aline",middleName:null,surname:"Drapeau",slug:"aline-drapeau",fullName:"Aline Drapeau"},{id:"84605",title:"Dr.",name:"Alain",middleName:null,surname:"Marchand",slug:"alain-marchand",fullName:"Alain Marchand"},{id:"84606",title:"Dr.",name:"Dominic",middleName:null,surname:"Beaulieu-Prévost",slug:"dominic-beaulieu-prevost",fullName:"Dominic Beaulieu-Prévost"}]}],mostDownloadedChaptersLast30Days:[{id:"43758",title:"Anxiety Disorders in Pregnancy and the Postpartum Period",slug:"anxiety-disorders-in-pregnancy-and-the-postpartum-period",totalDownloads:39763,totalCrossrefCites:11,totalDimensionsCites:20,book:{slug:"new-insights-into-anxiety-disorders",title:"New Insights into Anxiety Disorders",fullTitle:"New Insights into Anxiety Disorders"},signatures:"Roberta Anniverno, Alessandra Bramante, Claudio Mencacci and Federico Durbano",authors:[{id:"157077",title:"Dr.",name:"Federico",middleName:null,surname:"Durbano",slug:"federico-durbano",fullName:"Federico Durbano"},{id:"166382",title:"Dr.",name:"Roberta",middleName:null,surname:"Anniverno",slug:"roberta-anniverno",fullName:"Roberta Anniverno"}]},{id:"70711",title:"Fetal Growth Restriction",slug:"fetal-growth-restriction",totalDownloads:1706,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"growth-disorders-and-acromegaly",title:"Growth Disorders and Acromegaly",fullTitle:"Growth Disorders and Acromegaly"},signatures:"Edurne Mazarico Gallego, Ariadna Torrecillas Pujol, Alex Joan Cahuana Bartra and Maria Dolores Gómez Roig",authors:[{id:"202446",title:"Ph.D.",name:"Maria Dolores",middleName:null,surname:"Gómez Roig",slug:"maria-dolores-gomez-roig",fullName:"Maria Dolores Gómez Roig"},{id:"311835",title:"Dr.",name:"Edurne",middleName:null,surname:"Mazarico",slug:"edurne-mazarico",fullName:"Edurne Mazarico"}]},{id:"70405",title:"Hemostasis in Cardiac Surgery: How We Do it with Limited Resources",slug:"hemostasis-in-cardiac-surgery-how-we-do-it-with-limited-resources",totalDownloads:2694,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:null,title:"Contemporary Applications of Biologic Hemostatic Agents across Surgical Specialties - Volume 1",fullTitle:"Contemporary Applications of Biologic Hemostatic Agents across Surgical Specialties - Volume 1"},signatures:"Fevzi Sarper Türker",authors:null},{id:"64851",title:"Herbal Medicines in African Traditional Medicine",slug:"herbal-medicines-in-african-traditional-medicine",totalDownloads:9954,totalCrossrefCites:10,totalDimensionsCites:17,book:{slug:"herbal-medicine",title:"Herbal Medicine",fullTitle:"Herbal Medicine"},signatures:"Ezekwesili-Ofili Josephine Ozioma and Okaka Antoinette Nwamaka\nChinwe",authors:[{id:"191264",title:"Prof.",name:"Josephine",middleName:"Ozioma",surname:"Ezekwesili-Ofili",slug:"josephine-ezekwesili-ofili",fullName:"Josephine Ezekwesili-Ofili"},{id:"211585",title:"Prof.",name:"Antoinette",middleName:null,surname:"Okaka",slug:"antoinette-okaka",fullName:"Antoinette Okaka"}]},{id:"59779",title:"Effective Communication in Nursing",slug:"effective-communication-in-nursing",totalDownloads:6504,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"nursing",title:"Nursing",fullTitle:"Nursing"},signatures:"Maureen Nokuthula Sibiya",authors:[{id:"73330",title:"Dr.",name:"Nokuthula",middleName:null,surname:"Sibiya",slug:"nokuthula-sibiya",fullName:"Nokuthula Sibiya"}]},{id:"64858",title:"The Neurobiology of Anorexia Nervosa",slug:"the-neurobiology-of-anorexia-nervosa",totalDownloads:892,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"anorexia-and-bulimia-nervosa",title:"Anorexia and Bulimia Nervosa",fullTitle:"Anorexia and Bulimia Nervosa"},signatures:"Ashley Higgins",authors:null},{id:"63771",title:"The Role of Catheter Reshaping at the Angiographic Success",slug:"the-role-of-catheter-reshaping-at-the-angiographic-success",totalDownloads:536,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"angiography",title:"Angiography",fullTitle:"Angiography"},signatures:"Yakup Balaban",authors:[{id:"252647",title:"Associate Prof.",name:"Yakup",middleName:null,surname:"Balaban",slug:"yakup-balaban",fullName:"Yakup Balaban"}]},{id:"61866",title:"Plants Secondary Metabolites: The Key Drivers of the Pharmacological Actions of Medicinal Plants",slug:"plants-secondary-metabolites-the-key-drivers-of-the-pharmacological-actions-of-medicinal-plants",totalDownloads:5564,totalCrossrefCites:13,totalDimensionsCites:32,book:{slug:"herbal-medicine",title:"Herbal Medicine",fullTitle:"Herbal Medicine"},signatures:"Rehab A. Hussein and Amira A. El-Anssary",authors:[{id:"212117",title:"Dr.",name:"Rehab",middleName:null,surname:"Hussein",slug:"rehab-hussein",fullName:"Rehab Hussein"},{id:"221140",title:"Dr.",name:"Amira",middleName:null,surname:"El-Anssary",slug:"amira-el-anssary",fullName:"Amira El-Anssary"}]},{id:"17956",title:"Sexual and Reproductive Function in Chronic Kidney Disease and Effect of Kidney Transplantation",slug:"sexual-and-reproductive-function-in-chronic-kidney-disease-and-effect-of-kidney-transplantation",totalDownloads:11790,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"after-the-kidney-transplant-the-patients-and-their-allograft",title:"After the Kidney Transplant",fullTitle:"After the Kidney Transplant - The Patients and Their Allograft"},signatures:"Mahboob Lessan-Pezeshki and Shirin Ghazizadeh",authors:[{id:"26564",title:"Prof.",name:"Mahboob",middleName:null,surname:"Lessan Pezeshki",slug:"mahboob-lessan-pezeshki",fullName:"Mahboob Lessan Pezeshki"},{id:"26571",title:"Prof.",name:"Shirin",middleName:null,surname:"Ghazizadeh",slug:"shirin-ghazizadeh",fullName:"Shirin Ghazizadeh"}]},{id:"64747",title:"Bone Development and Growth",slug:"bone-development-and-growth",totalDownloads:3711,totalCrossrefCites:6,totalDimensionsCites:9,book:{slug:"osteogenesis-and-bone-regeneration",title:"Osteogenesis and Bone Regeneration",fullTitle:"Osteogenesis and Bone Regeneration"},signatures:"Rosy Setiawati and Paulus Rahardjo",authors:null}],onlineFirstChaptersFilter:{topicSlug:"medicine",limit:3,offset:0},onlineFirstChaptersCollection:[{id:"75604",title:"Normal Puerperium",slug:"normal-puerperium",totalDownloads:0,totalDimensionsCites:null,doi:"10.5772/intechopen.96348",book:{title:"Midwifery"},signatures:"Subrat Panda, Ananya Das, Arindam Mallik and Surajit Ray Baruah"},{id:"75596",title:"The Use of a Dynamic Elastomeric Fabric Orthotic Intervention in Adolescents and Adults with Scoliosis",slug:"the-use-of-a-dynamic-elastomeric-fabric-orthotic-intervention-in-adolescents-and-adults-with-scolios",totalDownloads:0,totalDimensionsCites:null,doi:"10.5772/intechopen.96391",book:{title:"Spinal Deformities in Adolescents, Adults and Older Adults"},signatures:"Martin Matthews and James Wynne"},{id:"75582",title:"Elimination of Plasmodium vivax Malaria: Problems and Solutions",slug:"elimination-of-plasmodium-vivax-malaria-problems-and-solutions",totalDownloads:1,totalDimensionsCites:null,doi:"10.5772/intechopen.96604",book:{title:"Current Topics and Emerging Issues in Malaria Elimination"},signatures:"Liwang Cui, Awtum Brashear, Lynette Menezes and John Adams"}],onlineFirstChaptersTotal:652},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/104514/davidson-clayton-azevedo-sodre",hash:"",query:{},params:{id:"104514",slug:"davidson-clayton-azevedo-sodre"},fullPath:"/profiles/104514/davidson-clayton-azevedo-sodre",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var t;(t=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(t)}()